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Abstract  
 
Abstract 
 
The field of tissue engineering has advanced and evolved to focus on biomimetic strategies to 
meet the rise in demands of tissue replacements for surgical reconstruction. One of the key 
strategies focuses on developing growth factor delivery systems, by incorporating growth 
factors into tissue scaffolds. While growth factors are crucial cell-inducing components, their 
limitations such as short half-lives and dose related adverse effects remain a challenge. To 
overcome these challenges, this thesis is focused on the development of a novel biomimetic 
tissue scaffold concept incorporating cell-mediated activation of growth factors for cartilage 
regeneration. The latent transforming growth factor-β1 (TGF-β1) was selected as a model 
latent protein due to its well established effects on cartilage as well as its ubiquity in many 
other tissue types. The thesis first focused on the development and characterisation of the 
tissue scaffold. A non-woven fibrous scaffold was fabricated by electrospinning, surface 
modified using ammonia plasma, followed by scaffold surface biofunctionalisation with the 
latent TGF-β1. Physiochemical characterisation revealed that: (1) the scaffold architecture 
closely resembled that of the native cartilage extracellular matrix; (2) the scaffold surface was 
chemically modified for subsequent biofunctionalisation reaction; and (3) the latent TGF-β1 
was incorporated onto the scaffold and the active TGF-β1 was detected upon acid and 
enzymatic activation. Biological effects of the biofunctionalised scaffold were assessed using 
human nasal chondrocytes in a serum free environment and compared with conventional 
TGF-β1 supplementation on non-biofunctionalised scaffolds (as control). The 
biofunctionalised scaffold group induced a lower cell metabolic activity and significantly 
higher gene expression of cartilage specific transcription factor Sox9 after 14 days. The 
second part of the thesis evaluated the chondrogenic efficacy of the biofunctionalised 
scaffolds, using the aforementioned chondrocytes and human mesenchymal stem cells (MSC), 
in an in-vivo rat model. Cell-scaffold constructs were implanted into subcutaneous pockets of 
athymic rats for six weeks. Gene expression and immunohistochemistry showed that the 
biofunctionalised group induced significant chondrogenic differentiation in chondrocytes and 
type II collagen production when compared to controls. Interestingly, a converse response 
was observed in MSC where the control group induced relatively higher chondrogenic 
potentials that the biofunctionalised group. This thesis demonstrates that the latent TGF-β1 
biofunctionalised scaffolds induced chondrocytic differentiation in chondrocytes and more 
importantly the proof of concept of cell-mediated activation of growth factors as a novel 
approach for functional tissue regeneration.  
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Chapter 1  
Introduction  
1.1 Background and Motivation 
Adult cartilage is predominantly an avascular, aneural and alymphatic tissue. It 
inherently lacks the ability to regenerate following destruction by disease or 
degeneration. Significant cartilage defects are seen clinically in congenital anomalies 
(e.g. microtia, cleft palate), following facial trauma and excision of tumours of the 
respiratory tract and in degenerative osteoarthritis (Fig. 1.1). However, current 
reconstructions based on either autograft, allograft, implants or prostheses - are less 
than ideal. 
 
Although autologous rib and ear cartilage are widely used due to their 
biocompatibility and transplant viability with minimal resorption phenomenon(1), 
autologous soft tissue harvest is often aesthetically imperfect. It involves multi-stage 
surgery and is associated with significant donor site morbidity(2) as well as surgical 
complications. The availability for autologous cartilage may also be limited when the 
defect requiring cartilage reconstruction is too large or when multiple revision 
surgeries are required(2). Allogeneic and xenogeneic transplantation carry the risks of 
transmission of infection and transplant rejection(1;3). Furthermore, due to the texture 
and shape of the native cartilage, it is difficult to surgically mould the native graft into 
the desired three dimensional shapes for transplantation. Donor availability is often an 
issue for allogeneic transplantation and this shortage worsens every year with the 
increasing demands(4). Artificial prostheses may be associated with infection, implant 
extrusion and adhesive breakdown at the host-prostheses interface(4). They also lack 
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the ability to adapt to environmental stresses and changes as does native cartilage(4). 
Due to the deficiencies of current available treatments, the field of cartilage 
engineering has emerged with the aim of generating a functional cartilage 
replacement to meet specific patient needs.  
 
 
 
Fig. 1.1. Examples of conditions requiring cartilage tissue for surgical reconstruction. (a) 
Congenital cleft lip and palate(5). (b) Congenital microtia. This is an intra-operative image 
with a cartilage framework graft pre-fabricated from the 6th, 7th and 8th autologous costal 
cartilage(6). (c) A complex facial gunshot injury involving the entire nasal, maxillae and 
mandibular bone as well as soft tissue(7). (d) Anteromedial compartment degenerative 
osteoarthritis of the knee(8). 
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1.2 Principles of Tissue Engineering 
Tissue engineering is a multidisciplinary field that applies the knowledge of 
engineering and biological sciences in the development of biological substitutes to 
restore, maintain  or improve health and tissue functionality(4). It consists of four 
fundamental components: (i) cells, (ii) scaffolds, (iii) bioactive cues, and (iv) 
environmental factors(9).  
 
In cartilage engineering, all four components contribute to the regeneration of 
functional tissue. Either chondrocytes or mesenchymal stem cells are key to the 
production of cartilage extracellular matrix (ECM). A biocompatible three 
dimensional (3D) scaffold would provide the foundation for the cells to adhere, 
proliferate and then be delivered to the recipient site. Bioactive cues such as growth 
factors and arginine-glycine-aspartate (RGD) peptide sequences are essential in 
signalling and inducing cells to proliferate and produce the appropriate ECM. Last but 
not least, chondrocyte survival and function will be largely influenced by 
environmental conditions such as pH, oxygen tension, and dynamic mechanical 
induction(9-11).  
 
Current challenges facing the tissue engineering of cartilage include the difficulty in 
maintaining chondrocytic differentiation and supplying the appropriate environmental 
cues to produce a functional cartilage tissue replacement. For many tissue engineering 
strategies expansion of cell numbers is vital. As a result, chondrocytes rapidly 
dedifferentiate leading to the expression fibroblastic markers (e.g. Col1A1) whilst 
losing cartilage specific transcription factors and genes such as Sox9 and 
Col2A1(12;13). In developing strategies to overcome these challenges, many studies 
have investigated the effects of various important parameters in scaffold fabrication 
such as the type of biomaterial(14;15), three dimensional scaffold architecture, effects 
of mechanical influence(16), as well as the incorporation of various growth 
factors(17-19) and cell adhesion motifs(20). 
 
To date, detailed cartilage regeneration studies of human hyaline cartilage have been 
predominantly focused on articular cartilage rather than nasoseptal, auricular or costal 
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cartilage. This was largely driven by the volume demand of new cartilage tissue to 
treat degenerative osteoarthritis(9;21). Articular cartilage samples have been more 
widely available to science due to the prevalence of joint replacement surgery. 
Nonetheless, the fundamental principles and advances of cartilage regeneration 
derived from articular cartilage studies provide a template for engineering of head and 
neck cartilage. This chapter reviews the native cartilage composition and structural 
architecture as the first fundamental step towards designing and producing the 
scaffold for tissue regeneration. This is followed by an overview highlighting the 
evolution and recent advancements in scaffold technology. Emphasis will also be 
given to state of the art strategies in biomimetic nanotechnology scaffold development 
for cartilage regeneration. 
24 
Chapter 1: Introduction 
 
1.3 A Review of Cartilage Biology 
1.3.1 Types of Cartilage 
There are three different types of cartilage in the body: hyaline, elastic and fibrous 
cartilage. Each can be found at specific sites and with different characteristic 
properties and functions. 
 
Hyaline cartilage can be found in joints, nose, trachea and ribs(22). In adults, its firm 
yet pliable character provides shock absorbent effect to mechanical loading in joints, 
and stent-like support to the nose and trachea, whilst allowing flexibility and recoil to 
the respiratory system during breathing(23). Its matrix contains collagen fibres, 
proteoglycans, and glycosaminoglycans. 
 
Elastic cartilage as its name implies, provides elastic properties to the epiglottis, 
external acoustic meatus, Eustachian tubes and ears(24). In addition to the matrix 
composition of hyaline cartilages, elastic cartilage also contains elastic fibres and 
lamellae which contribute to its resilience, pliability and elasticity(24).  
 
Fibrous cartilage is characterised by the abundance of collagen type I fibres in its 
matrix in addition to that of hyaline cartilage. It is present in intervertebral discs, 
menisci of knees, symphysis pubis, intra-articular discs of sternoclavicular and 
temporomandibular joints(24). 
 
1.3.2 Composition of Cartilage 
Cartilage is an avascular, aneural and alymphatic connective tissue which derives its 
nutrients and oxygen supply through diffusion from its surrounding tissue. It consists 
of cells, matrix macromolecules and water. Individual constituents have their own 
functions which are integrated and crucial for the survival and integrity of cartilage. 
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1.3.3 Chondrocytes 
The chondrocytes occupy an approximate average volume of 1-2% of the total 
cartilage volume in the adult human(25;26). However, the density of cells per cm3 
depends on the site of the cartilage. Human nasal cartilage contains approximately 
24.9 million cells per cm3, whereas the human femoral condylar and humeral head 
cartilage contains 14 and 15 million cells per cm3, respectively(21). The rate of in-
vitro expansion of cells also depends on the site of origin of the primary 
chondrocytes. For example, human nasal septal chondrocytes have a shorter doubling 
time of 2.6 days as compared to 3.4 days for human auricular chondrocytes(27). Cell 
density is also age dependent. It increases with increasing age but has been found to 
be inversely proportional with the GAG content(28). Cell density and donor site have 
their implications when considering tissue harvest for cell expansion.  
 
Although it is known that the typical shape of a chondrocyte is spheroidal(25), cells 
from different zones within the cartilage differ in shape and metabolic activity. For 
example, in the adult human articular cartilage, chondrocytes at the superficial zone 
are aligned parallel to the surface in the direction of shear stress and appear flat or 
discoid(29;30). As we proceed from the superficial to the deep zone, the cells 
gradually become more spherical then ellipsoid(26;30). Although chondrocytes reside 
in an environment of low oxygen tension, ranging from 10% at the surface to less than 
1% in deeper layers, they are still metabolically active as the cells derive most of their 
energy requirements through the glycolytic pathway(29). 
  
Chondrocytes express a number cartilage specific genes i.e. for type II collagen, the 
α1 (II) collagen gene (Col2A1); type IX collagen, α2 (IX) collagen (Col9A2); α2 (XI) 
collagen (Col11A2); aggrecan and link protein gene(31). Two of these genes in 
particular, Col2A1 and Col11A2, have been shown to exhibit a similar pattern of 
expression from as early as precartilaginous mesenchymal condensations(31;32) to 
the fully differentiated chondrocytes(32). Therefore the expression of these genes 
indicates a high level of chondrocytic differentiation. The expression of tissue specific 
gene is regulated by positive or negative transcription factors. The activation of the 
positive factors is often coupled with suppression of negative regulators in the control 
of the specific gene. Both Col2A1 and Col11A2 are regulated by the Sox protein 
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group Sox5, Sox6 and Sox9. Sox9 binds to and directly activates the cartilage-specific 
promoter sites of both Col2A1 and Col11A2. It also activates positive regulatory 
activities of Col9A1 and aggrecan gene. Sox5 and Sox6 are also vital for 
chondrogenesis as they bind to tissue-specific element of Col2A1 and aggrecan 
gene(31;32). Therefore, Sox5, Sox6 and Sox9 are also essential in determining the 
degree chondrocytic differentiation. 
 
Analyses of Col2A1, Col1A1 and Aggrecan gene expression have been used in 
numerous studies to determine the effects of various parameters in the maintenance of 
differentiation and induction of redifferentiation(10;33;34). Col1A1 on the other hand 
is an osteogenic marker as well as being a gene expressed by fibrocartilaginous and 
fibroblast-like cells(35;36). This gene is commonly used to characterise the degree of 
dedifferentiation of chondrocytes, which have undergone serial passage in-
vitro(34;37). Evaluation of gene expression in cells on matrices often correlates to the 
production of extracellular matrix components. 
 
1.3.4 Cartilage Extracellular Matrix 
The cartilage extracellular matrix consists of interstitial fluid and an integrated 
framework of structural macromolecules which are produced and organised by the 
chondrocytes. The interaction between the interstitial fluid and structural 
macromolecular framework determines the mechanical properties of the cartilage as 
well as protecting the chondrocytes from mechanical changes. Water contributes to as 
much as 80% of the wet weight of cartilage while the remainder consist of the 
structural macromolecules i.e. collagen, proteoglycans, and non-collagenous 
proteins(25).  
 
Interstitial Fluid 
It acts as a solvent to gases, proteins, metabolites and a high concentration of cations 
which are attracted by the highly negatively charged proteoglycans and 
glycosaminoglycans. The volume and behaviour of water is influenced by its 
interaction with the matrix macromolecules which carry negatively charged sulphate 
and carboxylate groups. These anionic groups attract positively charged ions such as 
sodium and result in an influx of water which leads to an increase in osmotic pressure. 
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This increase in osmotic pressure, within the collagenous network, confer to the 
mechanical properties of the native cartilage(25).  
 
Structural Macromolecules 
Collagens constitute the major portion of the dry weight of cartilage, representing 
60% of the dry weight of cartilage, while proteoglycans and non-collagenous proteins 
contribute 25-35% and 15-20%, respectively(25). The ability of cartilage to withstand 
tensile and compressive forces is primarily derived from the organisation of collagen 
fibrillar network and its interaction with proteoglycans and water. Type II, VI, IX, X 
and XI are found in the native cartilage. 
 
Collagen Type II 
Type II collagen is the most abundant collagen type in hyaline cartilage, accounting 
for up to 90-95% of the collagen content(25;26). These fibrils have a range of 
diameters which vary in the different regions of the cartilage. For example, in 
articular cartilage, they are approximately 20nm in diameter in the superficial zone. 
The diameter increases from 70-120nm, with increasing depth into the cartilage(26). 
The collagen type II molecule is composed of three identical α1(II) chains. Each α-
chain consists of repeating Glycine-X-Y sequences, where X and Y can be any amino 
acid but commonly proline and hydroxyproline respectively. The arrangements of 
these amino acid residues exhibit characteristic cross-striation periods of 60-70nm(38) 
which reflect the regularly staggered arrangements of amino acids, designated D1, 
D2, D3 and D4(38;39), of individual collagen fibrils(38). In the human collagen II, 
D3 and D4 periods have been shown to favour chondrocytic attachment, and 
migration due to the presence of one and two RGD sequences(39). The repeating units 
of hydrophobic (e.g., glycine and proline) and polar (e.g., hydroxyproline) groups 
containing amino acid residues also contribute to the ability to self-assemble and 
allow the formation of tightly packed final collagen triple helix confirmation(38;40). 
At the end of each triple helix, there are very short amino and carboxyl telopeptide 
domains. In this region, intra- and intermolecular crosslinks form between lysine 
residues with adjacent chains(26). An understanding of the molecular structure of 
collagen is important as this enables potential manipulation of chemical interactions 
when considering the potential functionalisation of synthetic biomaterials. 
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Other Collagen Types 
Collagen Type VI can be found mainly in the pericellular matrix, which is also know 
as the chondron. This highly branched filamentous network binds decorin and 
hyaluronan. There is also a high concentration of proteoglycan aggrecan associated 
with this network. Collagen Type VI has been used to as a marker for localisation of 
chondrocytes(41).  
 
Collagen Type IX has been found to contribute 2% of the total collagen in the hyaline 
cartilage(26). It is crosslinked to the surface of the Collagen Type II and may serve to 
form interfibrillar connections within the collagen network(26). Type XI collagen can 
be found within and on the surfaces of Type II fibrils. Its linkage with collagen type II 
restricts the lateral growth of the fibrils(26;42). The existence of the intra- and 
interfibrillar crosslinks of collagen may have implications when considering re-
enforcing the structural integrity of engineered fibrillar scaffolds. 
 
Non-collagenous Proteoglycans 
Decorin, which is present in abundance at the superficial zone and pericellular region, 
carries similar function like other leucine rich proteoglycan in limiting the diameter of 
collagen during fibril assembly. This small proteoglycan is present in similar 
concentration to the larger aggrecan. 
 
Aggrecan is the predominant proteoglycan in cartilage, accounting for 35% of its dry 
weight as well as constituting to approximately 90% of the total proteoglycan 
content(25;43;44). This large aggregating proteoglycan consist of a long 300kDa core 
protein “backbone” which contains several different binding sites and functional 
regions(45). Aggrecan can bind non covalently with hyaluronan to form high 
molecular weight aggregates of greater than 200MDa(46). This association however 
is stabilised by the link protein(45;47). Aggrecan also provides an extensive region 
for the binding of polyanionic glycosaminoglycan (GAG) chains. Majority of the 
GAG chains on aggrecan are composed of chondroitin sulphates which are repeating 
disaccharide units of glucoronic acid and N-acetyl-galactosamine. Each of these GAG 
chains are anionic and highly hydrophilic, producing high intermolecular electrostatic 
repulsion, osmotic properties and swelling pressure. These aggregating proteoglycans 
when assembled onto hyaluronan form a highly hydrated gel which is entrapped 
29 
Chapter 1: Introduction 
 
within the reinforcing network of collagen Type II fibrils. This provides the native 
cartilage tissue the ability to withstand compressive forces(26;45). Other 
proteoglycans and proteins with known functions include perlecan and 
chondroadherin which contribute to cell-matrix adhesion(26). 
 
Every component of the ECM contributes to the integrated dynamic structural and 
functional complexity of the native tissue – providing the ideal environment for cells 
to perform specific functions. Therefore, an understanding of the composition and 
structural organisation of native cartilage tissue is essential for producing a successful 
three dimensional scaffold for cartilage tissue engineering. 
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1.4 Development of Tissue Scaffolds in Cartilage Tissue 
Engineering 
1.4.1 Principles of Scaffold Development 
Tissue engineering requires a scaffold as an intermediate vehicle which offers support 
and provides cues to simulate the native environment for cell proliferation, 
differentiation and matrix production(48). This will form the basis for tissue 
replacement at the required site. Ideally, the material used should include the 
following properties(9;49;50): 
1. Biocompatible. The scaffold should naturally integrate with the surrounding 
host tissue without the activation of immune response as well as being non-
cytotoxic. 
2. Biomimetic. The scaffold provides cell inducing cues and carry features 
which resemble the native tissue environment therefore promotes new tissue 
formation. 
3. Biodegradable. The scaffold is metabolised in the body and excreted without 
a trace after fulfilling its purpose.  
4. Porous. This allows cell infiltration and diffusion of nutrients and waste. 
5. Mechanical support. Ideally the mechanical strength of the scaffold should 
match that of its native counterpart until sufficient support is generated by the 
neotissue. 
6. Shelf life. It is important to ensure that the scaffold does not lose its desired 
supportive features prior to the implantation in-vivo. 
7. Easy to sterilise. This is important as infected implants are notoriously 
difficult to treat. 
8. Surgically easy to handle. The scaffold should be physical easy to handle to 
allow surgeons to manipulate the scaffold into the desired shape prior to 
implantation. 
 
Generally, a polymer is selected, for the use as a biomaterial scaffold, based on these 
criteria. Many research studies have been conducted on the usage of natural and 
synthetic polymers as scaffolds for tissue engineering. Natural or native materials 
which have been investigated include alginates(33;51), chitin(52-54), collagen(34;55-
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59), elastin(55;57;58) and hyaluronan(20;60-62) etc while synthetic polymers such as 
poly(glycolides) and poly(lactides)(15;49;63;64) have been commonly tested and 
even utilised for biomedical applications. 
 
Natural polymers have the advantage of being biocompatible and that they contain 
information that facilitates cell attachment or maintenance of differentiated 
function(4). However, many natural materials suffer batch variability, problems of  
availability of materials in larger scale(4), high cost and immunogenicity. Synthetic 
materials on the other hand have the advantage of being versatile in that their physical 
and chemical properties can be tailored to allow precise control over molecular 
weight, degradation time, hydrophobicity and other attributes(65). Recently, the 
advantages of both natural and synthetic materials have been combined in strategies in 
the production of scaffolds for tissue engineering, where critical amino acid sequences 
or components from natural polymers were grafted onto synthetic scaffolds(52;56;66-
69). A well established example of this in Plastic and Reconstructive surgery is the 
Integra® Dermal Regeneration Template, where bovine type I collagen and 
chondroitin sulphate has been crosslinked to a poly(dimethyl siloxane) (PDMS) 
membrane to form a bilaminar silastic construct for the treatment of burns and 
scars(70;71). The PDMS layer acts as an epidermal barrier analogue to control fluid 
loss and prevent pathogen invasion while the co-type I collagen-chondroitin sulphate 
layer serves as an intermediate matrix for soft tissue and vascular integration. Several 
US Food and Drug Administration (FDA) approved synthetic biomaterials have been 
reviewed, in the following section, as potential scaffold materials for this project. 
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1.4.2 Synthetic Biomaterials for Tissue Engineering 
To date, many synthetic polymers have been approved by the FDA(15). Currently, 
suture materials, craniomaxillofacial and orthopaedic fixtures which are commercially 
available such as the Bio-Anchor, Lactosorb Screws and Plates and Biologically Quiet 
Interference Screw, are made of Poly(L-lactide), 82/18 Poly(L-lactide-co-glycolide) 
and 85/15 Poly(D,L-lactide-co-glycolide), respectively. These biocompatible 
polymers and their chemical and physical properties will be discussed as follows. 
 
1.4.2.1 Poly (glycolide) (PGA) 
PGA is a linear aliphatic polyester (Table 1.1). The first synthetic absorbable suture, 
Dexon, was made of PGA. The intermediate dimer, glycolide, is used to synthesise 
PGA by ring opening polymerisation. This produces a high molecular weight 
material, which is 45-55% crystalline. The high degree of crystallisation is associated 
with high tensile strength, modulus and lower degradation time. In addition, due to its 
high crystallinity, PGA is not soluble in most organic solvent with the exceptions of 
highly fluorinated organic solvents such as hexafluoroisopropanol. With high tensile 
strength and modulus, PGA fibres are too stiff to be used as suture material except 
when it is braided. Sutures made from PGA have been reported to lose approximately 
50% of their strength after two weeks and almost 100% loss of mechanical properties 
between 4 – 6 weeks, and are completely absorbed in four to six months(49;72). 
However, the stiffness and degradation time can be manipulated by copolymerisation 
with other materials such as lactides in poly(lactide-co-glycolide) (PLGA). PGA has 
been shown to be biocompatible for chondrocytic culture(73-75).  
 
1.4.2.2 Poly(lactide) (PLA) 
Lactide, which is the cyclic dimer of lactic acid, exists in two optical isomers - 
dexorotary and levorotary which are signified by a D and L, respectively. L- lactide is 
the naturally occurring stereo-isoform, while DL-lactide is the mixture of D-lactide 
and L-lactide. Lactides undergo ring opening polymerisation process which is similar 
to that of PGA (Table 1.1). With the addition of a methyl group, PLA is more 
33 
Chapter 1: Introduction 
 
hydrophobic than PGA but soluble in common organic solvents such as chloroform, 
dichloromethane and dimethylformamide.  
 
Poly L-lactide (PLLA) is semicrystalline at 37%. Its hydrophobicity accounts for its 
slow degradation time of more than 6 months. It has been shown that PLLA exhibits 
superior ability in maintaining structural integrity and in supporting chondrocytic 
proliferation when compared to other members of its poly α-hydroxy ester family 
such as PGA, PDLGA 50:50, PDLGA 85:15, and PDLLA(15). This is a promising 
factor for cartilage tissue engineering as structural stability is required and is 
associated with better cellular proliferation. 
 
Poly(DL-lactide) (PDLLA) is amorphous due to its random distribution of both the 
isomers. Therefore, it lacks the ability to arrange itself into a crystalline organised 
structure. This polymer has lower tensile strength and higher elongation. It degrades 
rapidly as soon as it comes into contact with water. Its application will therefore be 
more relevant as a drug delivery vector. 
 
1.4.2.3 Poly(lactide-co-glycolide) (PLGA) 
Copolymers of glycolides with lactides, regardless of their subtypes, are amorphous 
and tend to degrade rapidly (Table 1.1). Both L- and DL-lactide have been produced 
as devices and drug delivery systems. Interestingly, the half-lives and mechanical 
properties of the copolymer do not follow the linear relationship of the copolymer 
composition ratio (Fig. 1.2). For instance, PDLLGA 50:50 which consists of 50% 
lactide and 50% glycolide degrades faster than either of the homopolymer alone. The 
ratios 85:15 and 82:18 have been used to manufacture interference screws, suture 
anchors, plates and screws for craniomaxillofacial surgery. Degradation starts as soon 
as the material comes into contact with water(15). It has been shown that electrospun 
PDLLGA 85:15 and PDLLA fibres swell and occlude the pores of the scaffold as 
early as day 3. This may obscure the migration of cells. 
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Fig. 1.2. Half-lives of implanted PLA and PGA homopolymers and copolymers(49). The 
half-life of a polyester decreases when it is co-polymerised with another polyester. The half-
lives are at their lowest when the biomaterials are co-polymerisation at equal ratios, as 
illustrated above at the midpoint of the curve.  
 
1.4.2.4 Poly(ε-caprolactone) (PCL) 
The PCL has a degradation time of about 2 years although this can be adjusted to 
degrade more rapidly by copolymerising with other materials such as PDLLA. PCL 
alone, like PLLA, has been shown to maintain its three dimensional structural 
integrity whiles other polymers such as PGA, PDLLGA 85:15 and PDLLA have 
degraded (Table 1.1). PCL homopolymer has been shown to be less effective in 
supporting chondrocytic proliferation as the cells have been found to attach poorly to 
the polymer(76). However, the copolymer of PCL and glycolide has been 
manufactured as a monofilament suture, Monocryl® by Ethicon.  
 
1.4.2.5 Poly(dioxanone) (PDS) 
The poly(dioxanone) is a polyether-ester family which is polymerised from p-
dioxanone by the ring-opening step (Table 1.1). It has been known clinically as the 
monofilament suture, PDS®, which is marketed by Ethicon. The PDS® polymer 
typically has a high crystallinity of 55%. PDS® has been commonly used for its 
strength, non-reactive and non-toxic properties as compared to Vicryl and Dexon. It 
typically loses 50% of its strength in 3 weeks and is completely absorbed in six 
months. 
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In view of the physical properties and the biocompatibility of the above materials, 
PLLA has been selected, for its biocompatibility and long degradation time, as the 
biomaterial of choice for the fabrication of a three dimensional scaffold in this project. 
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1.4.3 Evolution of Scaffold Fabrication Technology 
Traditionally, many engineered biomaterial scaffolds were designed and produced to 
support cell culture and to match the properties of the desired native tissue at a 
macroscopic level. For example, in the 1980s, the type I collagen-chondroitin 
sulphate-PDMS scaffold developed for Integra® Dermal Regeneration Template was 
produced by a freeze-drying technique(77) to achieve a highly porous scaffold 
architecture. Scaffolds which were produced by this method were considered to be 
microporous (Fig. 1.3a). In 1997, in pioneering work by Cao and Vacanti et al., 
bovine articular chondrocytes seeded on a PLA coated PGA fibrous scaffold moulded 
into the shape of a human auricle were evaluated using an in-vivo mouse model (Fig. 
1.3b)(78). The fibre diameter of the PGA scaffold was 15µm which was almost 
equivalent to the size of a cell (10-20µm), and two orders of magnitude larger than a 
natural ECM fibrils (Fig. 1.3c). As the majority of native ECM (cartilage included) 
consists of a three dimensional, complex nanoscaled fibrillar network of not only 
structurally but also functionally integrated nanoscaled structures – the current trend 
in engineering tissue scaffold is to mimic the nanofibrous architecture of ECM 
proteins(9;79). This is the key difference from the preceding strategies which lack the 
nanoscaled features of the native ECM. The tissue engineered allogeneic airway 
transplantation reported by Macchiarini et al., in 2008, further emphasises this 
argument. The donor airway was decellularised leaving behind the ECM “skeleton” 
for subsequent recolonisation with the recipient cells(80) (Fig. 1.3d). This ECM 
“skeleton” may have provided the recipient cells with a near ready-made environment 
for cell survival, as indicated by the immediate successful clinical outcome.  
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Fig. 1.3. Pioneering tissue engineered scaffolds for skin and cartilage regeneration. (a) 
Scanning electron microscopy image (at 100× magnification) of the type I collagen-
chondroitin sulphate scaffold which was fabricated with a freeze drying technique, which 
formed the basis of the Integra® Dermal Regeneration Template(77). (b) Human ear-shaped 
PLA coated PGA scaffold seeded with bovine articular chondrocytes and implanted into the 
dorsum of an athymic nude mouse(81), and (c) Scanning electron microscopy of the cell-
scaffold construct prior to implantation(78). Note the micron size PGA fibres. Scale bar = 
50µm. (d) Pre-implanted segment of tissue engineered allogeneic airway which was 
decellularised and reseeded with recipient’s bronchial epithelial cells and mesenchymal stem 
cell derived chondrocytes(80).  
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1.4.4 Implications of Nanoscale Architecture of Scaffolds 
The cartilage ECM naturally consist of a three dimensional complex integrated 
network of not only structurally but also functionally interlinked nanoscaled 
structures. Based on this knowledge, many studies have investigated the role of 
nanoscale fibrous scaffolds (NFS) in tissue regeneration. The scaffold architecture 
governs how cells spread and bind, leading to changes in intracellular signalling 
pathways which ultimately result in a modification of gene expression and cell 
behaviour(82) (Fig. 1.4). Cells seeded on microscale scaffolds tend to flatten as 
though they were cultured on flat two dimensional (2D) surfaces. This 2D culture 
condition clearly differs from the natural three dimensional environment of the ECM 
which is vital for cell behaviour and function(83). Nanoscaled fibrous scaffolds on the 
other hand, being one to two orders of magnitude smaller than the cells, offer a closer 
simulation of the natural nanofibrous matrix for cartilage cells, increasing cell binding 
sites hence directing the desired cell behaviour and functions, as illustrated above. 
Scaffolds with nanoscale architecture also have a higher surface area to volume ratio 
for the adsorption of proteins and the binding of ligands, and this means that a higher 
number of binding sites and guidance cues are presented to cell receptors(82). This 
has strong implications to biomimicking the functions of native ECM in scaffold 
production. 
 
 
39 
Chapter 1: Introduction 
 
 
Fig. 1.4. Scaffold architecture influences cell binding hence cell behaviour and function. This 
figure illustrates that nanoscaled fibrous scaffolds provide a three dimensional environment 
for cells which better resemble the fibrous ECM of cartilage. Nanoscale scaffold architecture 
also increases the surface area for the adsorption of signalling molecules which in turn 
increases the binding sites for cells [figure adapted from Stevens et al., Science 2005(82)]. 
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1.4.5 Nanoscaled Fibrous Scaffold Fabrication Techniques 
As illustrated above, one of the prime components for structural integrity of cartilage 
is the collagenous fibrous network. Therefore when designing tissue scaffold systems 
for the first instance, it is vital to consider a three dimensional fibrous scaffold 
structural architecture in the nanoscale. Currently, three well established techniques 
are used in producing nanoscale fibrous scaffolds, namely: self assembly, phase 
separation and electrospinning(82;84). 
 
1.4.5.1 Self-assembly 
Self-assembly is a process of autonomous self-organisation of molecules into patterns 
and structures without human intervention(85). It occurs commonly throughout nature 
and technology, mediated by non-covalent interactions such as van der Waals, 
electrostatic and hydrophobic interactions, hydrogen and coordination bonds(85). For 
instance, amphiphilic molecules possessing both hydrophilic and hydrophobic 
segments, may self-assemble into well ordered structures when dispersed in aqueous 
solvents(86). A naturally occurring example and commonly used biomaterial for 
tissue culture scaffold is collagen. Its propeptides self-assemble into procollagen and 
ultimately nanoscaled fibrils.  
 
Synthetic polypeptide based systems have been found to be capable of fabricating 
nanoscale scaffolds with fibre diameter typically around 10nm(87;88), and have been 
shown to support the growth of various cell types(89-92). In cell culture, these 
scaffolds physically behave like hydrogel systems engulfing the cells in a three 
dimensional manner(89;91;92). This technique produces fibres with diameter which 
are typically smaller when compared to that of the native ECM (Fig. 1.5). An 
advantage of using peptide self-assembly is that it has the potential to carry many 
more biologically compatible motifs on its surface as compared to other synthetic 
polymeric biomaterials such as polyesters. However, its low yield in productivity and 
the complexity of its fabrication procedure may limit its use for tissue engineering at a 
larger scale(84). 
 
41 
Chapter 1: Introduction 
 
 
Fig. 1.5. An example of self-assembled peptide used in a study of wound healing. A single 
peptide is shown and then thousands of peptides self-assemble to form a single nanofibre; 
trillions of peptides or billions of nanofibres form the scaffold (figure adapted from Schneider 
et al., PLoS ONE 2008)(92). Positive and negative charges are labelled in blue and in red, 
respectively. Scale bar = 1µm 
 
1.4.5.2 Phase Separation 
Phase separation is a technique of separation of a polymer solution into polymer-rich 
and solvent-rich domains, which is either induced thermally or by the addition of a 
non-solvent of a polymer to form a gel, followed by a cooling process to fix the 
morphology and a freeze drying process to remove the solvent. This technique 
produces three dimensional fibrous network with fibre diameter ranging between 
50nm to 500nm and with porosity as high as 98%(93) (Fig. 1.6). PLLA scaffolds 
produced by phase separation were shown to favour cell attachment, have higher 
adsorption of proteins such as fibronectin and vitronectin, as well as promoting 
differentiation when compared to solid walled porous scaffolds with equal 
porosity(94;95). Scaffolds fabricated from synthetic and natural polymers as well as 
composites of both, have been shown to support chondrocytic proliferation with 
desirable mechanical properties(96-99). Phase separation offers the ability to control 
the fibre diameter and  porosity of the scaffold, as well as tailor its mechanical 
properties by manipulating several processing parameters such as polymer 
concentration, type of solvent, solvent exchange, gelation temperature(84;93;100). In 
addition, since this process of scaffold fabrication takes the shape of its moulds, it 
enables the scaffolds to be fashioned to any desired anatomical shape(100). Batch to 
batch consistency can be achieved with this technique but it requires experienced 
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laboratory skills. Although scaffold production with phase separation requires few 
specialised equipments it lacks the ability to align the fibres as seen in the 
electrospinning technique, when considering guiding the direction of growth of 
certain cell types. 
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Fig. 1.7. Schematic representation of a typical electrospinning system. The polymer solution 
is delivered, at a constant rate, to the tip of the charged spinneret. Electrospinning initiates 
from the Taylor Cone (depicted top right) when the charge overcomes the forces of surface 
tension. The electrospun fibres are then collected on the grounded target. (Figure adapted 
from an image courtesy of Dr. Julian George, Imperial College London).  
 
The technique of electrospinning provides the ability to tailor-design the desired three 
dimensional nanoscaled architecture of the scaffold(48) and requires relatively simple 
equipment. It has the advantage over self-assembly and phase separation methods as it 
allows fibres to be either randomly orientated or aligned in parallel by rotating the 
grounded target collector at various speed(103). Aligned natural and synthetic 
electrospun fibres, such as collagen and polyesters, have been shown to provide 
topographical guidance to cell attachments orientating cells along direction of 
fibres(55;63;102;104;105). This is one of the strengths of electrospinning in 
mimicking the natural structural architecture of many tissue types such as neural, 
musculoskeletal, dermal and vascular tissues, where direction of tissue growth is 
crucial in determining the correct physiological function of the organ. It is known that 
scaffold three dimensionality and fibre diameter are associated with cellular 
differentiation and proliferation, which are important crucial points in cartilage tissue 
engineering(106). These properties mimic the three dimensional native environment 
and nanoscale natural collagen network. In addition to this, as mentioned above, with 
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the presence of nanoscaled fibrous scaffolds, very high surface area to volume ratio 
can be achieved for protein adsorption(82), cell incorporation and proliferation(63). 
The 3D architecture of electrospun scaffolds have interconnected interfibrillar space 
or “pores” which are vital for diffusion of nutrient and gaseous exchange as well as 
waste disposal(63). In electrospinning, the ability to control the scaffold fibre size, 
morphology and architecture is governed by several processing parameters as 
described in the following section. 
 
For cartilage tissue engineering, various types of biomaterial scaffolds have been 
fabricated with electrospinning (Table 1.2). In these studies, human mesenchymal 
stem cells (hMSC), bovine and human chondrocytes have been used to characterise 
the scaffolds as summarised in Table 1.2. 
 
As described in the above sections on scaffold fabrication techniques, electrospinning 
has been selected for the following reasons: 
1. The electrospinning set up is simple, easy and relatively cheap to build. It is 
technically easy and simple to perform. Therefore it is a cost effective way of 
producing nanoscale fibrous scaffolds.  
2. As compared to self-assembly, its high yield in scaffold productivity means 
that it is suitable for scaffold fabrication at a large scale. 
3. It has the ability to produce and tailor the scaffold fibre diameter to the desired 
size in order to mimic the natural cartilage ECM structural framework, when 
self-assembly may produce fibrous scaffolds with fibre diameters that are 
typically an order of magnitude smaller.  
4. It is also the only technique capable of controlling the alignment and 
orientation of scaffold fibres. This is known to guide cell attachment hence 
influencing cell behaviour. 
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1.5 Electrospinning 
1.5.1 Formation of Nanofibres 
Two major forces involved in the formation of electrospun nanoscaled polymer fibres 
are surface tension and self-repulsive electrical forces. When an electrical field is 
applied across a polymer solution, ions are generated. For a fixed amount of fluid, the 
surface tension tends to retain the fluid in a spherical shape, while molecular self-
repulsion between the charged ions encourages not only an alteration to its shape, but 
the formation of a jet towards a field of opposite or zero charge(107). In 
electrospinning, a drop of polymer solution suspended from a conducting spinneret, 
receives an electrical charge. When the electrical charge is increased to a point where 
the self-repulsive charge overcomes the forces of surface tension of the polymer 
solution - an accelerating jet is formed towards the grounded target(108).  
 
This initial segment of the polymer jet increases in length along its axis as a result of 
the self-repulsive forces. As the jet travels in mid air, the solvent evaporates, leaving 
behind a charged polymer fibre which continues to be elongated under the influence 
of the self-repulsive forces. The increase in length of a given segment of the jet is 
accompanied by gradual but enlarging lateral arching and bending of the segment. 
This lateral arching of the jet has been observed to increase in magnitude and displace 
radially from the axis of the initial straight jet. This is related to the self-repulsive 
charges acting from segments above and below, forcing the jet path to bend and 
radiate outwards (Fig. 1.8)(107;108). This bending phenomenon has been referred to 
as the bending instability of electrospinning. Despite the bending instability, the 
overall flow of direction of the jet remains on course towards the grounded target. The 
bending instability causes the overall jet to “whip” in mid-air, thereby encouraging 
further evaporation of solvent as well as thinning and elongation of the polymer jet – 
ultimately forming nanoscaled polymer fibres(109).  
 
Knowing the importance of self-repulsive electrical forces and surface tension in the 
formation of electrospun fibres, several key processing parameters further influences 
the interplay between these two forces. These electrospinning parameters are 
discussed in the following section. 
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Fig. 1.8. Schematic illustration of the bending instability mechanism of electrospinning. (a) 
depicts the initiation of the bending instability in a segment of electrospun polymer jet. Self-
repulsive electrical forces arising from a segment below induces an upward and outward 
motion (F1) while the repulsive charges from on-coming segments bring about a downward 
and outward motion (F2). The consequence of these forces (F1 and F2) is a radial exponential 
expansion of the electrospun fibre path, deviating away from the original straight axis (F3). (b) 
illustrates the directions of the resultant forces (F3) of two adjacent electrospun fibre segments 
[figure adapted from Reneker et al., Polymer 2008(107)]. 
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1.5.2 Electrospinning Parameters 
There are several important parameters which influence and control the scaffold fibre 
diameter, morphology, and alignment(101;110-112). They include: 
1. Type of material including its molecular weight 
2. Type of solvent 
3. Solution concentration/ viscosity 
4. Ionic charge modification of the solution 
5. Feed rate of the solution 
6. Accelerating voltage 
7. Target distance 
8. Type of collector 
 
1.5.2.1 Type of Materials 
Natural and synthetic polymers such as collagen and poly(α-hydroxy) esters are 
common materials used in studies for tissue engineering. The biomaterials which have 
been utilised in electrospinning were commonly polymers of high molecular weight. 
The molecular weight of the polymer used affects the fibre diameter i.e. higher 
molecular weight polymer yields fibres with larger diameter due to the increase of 
number of chain entanglements of the polymer molecules. The choice of material will 
also determine the type of solvent as certain polymer such as PGA only dissolves in 
fluorinated solvents. 
 
1.5.2.2 Type of Solvent 
Synthetic polymers require organic solvents while some natural polymers may also be 
water soluble. For example, chloroform is commonly used to dissolve poly(α-
hydroxy) esters(113;114) while hexafluoro-isopropanol (HFIP) has been used as a 
solvent for both synthetic and natural polymers  such as PGA, PLGA(52;63;115), 
collagen and elastin(58). 
 
The choice of solvent is important. The volatility of the solvent will allow the fibres to 
dry in mid air prior to its deposition on the grounded target collector. This is very 
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important as any remaining solvents on deposition will re-dissolve the underlying 
fibres leading to formation of fused fibres, junctions, bundles or even the collapse of 
the entire scaffold. Fused fibres, junctions and bundling effects(101)(Fig. 1.9) may 
effect cellular migration, proliferation and mechanical properties of the scaffold. 
Conversely, utilisation of a highly volatile solvent such as dimethylchloride may 
result in intrafibrillar pores (Fig. 1.9) which may lead to a shorter degradation time 
and a change in scaffold mechanical properties. The formation of these pores is 
thought to be due to the rapid phase separation effects during the electrospinning 
process(110). Different types of solvents also carry different levels of electrical 
conductivity which will influence the fibre diameter and formation of beaded 
fibres(112). Therefore a precise balance of biomaterials and its solvents are crucial 
starting points to electrospinning. 
 
 
Fig. 1.9. SEM images illustrating various fibre morphologies produced with electrospinning. 
(a) fusion of adjacent fibres (white arrows), scale bar shows 10µm(116); (b) & (c) 
intrafibrillar pores, scale bar shows 1µm and 500nm respectively(110); (d) beaded fibres, 
scale bar shows 5µm(117). 
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1.5.2.3 Solution Concentration and Viscosity 
The solution concentration or its corresponding viscosity is an effective parameter to 
control fibre morphology and diameter(101;112;118). At low concentrations, more 
beaded structures are formed instead of smooth fibres as the forces of surface tension 
predominate over self-repulsive forces. It is also difficult to produce fibres at the 
higher end of solution concentration as the solution becomes too viscous to be 
electrospun. Therefore there is an optimal window of solution concentration to fibre 
formation. Within this processing window, a common trend of fibre morphology 
change has been reported. At lower concentration, the fibres are irregular and beads-
on-strings (Fig. 1.9) as well as junctions and bundles are produced. As we increase the 
solution concentration, the fibres gradually become more uniform, cylindrical with 
fewer beads and junctions but with the increase in fibre diameter(112;118).   
 
1.5.2.4 Ionic Charge Modification of the Polymer Solution 
The addition of salt to the solution yields uniform, beadless fibres with smaller 
diameter. In the presence of salt such as sodium chloride, sodium or potassium 
phosphate, the charge density of the polymer solution is increased. This increase in 
charge density on the surface of the solution increases the elongation forces of the jet, 
as the overall tension in the fibres depends on the self-repulsion of the excess charges 
on the jet(118). 
 
Apart from the change in the charge density of the solution, the sizes of the ions also 
play an important role in determining the fibre diameter. Ions with smaller atomic 
radii carry a higher charge density and thus confer higher mobility under the influence 
of an external electric field. For example, electrospinning with the addition of sodium 
chloride instead of potassium phosphate yields fibres with smaller diameter(118). 
 
1.5.2.5 Rate of Delivery of Polymer Solution 
To obtain different fibre morphologies, a certain amount of polymer solution in the 
shape of a droplet which is suspended at the end of the needle should be maintained in 
order to form a Taylor cone which is at equilibrium(118). Varying the rate of delivery 
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of the polymer solution will in turn affect the size of this droplet. At lower feeding 
rate, the diameter of the fibres are relatively smaller as compared to spinning at higher 
feed rate. With a higher feed rate, more polymer solution is being carried away by the 
jet therefore yielding fibres with thicker diameter. However, Tan et al have reported 
that the solution feed rate has no significant impact on fibre diameter especially at 
lower polymer concentration(112). 
 
1.5.2.6 Accelerating Voltage 
When an electric potential is applied to the spinneret, the polymer solution within 
becomes charged. The surface of the droplet at the tip of the spinneret also becomes 
charged via the motion of ions. This charged solution reservoir is separated from an 
oppositely charged grounded target. This creates a static electric field difference. 
When the strength of the electric field is increased to a certain threshold level, the 
forces associated with surface tension of the polymer solution are overcome by the 
repulsion forces of the charged ions. This manifests itself to the naked eye as the 
Taylor Cone (Fig. 1.10) where the hemispherical shaped droplet is distorted into the 
shape of a cone pointing towards the grounded target(118). If the voltage is further 
increased, a jet of the solution is formed towards the target.  
 
Fig. 1.10. A Taylor Cone in electrospinning. This image demonstrates the typical conical 
shape of a charged pendant drop of polymer solution at the tip of a spinneret. A polymer jet 
can be seen at the bottom of the image indicating the initial process of electrospinning [figure 
adapted from Loscestales et al., Science 2002(119)]. 
 
With the solution concentration or viscosity and feed rate being constant, an increase 
in the applied voltage leads to an increase in the jet velocity. As a result, more 
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solution is being removed from the tip of the droplet. For this reason, fibres spun at 
higher voltage exhibit larger average diameter(101). High voltage also produces 
smaller but non uniform fibre diameter when the self repulsive forces of the charged 
polymer ions causes multiple smaller jets to occur. However, care must be taken not 
to increase the applied voltage such that the droplet is reduced completely. This is 
because once the electrospinning process occurs within the spinneret, fibre 
morphology will be changed yielding beaded structures(101).  
 
1.5.2.7 Target Distance 
The choice of target distance involves taking various factors into consideration. An 
adequate distance is needed between the spinneret and the collector to allow the 
whipping effect of the polymer jet. This facilitates the evaporation of the solvent from 
the polymer as well as elongation of the jet which leads to further thinning of the 
fibres. However, care must be taken not to exceed the distance between the spinneret 
and other surrounding structures such as the wall of the electrospinning container. 
This is because the charged polymer deposition will find the path of least resistance 
i.e. the fibres will be deposited on to other structures in closer proximity other than 
the collector despite being the only object of high conductivity. 
1.5.2.8 Type of Collector 
The type of collector strongly influences the alignment of fibres. To collect random 
fibres, a flat conducting plate can be used(102) (Fig. 1.11a). To collect aligned fibres, 
various set-up have been reported and they include parallel rods, dual rings, rotating 
discs and mandrels(48;102;120) (Fig. 1.11b). Fibre bundles can also be formed by 
winding a conducting wire as an electrode on an insulated rod or cylinder(53). Fibre 
diameter and alignment can also be affected by the speed of the rotation of a mandrel. 
The degree of fibre alignment increases initially with the increase of the speed of 
rotation. The highest attainable alignment is obtained up to a certain rotating speed, 
after which no further improvements will be achieved(53).  
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a b 
Fig. 1.11. Examples of types of collectors. (a) A flat aluminium collector with mounted glass 
cover slips. (b) A rotating mandrel with aluminium rods. 
 
An understanding of the intricate interplay between each electrospinning parameters 
is essential for the production of a fibrous scaffold which mimics the structural 
architecture of the native ECM. The parameters presented above are the key 
governing parameters which determine the final electrospun fibre morphology, size, 
and alignment. In engineering a biomimetic scaffold design, apart from fabricating the 
scaffold physical structure with physical and chemical properties to match the desired 
native tissue, it is also essential to consider designing the scaffold to possess as close 
as possible the natural physiological supportive function. The incorporation of 
bioactive molecules into a scaffold design is crucial to provide the appropriate signals 
for cell guidance.  
1.6 Overview of Cell-Instructive Signals of the Extracellular 
Matrix 
Cells in the native tissue constantly receive multiple signals from and interact with 
their surrounding ECM. These signals can be classified into either biophysical or 
biochemical. Both types of signals govern a wide range of cell behaviour and are 
crucial for cells to perform specialised functions. Initially, these stimuli bind to or are 
sensed by the cell surface receptors which transduce the signals across the cell 
membrane. These signals then activate various intracellular signalling pathways 
which then congregate to regulate gene expression – ultimately determining cell fate, 
proliferation as well as differentiation. Once the cells are isolated from their natural 
environment, they are removed from these vital signals – resulting in the lost of 
specific cell phenotype. Therefore, in tissue engineering, it is crucial to recapitulate 
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the dynamic signalling complexities of the tissue-specific ECM. The biophysical and 
biochemical signals from the ECM surrounding a cell can be derived from four 
sources: (1) structural macromolecules; (2) non-structural bioactive molecules; (3) 
environmental mechanical stresses; and (4) cell-cell interactions(121;122). 
 
Structural macromolecules such as fibronectin, collagen, GAGs and proteoglycans 
have a common role in establishing cell adhesion and anchorage, as well as providing 
the key structural properties to accommodate specific cell types. Structural 
macromolecules largely transmit biophysical type signals and are detected by cell 
surface receptors such as integrins(122). When integrins bind to the macromolecules, 
specific intracellular signalling pathways are activated resulting in the regulation of 
cell migration, proliferation, differentiation, alteration in cell cycle and apoptosis. 
Fibronectin is a large glycoprotein which consists of three repeating modules – type I, 
II, and III, separated by connecting sequences(123). The type III module carries 
several RGD sequences which mediate cell adhesions via integrins(124;125). It also  
plays a role in the assembly of certain ECM proteins (e.g. collagen and latent 
transforming growth factor binding protein) as well as the regulation of growth factor 
incorporation into the ECM(126;127). As outlined in section 1.3.4, the nanoscaled 
collagenous framework provides the structural foundation for the assembly of ECM 
as well as the integration of signalling motifs for cells. GAG and proteoglycans, being 
highly hydrated macromolecules, provide a means for the diffusion of free and 
soluble non-structural bioactive molecules(121).  
 
Mechanical stresses from the environment can be transmitted to cells via structural 
macromolecules as well as from neighbouring cells. These mechanical signals, which 
act at the cell-ECM/ cell-cell interfaces, are converted to intracellular signalling 
cascades which modulate gene and protein expression(128). In cartilage tissue 
engineering, mechanical induction of chondrocytes have been known to be one of the 
favourable method to modulate chondrogenesis in-vitro and in-vivo(10;16;129). 
 
Non-structural bioactive molecules (bioactive molecules in short) have also been 
classified as “soluble factors” in other review articles(122). Bioactive molecules that 
are commonly involved in tissue engineering consist of predominantly growth factors 
and certain hormones. Although the latter is generally related to the endocrine, 
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gastrointestinal, reproduction and immune systems, hormones do play a role in tissue 
regeneration. For example, hormones (natural or synthetic) such as insulin and 
dexamethasone promote mitosis and protein synthesis. They are frequently used to 
induce chondrogenic differentiation in-vitro in conjunction with growth factors(130-
132). Growth factors are polypeptides which are secreted by cells and bound to the 
ECM. The association of growth factors with the ECM prevents unnecessary 
degradation or loss of important information. The release or activation of the growth 
factors can be initiated by cells as required at a later stage. In the native ECM, 
multiple growth factors act synergistically and are required in minute amounts. They 
are also required at appropriate times, concentration as well as ratio(122). This 
dynamic spatial and temporal balance of growth factor delivery remains a challenge to 
tissue engineers. In order to recreate the multidimensional as well as multidirectional 
integration of information for cells, the incorporation of non-structural bioactive 
molecules into nanoscale scaffold designs would be highly beneficial to promote 
specific tissue regeneration. This process has been referred to as the 
biofunctionalisation of scaffolds. Scaffolds of synthetic materials such as poly(α-
hydroxy) esters often require this process as they often lack functional surface 
chemical properties for biochemical and cellular interaction.  
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1.7 Biofunctionalisation of Scaffolds with Growth Factors 
Biofunctionalisation often involves scaffold surface modification followed by 
physical and/or chemical linkage of certain biologically active compounds onto the 
scaffolds. Scaffold surface modification techniques commonly involve the use of 
either plasma or chemical treatments e.g. concentrated hydrochloric acid, diamine 
compounds(133). These surface modification techniques introduce reactive chemical 
groups such as amine, hydroxyl or carboxyl, which are recognisable by cells as well 
as form a platform for subsequent biochemical reaction with natural ECM 
components and bioactive compounds. These bioactive compounds include several 
native ECM components such as RGD peptide sequences for cell attachment, collagen 
and chondroitin sulphate, as well as cell-inducing growth factors e.g. transforming 
growth factor-β1 (TGF-β1) and basic fibroblast growth factor (bFGF)(56;66;67;134-
136).  
 
Growth factors play a vital role in the induction, promotion and maintenance of 
differentiation as well as the function of cells - particularly in the regeneration of 
cartilage tissue, which inherently lack the capacity to regenerate. Nonetheless, the use 
of growth factors in tissue regeneration is associated with several drawbacks. In 
general, growth factors have short half-lives, e.g. TGF-β1 (<30min), insulin-like 
growth factor (10-12min)(50). This means that a constant supply is required manually 
in in-vitro culture. Similar approach to supply growth factors may be manually 
impractical for in-vivo studies. Combined with the potential uncontrolled dose related 
adverse effects, these drawbacks of growth factors deter the translation of its 
application to the in-vivo or clinical setting. These challenges have persuaded 
researchers to incorporate growth factors into scaffold designs with controlled release 
systems. The controlled release of growth factors can also be tailored into biomimetic 
scaffold design(137).  
 
Several methods of growth factor incorporation have been described(50): (i) by direct 
blending or emulsion of the growth factors with the biomaterials during the scaffold 
synthesis and fabrication stage, (ii) by physical adsorption through the immersion of 
scaffold in the growth factor solution, and (iii) by pre-chemical linkage to or 
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encapsulation by a carrier prior to step i. Currently numerous studies have 
“immobilised” or “incorporated” growth factors such as TGF-β1, FGF and IGF in 
tissue scaffold systems with sustained release properties(134;136;138-141). Although 
the results of current studies have been encouraging, further refinements need to be 
made. 
 
The majority of these scaffold release systems are hydrogel based, where release of 
growth factors is by diffusion or degradation of the scaffold matrix(50;140). This 
often results in a “burst” release as well as a loss of scaffold mechanical and 
supportive properties required for cartilage tissue engineering(142). In addition, these 
studies utilised the active form of the growth factors and inevitably involved various 
processing steps which may result in a reduction of the bioactivity. At some point 
during the process of incorporation into delivery systems, growth factors may come 
into contact with chemicals such as crosslinking agents, various solvents as well as 
scaffold materials which may alter their true potential as well as bioactivity(143). For 
these reasons, our main aim is to incorporate the latent form of the TGF-β1 onto 
electrospun scaffold system for tissue regeneration. The growth factor remains 
immobilised on the scaffold and protected by its latent protein until its activation by 
cells.  
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Chapter 2  
Scope of the Thesis 
The main objective of this research is to develop a structurally and functionally 
biomimetic scaffold for cartilage tissue regeneration. By designing and producing a 
scaffold system that mimics the nanoscale architecture as well as the functional 
aspects of the cartilage extracellular matrix, the outcome of this project may provide a 
platform technology to overcome the well known poor regenerative capacity of 
cartilage. 
 
To achieve this, specific aims of this project are to: 
1. Examine and characterise the nanoscale architecture of the native cartilage 
extracellular matrix; 
2. Fabricate a nanoscale fibrous scaffold by electrospinning; 
3. Biofunctionalise the electrospun scaffold by incorporating the latent TGF-β1; 
4. Biological evaluation of the biofunctionalised scaffold by in-vitro and in-vivo 
culture. 
 
The purpose of Chapter 1 was to provide a background review of the field of 
cartilage tissue engineering, including the biology of cartilage, recent advances in 
scaffold fabrication and biofunctionalisation. Chapters 3 - 5 discuss the main 
experimental results of this research, which also include related literature reviews, 
experimental methodologies and suggestions for further work. Final conclusions and a 
general overview for further investigations are presented in Chapter 6. The following 
sections highlight the scope and aspects of each results chapter. 
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2.1 Structural Analysis of Native Hyaline Cartilage and 
Fabrication of Nanostructured Fibrous Scaffold by 
Electrospinning 
In order to design and produce a tissue scaffold which structurally mimics the native 
cartilage architecture, the first step was to examine and understand the structural 
morphology and nanoarchitecture of the native cartilage ECM. In Chapter 3, human 
articular hyaline cartilage and reconstituted bovine nasal septal collagen were 
examined under scanning electron microscopy. The outcome of the analysis formed 
the basis for the subsequent scaffold fabrication step by electrospinning. 
 
Electrospinning is a technique capable of producing three dimensional nanostructured 
polymer scaffolds that closely mimic the structural architecture of the native ECM. 
Chapter 3 then describes the parametric characterisation of the newly custom-built 
electrospinner. The optimal parameters to produce uniform nanostructured 
electrospun fibrous scaffolds were determined for further scaffold production in this 
thesis. 
 
2.2 Biofunctionalisation of Electrospun Scaffold with Latent 
TGF-β1 
Apart from designing the scaffold structural architecture to mimic the native ECM, 
the functional aspects of tissue scaffolds are equally essential. Bioactive cues such as 
growth factors play a vital role in guiding cell behaviour and have been used to 
promote the appropriate cell responses. The TGF-β1 is a well known chondrogenic 
growth factor. However, its use in the in-vivo setting may be impractical due to its 
limitations such as a short half-life and potential dose-related adverse effects. To 
address these challenge, the proposed concept detailed in Chapter 4 focused on 
developing a cell-mediated activation of growth factor scaffold system, using the 
latent form of the TGF-β1 as the model growth factor. Chapter 4 also included the 
physicochemical characterisation as well as the short term in-vitro biological 
assessment of the biofunctionalised scaffolds using primary human nasal 
chondrocytes. 
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2.3 In-vivo Assessment of Latent TGF-β1 Biofunctionalised 
Scaffold 
Chapter 5 is focused on determining the long term outcome of the latent TGF-β1 
biofunctionalised scaffolds in an in-vivo setting. The scaffolds and their controls were 
seeded with primary human nasal chondrocytes and human mesenchymal stem cells, 
prior to the implantation in the dorsal subcutaneous layer of athymic rats. 
Chondrogenic effects of the scaffolds were determined using gene expression studies 
and immuno-detection of cartilage matrix production. 
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Chapter 3  
Structural Analysis of Native Cartilage and 
Scaffold Fabrication by Electrospinning 
3.1 Introduction 
In hyaline cartilage tissue, the type II collagen is one of the main components that 
provides structural integrity and confers the ability to withstand external and internal 
mechanical forces. The knowledge and understanding on the structural organisation 
and architecture of the native cartilage ECM is vital for the production of a successful 
biomimetic tissue scaffold for cartilage regeneration. Scaffolds in tissue engineering 
provide the foundation for cell growth as well as instructive cues for functional tissue 
regeneration. The initial aim of this chapter is focused on examining the structural 
architecture of the native hyaline cartilage. The hyaline cartilage analysed in this 
chapter was of human articular source due to its availability. Bovine nasoseptal 
collagen was also evaluated as a comparison. After the structural evaluation of the 
native hyaline cartilages, the following aim of this chapter is focused on producing a 
non-woven fibrous scaffold with electrospinning.  
 
Electrospinning is a technique capable of producing polymer fibres with diameters 
ranging from 5µm to 5nm by accelerating a jet of polymer solution which is 
electrically charged in an electric field towards a grounded target of opposite 
polarity(101;112;117). Due to the inherent capability of producing nanoscaled fibres 
which mimic the structural features of the native extracellular matrix, the 
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electrospinning technique has become a major tool in the production of scaffold for 
the study of tissue engineering(15;52;53;55;63;102;115;144).  
   
Our in-house built electrospinner was constructed early in the year 2006 (Fig. 3.1). 
The set-up consists of an electrospinning chamber, a syringe driver, a high voltage 
power supply, a motor to rotate mandrel collectors, gastight glass syringes, stainless 
steel needles and Teflon tubing. The electrospinning chamber was grounded to 
adjacent steel grounding pipes. 
 
 
Fig. 3.1. The electrospinning set up. On the right is the in-house built electrospinning 
chamber. It receives the polymer solution at a constant rate which is controlled by the syringe 
pump (Cole-Palmer, UK) situated in the centre. The high voltage supplier (Glassman High 
Voltage Inc.) on the left creates the electrical field difference necessary for electrospinning. 
The entire system is set up in a fume hood.  
 
The set-up required extensive characterisation in order to determine optimal settings 
and parameters for the consistent control of electrospinning. This is important 
considering the electrospinner will be used to fabricate three dimensional nanoscaled 
fibrous scaffolds for tissue engineering studies within the department. Numerous 
studies have reported the important governing parameters in 
electrospinning(101;112;117). However, these parameters may be set-up dependent; 
therefore this chapter sought to design a study to determine the optimal processing 
parameters and their consistencies for the production of nanoscaled fibres from 
biopolymers.  
 
Poly(L-lactide) (PLLA) was the biopolymer of choice for this thesis as it has been 
shown to maintain structural integrity while the rest of its counterparts such as PGA, 
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PDLGA 50:50, PDLGA 85:15, and PDLLA degrade in aqueous solution. It has also 
been reported to be superior in promoting chondrocytic proliferation when compared 
to other members of its poly α-hydroxy ester family(15).  
 
3.2 Materials and Methods 
3.2.1 Structural Analysis of Human Native Hyaline Cartilage and 
Reconstituted Bovine Nasal Collagen 
3.2.1.1 Preparation of Human Native Hyaline Cartilage for Scanning 
Electron Microscopy 
Adult human articular hyaline cartilage was obtained with informed consent from a 
female patient undergoing hip hemiarthroplasty after a femoral neck fracture. Strips of 
the cartilage were sectioned perpendicular to its perichondrial surface down to the 
underlying bone. The strips were immediately fixed in 2.5% glutaraldehyde followed 
by the stepwise dehydration and critical point drying process (Appendix 1.1). The 
processed cartilage strips were then analysed with scanning electron microscopy 
(SEM, see below). 
 
3.2.1.2 Preparation of Bovine Collagen Films on Cover Slips 
Bovine collagen solution of 1%(w/v) (Collagen from bovine nasal septum, Sigma-
Aldrich, UK) was prepared by dissolving the collagen in 5%(v/v) acetic acid (pH 3.0). 
It was magnetically stirred until fully dissolved (5 minutes). 12.5µL of the collagen 
solution was pipetted onto the centre of 10mm diameter glass cover slips (Agar, UK). 
They were then left in the sterile hood over night to dry. 
 
Non Self-assembled Collagen 
To study the structural features and self-assembly of collagen, three of the above 
coated cover slips were sputter coated for SEM (see following section on SEM). 
These samples were not subjected to incubation in culture media, the step-wise 
dehydration and critical point drying in order to elucidate the effects of immediate 
drying on collagen after sputter coating the cover slips.  
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Self-assembled Collagen 
A separate group of collagen films were subjected to incubation in Dulbecco’s 
modified Eagle’s medium (DMEM – Invitrogen, Paisley, UK) at pH 7.5, 37°C for 12 
hours to allow the self-assembly process to occur. The culture media was then 
removed before step-wise dehydration and critical point drying was performed on the 
samples (Appendix 1.1).   
 
3.2.1.3 Comparison of Collagen Fibre Diameters of Human Native 
Hyaline Cartilage and Reconstituted Bovine Collagen 
Three different SEM images from three different samples of native human hyaline 
cartilage and reconstituted bovine nasal septal collagen were obtained. Five collagen 
fibre diameters were measured on each image. A total of 45 collagen fibre diameters 
of both groups were measured using Image J software (National Institute of Health, 
USA). The means and standard deviations of both groups were calculated using SPSS 
12.0 software package (SPSS Inc., Chicago, USA). 
 
3.2.2 Parametric Study of Electrospinning 
3.2.2.1 Preparation of Solution and Determination of Type of 
Solvents for Electrospinning 
The polymer PLLA (PURAC Biochem, UK) with an average molecular weight of 
300kDa, was used in this study. To determine the type of solvents to be used in this 
parametric study, several combinations of polymer solutions were prepared by 
dissolving the PLLA in dichloromethane (DCM, AGTC Bioproducts, UK) only,  or in 
DCM and dimethylformamide (DMF, AGTC Bioproducts, UK), at three different 
weight ratios of 9:1, 8:2 and 7:3, at the polymer concentration of 5.0%(w/w). The 
polymer solutions were electrospun and analysed with scanning electron microscopy 
as described below. 
 
For the parametric study, PLLA solution was prepared by dissolving the PLLA in 
DCM and DMF at the weight ratio of 7:3, at the polymer concentrations of 1.0% - 
7.5%(w/w). As discussed in the results section later, the weight ratio of DCM to DMF 
of 7:3 was chosen because it produced fibres which were smooth and without pores. 
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DCM and DMF were initially measured according to the weight ratio of 7:3. The two 
organic solvents were kept separate. The weight of PLLA was then measured, added 
to the measured DCM and stirred magnetically until fully dissolved. DMF was then 
added to the solution and magnetically stirred until the two solvents were mixed 
thoroughly. The polymer solution was then ready to be electrospun. 
 
3.2.2.2 Target Distance 
The target distance which is the distance between the needle and the collector was set 
at 10cm. As the distance between the tip of the needle to the side walls were 12-15cm 
depending on the position of the needle, the target distance of 10cm was chosen due 
to the fact that the closest object regardless of its material will be the site of first 
deposition of the fibres. On the other hand, sufficient distance was required for the jet 
to travel, the evaporation of solvent as well as the thinning and elongation of the 
polymer jet. 
 
3.2.2.3 Types of Collector 
Two types of collectors were used – parallel aluminium rods of a mandrel and 
1×1.5cm2 glass cover slips mounted on a flat aluminium plate (Fig. 1.10). The latter 
was chosen for the lower polymer concentration 1.0 and 1.5%(w/w) when the 
formation of the initial jet was not observed. This ensured the collection of any 
fragmented fibres or electrosprayed droplets.  
 
3.2.2.4 Accelerating Voltage  
The high voltage was applied to the tip of the needle and this was regulated by the 
high voltage supply (Glassman High Voltage Inc., UK) to generate the polymer jet. 
The voltages used were 6, 10, 15, 20 and 25kV. The lower limit of the accelerating 
voltage parameter was set at 6kV as this has been found in this study to be the voltage 
where the initiation of the polymer jet occurred. Voltage of 25kV was chosen as the 
top limit because above this limit, static discharge occurred around the grounding 
wires. When investigating the effects of accelerating voltage at each polymer 
concentration, the rate of polymer solution delivery was set constant at 0.2mL/hr. This 
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rate of polymer solution delivery was selected as it was found to be the initial rate 
where the polymer solution droplet at the tip of the spinneret could be maintained 
during the electrospinning process. At a rate less 0.2mL/hr, where the removal of 
polymer solution by electrospinning exceeds the rate of delivery to the spinneret tip - 
the droplet was found to recede into the spinneret. This was consistent with previously 
reported studies(101;118). 
 
3.2.2.5 Rate of Delivery 
For each concentration, 5mL of the polymer solution was fed into a gastight glass 
syringe (Hamilton, USA) which was controlled by a syringe pump (Cole-Parmer, UK) 
at a constant feed rate of 0.2, 0.4, 0.6, 0.8 and 1.0mL/hour. Teflon tubing was used to 
connect the syringe to the needle which inner diameter of 0.51mm which was set up 
horizontally. Qualitative observations such as the subjective rate of fibre production 
during electrospinning were recorded (see raw data presented in Appendix 1.5). When 
investigating the effects of rate of delivery at each polymer concentration, the 
parameters were set constant at target distance of 10cm and accelerating voltage of 
10kV.  
 
3.2.3 Scanning Electron Microscopy 
The native hyaline cartilage, bovine collagen and the electrospun fibres were mounted 
directly onto carbon tabs on aluminium stubs for SEM. They were then sputter coated 
with 20nm thickness of gold using an Emitech K550 sputter coater (EM Technologies 
Ltd., UK) operating at 20mA for 2 minutes. The morphology of the fibres was then 
observed under scanning electron microscopy (FESEM; Gemini LEO1525) at 
accelerating voltage of 4kV and working distance of 6-8mm. Triplicate samples were 
taken and more than three fields of view were obtained. 
 
3.2.4 Electrospun Fibre Diameter and Bead Measurements 
Three samples of electrospun fibres were collected from three different areas of the 
target collector, for every change of parameter. For every sample collected, three 
images were obtained from three different areas using SEM. Approximately 5 fibres 
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per image were measured using Image J software (National Institute of Health, USA) 
(Appendix 1.4). This equated to a total of 45 electrospun fibre diameters for every 
change of parameter. For fibres which were not circular but ribbon shaped, 
measurements of widths and heights were taken and an average was calculated. In 
order to determine whether sample sizes (i.e. number of fibre diameters measured per 
parameter change) were sufficient to establish, with a confidence of 95% (z = 1.96), 
mean parameters (fibre diameters) with an error margin of ± 5%, the following 
formula was used: 
2
2/ ⎥⎦
⎤⎢⎣
⎡ ×=
E
zn σα         (3.1) 
where, zα/2 is the positive value that is at the vertical boundary for the area of α/2 in 
the right tail of the standard normal distribution, σ is the population standard 
deviation, n is the sample size, and E is the error. 
 
The margin of error, E = critical value (z) x standard error of the statistic,         (3.2) 
where z = 1.96, standard error (SE) = σ /√ n 
 
For example, at a polymer concentration of 2.5%, rate of delivery of 0.2mL/hr and 
6kV, the mean = 0.312, SD = 0.02 and n = 45 (see Appendix 1.5). 
Thus, SE  = σ /√ n  = 0.02 /√ 45 = 0.0030 
Therefore, the margin of error = 1.96× 0.02/√45 = 0.005 
 
The number of beads and circularity were also measured using Image J. Circularity is 
defined as 4π×(area/perimeter2). A value of 1 indicates a perfect circle. As the value 
approaches 0, it indicates an increasingly elongated polygon (Appendix 1.4). The 
edges of the beads were traced and circularity was measured using Image J (Fig. 3.2). 
The data were processed and results were represented as graphs and bar charts using 
Microsoft Excel software.  
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Fig. 3.2. A typical SEM image of showing the analysis of beads in electrospun PLLA fibres. 
This image illustrates the method employed for the measurement of fibre bead numbers and 
circularity using the Image J software. The black lines encircle the beads, while the numbered 
labels indicate the number of beads that has been included for analysis. 
 
3.2.5  Statistical Analyses 
The means and standard deviations of the native human collagen, bovine collagen, the 
electrospun fibre diameters and bead measurements were calculated using the SPSS 
software package SPSS 12.0 software package (SPSS Inc., Chicago, USA). The 
Mann-Whitney U Test for two independent samples was performed using SPSS to 
determine statistical significance between the fibre diameters of the native human and 
bovine collagens. Statistical significance between various electrospinning parameters 
was also determined. The p value of <0.05 was considered to be significant. 
 
3.3 Results 
3.3.1 Structural Analysis of Human Native Hyaline Cartilage and 
Bovine Nasal Collagen  
The structural analysis of human hyaline cartilage with SEM confirmed that the native 
cartilage ECM consisted of densely packed fibrous collagenous network. These 
complex networks of collagen engulf lacunae which house chondrocytes and exhibit 
randomly aligned architecture (Fig. 3.3a and b). The lacunae typically measured 20 – 
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25µm. On high magnification, the characteristic cross-striated pattern of collagen was 
observed along the fibres (Fig. 3.2c).  
 
a b 
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Initially, the reconstituted collagen exhibited fragmented grain like appearance on 
SEM, when dried immediately upon coating the cover slips and no collagenous fibres 
were observed (Fig. 3.4a). After being incubated in culture media at 37°C overnight, 
the collagen was seen in fibrillar form and exhibited a continuous interwoven network 
(Fig. 3.4b). These networks of collagen appeared randomly aligned but lack the 
interconnecting interfibrillar space found in the native hyaline cartilage. The fibre 
diameters of the bovine collagen (0.100 ± 0.020µm) were observed to be significantly 
lower (p<0.05) than that of human native collagen (0.171 ± 0.049µm). 
 
 
Fig. 3.4. Representative SEM images of reconstituted collagen from bovine nasal septum. (a) 
A sample of collagen solution [in 5%(v/v)acetic acid] subjected to the effects of immediate 
drying. SEM analysis demonstrated grain-like fragments of the collagen. (b) A sample of 
collagen solution [in 5%(v/v)acetic acid] subjected to further  incubation in cell culture media, 
prior to the drying step. The samples which were further incubated with media exhibited 
continuous interconnecting network of collagen fibres. The typical cross-striated pattern can 
also be seen on the collagen fibres. The scale bars show 500nm.  
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3.3.2 Parametric Study of Electrospinning 
The important processing parameters of our custom-built electrospinner have 
characterised. The effects of these parameters on electrospun fibre size and 
morphology are described in individual sections as follows. 
 
3.3.2.1 Effects of Type of Solvent 
The fibres electrospun from PLLA dissolved in pure DCM were found to contain 
pores along the fibres (Fig. 3.5a). These fibres also contained beads and were not 
uniform in size. A gradual progression of reduction in pores and beads were found 
with increased DMF content. With the initial addition of DMF to the solvent 
(DCM:DMF 9:1), a reduction of pores along fibres were observed while beads were 
still present (Fig. 3.5b). At a DCM:DMF solvent ratio of 8:2, the pores on fibres were 
no longer present however the beads were still observed on fibres. Interestingly, the 
fibre morphology at this solvent ratio appeared to be relatively uniform compared to 
the fibres electrospun at a DCM:DMF solvent ratio of 9:1 (Fig. 3.5c). Finally, fibres 
electrospun at a DCM:DMF solvent ratio of 7:3, appeared smooth, uniform in fibre 
size, beadless and contained no pores (Fig. 3.5d). This final solvent ratio was used for 
all subsequent electrospinning parametric experiments of this study. 
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3.3.2.2 Effects of Polymer Concentration 
The effects of various accelerating voltages as well as rates of polymer solution 
delivery on fibres electrospun at various polymer concentrations are represented in 
Fig. 3.6 and 3.7. The results showed that the fibre diameters were significantly 
increased with increasing polymer concentration (p<0.05). Both graphs in Fig. 3.6 and 
3.7 exhibited a sigmoid trend where the rise in fibre diameters were gradual and 
largely under 0.5µm, below a polymer concentration of 4.0%(w/w). The fibre 
diameters then increased rapidly between polymer concentrations of 4.0 and 
5.0%(w/w) – reaching predominantly micron scale at a polymer concentration of 
5.0%(w/w) and above. 
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Fig. 3.6. The effects of various accelerating voltages(kV) on electrospun fibre diameter at 
different polymer concentration. The rate of delivery of polymer solution was set constant at 
0.2mL/hr while the target distance was 10cm. Below a polymer concentration of 4.0%(w/w), 
fibre diameters were submicron, while a polymer concentration of 5.0%(w/w) produced fibres 
largely in the micron scale. Fibre diameter was observed to increase with increasing polymer 
concentration. The trend was statistically significant for p<0.05 at each accelerating voltage. 
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Fig. 3.7. The effects of various rate of polymer solution delivery(mL/hr) on electrospun fibre 
diameter at different polymer concentration. The accelerating voltage was 10kV while the 
target distance was 10cm. At a given rate of delivery of polymer solution, the increase in 
polymer concentration significantly increased the fibre diameter (p<0.05). 
 
The minimum polymer concentration to produce fibres of any morphology was found 
to be at 1.5%(w/w). Below this concentration, few fibres were produced and the 
effects of electrospraying were observed especially at higher accelerating voltage of 
20kV and above. These were seen as nanoscaled circular shaped deposition on the 
collector when examined under the SEM (Fig. 3.8a). At polymer concentration of 1.0 
- 1.5%(w/w), fibres were produced but were found to be in fragmented (Fig. 3.7a and 
b). There was a gradual rise in fibre diameter with the increase of polymer 
concentration from 2.5 – 4.0%(w/w) (Fig. 3.6 and 3.7). A steep rise in fibre diameter 
(approximately two to four fold) occurred between polymer concentrations of 4.0 – 
5.0%(w/w). However, few fibres were produced at a polymer concentration of 
7.5%(w/w). At polymer concentration of 5.0 and 7.5%(w/w), excess polymer solution 
was frequently observed to plug the tip of the needle, clogging the flow of delivery. 
This required frequent removal of the polymer plugs to facilitate electrospinning 
(approximately 3-4 times in a 5 minute period). This problem did not occur when the 
electrospinning process was performed at a polymer concentration of 2.5%(w/w) and 
below. 
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a 
 
Fig. 3.8. Representative SEM images of PLLA fibres electrospun at pol
1.0 and 1.5%(w/w). (a) The electrosprayed droplets of polymer can be
indicated by the arrows [polymer concentration 1.0%(w/w), 0.2m
increasing the polymer concentration from 1.0 to 1.5%(w/w), fibres we
electrosprayed droplets. However, these fibres were short and 
concentration 1.5%(w/w), 0.2mL/hr, 6kV].  
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3.3.2.3 Effects of Accelerating Voltage 
The effects of various accelerating voltages at a given polymer concentration are 
illustrated in Fig. 3.6. Alterations in accelerating voltage did not significantly 
influence the diameter of electrospun fibres, except at several parameters which will 
be discussed as follows.  
 
At a polymer concentration of 1.0%(w/w), the fibre diameters produced at various 
accelerating voltage were essentially less than 0.100µm, except at an accelerating 
voltage of 20kV where the fibre diameter of fibre were significantly increased by 
approximately 1.5-folds (0.130 ± 0.049µm). The electrospraying effects were also 
observed at high accelerating voltages of 20 and 25kV (Fig. 3.8a). 
 
The fibres electrospun at a polymer concentration of 1.5%(w/w) yielded diameters 
within the range of 0.100 – 0.200µm. Interestingly, the trend of increased of fibre 
diameter at a higher accelerating voltage observed at 20kV, polymer concentrations of 
1.0, where also observed at a polymer concentration of 1.5%(w/w) – where the fibre 
diameters were significantly increased (30%, p<0.05) at an accelerating voltage of 
25kV (0.173 ± 0.047µm). Beads were observed in all samples at polymer 
concentration of 1.0 and 1.5%(w/w).  
 
At a polymer concentration of 2.5%(w/w), the fibre diameters ranged from 0.220 ± 
0.013µm to 0.312 ± 0.020µm, with the exception of fibres electrospun at 10kV. At an 
accelerating of 10kV, the fibre diameters increased by approximately 56% (0.501 ± 
0.023µm), which was also considered statistically significant within the range of 
accelerating voltage (p<0.05).  
 
At a polymer concentration of 3.0%(w/w), the fibre diameters electrospun at 6kV 
(0.242 ± 0.058µm) were the smallest within the range of accelerating voltages. For 
fibres electrospun at 10 – 25kV, the fibre diameters ranged between 0.309 ± 0.063µm 
to 0.362 ± 0.098µm with no significant differences. 
 
There were no significant effects observed at various accelerating voltages (from 6 - 
25kV) on the fibre diameters electrospun at a polymer concentration of 4.0%(w/w). 
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The fibre diameters ranged between 0.515 ± 0.110µm to 0.631 ± 0.203µm. 
Interestingly, although no statistical significance were found, at polymer 
concentrations of 3.0 and 4.0%(w/w), an increase in the fibre diameters was observed 
at an accelerating voltage of 15kV. The trend was also observed in fibres electrospun 
at a polymer concentration of 2.5%(w/w) and accelerating voltage of 10kV as 
mentioned above. 
  
At a polymer concentration of 5.0%(w/w), the fibre diameters fell within the range of 
2.493 ± 0.106µm to 2.702 ± 0.121µm. The increase in accelerating voltage did not 
influence the fibre diameter significantly, except at an accelerating voltage of 25kV 
where the average fibre diameter was significantly reduced by approximately 75% - 
from 2.489 ± 0.115µm (accelerating voltage 20kV) to 0.608 ± 0.035µm (p<0.05). At 
an accelerating voltage of 15kV, the fibre diameter was found to be the largest within 
its group (2.702 ± 0.121µm), even though no statistical significance was observed. 
This was consistent with the trends observed on fibres electrospun at accelerating 
voltages of 10 – 15kV and polymer concentration 2.5, 3.0 and 4.0%(w/w). 
 
At a polymer concentration of 7.5%(w/w), fibre diameters was observed to range 
between 2.031 ± 0.112µm (accelerating voltage of 6kV) to 1.448 ± 0.333µm 
(accelerating voltage of 25kV). Interestingly, at an accelerating voltage of 10kV, the 
average fibre diameter was significantly larger at 2.982 ± 0.156µm while at 
accelerating voltage of 25kV the fibre diameter was significantly smaller by 
approximately 40 - 50% (p<0.05).  
 
78 
Chapter 3: Structural Analysis of Native Cartilage and Parametric Study of Electrospinning 
 
3.3.2.4 Effects of Rate of Delivery of Polymer Solution 
At a polymer concentration of 1.0 – 1.5%(w/w), the rate of delivery of the polymer 
solution did not significantly change the diameter of the fibres (Fig. 3.7). The fibre 
diameters fell within the range of 0.065 ± 0.022µm to 0.081 ± 0.016µm at a polymer 
concentration of 1.0%(w/w) while at polymer concentration of 1.5%(w/w) the 
diameter of fibres ranged between 0.093 ± 0.029µm and 0.127 ± 0.033µm. However, 
at polymer concentration of 1.5%(w/w), the rate of delivery of 0.2mL/hr produced 
significantly larger (0.127 ± 0.035µm) by 20-30% when compared to fibres spun 
within its group (rate of delivery of 0.4 - 1.0mL/hr). Interestingly, at a polymer 
concentration of 2.5%(w/w), the rate of delivery of 0.2mL/hr also produced 
significantly larger fibre diameters (0.501 ± 0.023µm), which were 2 – 3 folds 
increase relative to its group (at rate of delivery of 0.4 - 1.0mL/hr). In contrast, the 
fibres electrospun at a rate of delivery of 1.0mL/hr (0.154 ± 0.008µm) were 
significantly smaller than fibres produced between the rate of delivery of 0.2 – 
0.8mL/hr.  
 
The fibre diameters electrospun at a polymer concentration of 3.0%(w/w) were within 
the range of 0.242 ± 0.058µm to 0.362 ± 0.098µm, whereas at a polymer 
concentration of 4%(w/w), the range of fibre diameters produced were approximately 
twice the size at 0.538 ± 0.110µm to 0.631 ± 0.203µm. At a polymer concentration of 
4.0%(w/w), rate of delivery of 0.8 and 1.0mL/hr yielded significantly smaller fibre 
diameter (0.542 ± 0.163µm and 0.538 ± 0.193µm, respectively) within its 
experimental group (p<0.05). 
 
Although no statistical significance was observed in diameters of fibres electrospun at 
a polymer concentration of 3.0%(w/w) between 0.2 – 0.6mL/hr, the fibre diameters 
were significantly reduced by approximately 40 – 50% when the rate of delivery was 
increased to 0.8 – 1.0mL/hr (0.168 ± 0.045µm and 0.177 ± 0.039µm, respectively). 
Similar trends in fibre diameter were observed in fibres electrospun at polymer 
concentration of 4.0%(w/w). The fibre diameters produced at a rate of delivery of 0.2 
– 0.6mL/hr ranged between 0.530 ± 0.244µm to 0.631 ± 0.203µm, which decreased 
significantly with increased rate to 0.8 – 1.0mL/hr, yielding smaller fibre diameters 
within the range of 0.386 ± 0.181µm to 0.437 ± 0.107µm. 
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At a polymer concentration of 5.0%(w/w), the effects of varying the delivery rate of 
the polymer solution were similar to that seen in polymer concentration of 2.5 and 
5.0%(w/w), where the fibre diameters were the largest at rate of delivery of 0.2mL/hr 
(2.493 ± 0.106µm) and smallest at 1.0mL/hr (0.808 ± 0.055µm). There were no beads 
found at a polymer concentration of 5.0%(w/w) (Fig. 3.9a) but micron sized fibres 
were observed at this concentration. With the increase of the rate of delivery of 
polymer solution, the production of fibres was found to be quicker and the 
morphology of the fibres became more ribbon in shape (Fig. 3.9b).  
 
a 
Fig. 3.9. Representative SEM images of electrospun PLLA fibres. (a) E
grossly uniform without beads. The electrospinning parameters we
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At a polymer concentration of 7.5%(w/w), the rate of delivery of 0.4 – 1.0mL/hr 
produced fibre diameters ranging from 0.787 ± 0.059µm to 1.152 ± 0.067µm. 
However, the differences in fibre diameter at this range of rate of delivery (0.4 – 
1.0mL/hr) were not significant. At a rate of delivery of 0.2mL/hr, the fibre diameter 
was found to be significantly larger by 3 - 4 folds when compared to the rest of the 
rate of delivery at this polymer concentration. The accelerating voltage did not 
influence fibre production but the increase of rate of delivery increased the rate of 
fibre deposition. Fibres were also ribbon in shape and there were no beads on the 
fibres (Fig. 3.10). 
 
 
Fig. 3.10. SEM image of electrospun PLLA fibres. Fibres spun at this concentration yields 
micron sized fibres. Note the ribbon-like appearance of the fibres. Electrospinning parameters 
were set at a polymer concentration of 7.5%(w/w), 1.0mL/hr, 10kV and 10cm target distance.  
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3.3.2.5 Characterisation of Beads on Fibres 
The production of beads on fibres was also observed to be associated with the 
increase in the rate of polymer solution delivery. For this reason, fibres spun at 
various rates for polymer concentration of 2.5 – 4.0%(w/w) were examined for the 
possible correlation with the production of beads. This range of polymer 
concentration was selected to be analyse primarily because below a polymer 
concentration of 2.5%(w/w), fragmented fibres have been found; while above a 
polymer concentration of 4.0%(w/w), the fibre diameters were largely micron scale 
which were beyond the desired range of fibre diameter for this thesis. The number of 
beads produced, increased with the increase in the rate of polymer solution delivery 
up to a rate of 0.6mL/hr and then plateau thereafter (Fig. 3.11). An apparent trend was 
observed on the circularity of beads with the increase in polymer concentration. The 
circularity of beads decreases with increasing polymer concentration, however, this 
effect is statistically insignificant as indicated by the standard errors in the data (Fig. 
3.12). Further investigations will involve examining a larger sample size of 
electrospun fibres within this range polymer concentration. 
  
82 
Chapter 3: Structural Analysis of Native Cartilage and Parametric Study of Electrospinning 
 
 
0
50
100
150
200
0 0.2 0.4 0.6 0.8 1
Rate (mL/hr)
B
ea
d 
C
ou
nt
a 
 
0
50
100
150
200
250
300
0 0.2 0.4 0.6 0.8 1
Rate (mL/hr)
B
ea
d 
C
ou
nt
 
0
50
100
150
200
0 0.2 0.4 0.6 0.8 1
Rate (mL/hr)
B
ea
d 
C
ou
nt
Fig. 3.11. The effects of rate of delivery on beaded fibre production of
polymer concentrations: (a) 2.5%(w/w), (b) 3%(w/w) and (c) 4%(w/w).
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on fibres has been found to increase with increasing rate of polymer solution delivery up to a 
rate of 0.6mL/hr, and then appeared to plateau from 0.6 – 1.0mL/hr. 
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Fig. 3.12. The effects of polymer concentration 2.5, 3.0 and 4.0%(w/w) on circularity of 
beads on fibres electrospun at various rates of delivery of polymer solution. Blank, striped, 
and black bars represent polymer concentration 2.5, 3.0 and 4.0%(w/w) respectively. There is 
an apparent trend in the circularity of beads with an increase in polymer concentration. 
However, the effect was not statistically significant as illustrated by the error bars in this 
figure. (n = 3 – 280, as the number of beads produced were associated with the rate of 
delivery. See Fig. 3.11) 
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3.4 Discussion 
The first part of this chapter emphasised on the importance of recognising and 
understanding the nanoscaled fibrous collagenous architecture of the hyaline cartilage 
extracellular matrix. The structural characteristics of the cartilage ECM would form 
the “reference point” for the fabrication of a structurally biomimetic scaffold. The 
natural cartilage ECM has porosity in the range of 0.75 – 0.8. Its interfibrillar pore 
size has been reported to be approximately 2.0 – 6.5nm. This together with the 
presence of the proteoglycan network contributes to a very low permeability value in 
the range of 10-15 – 10-16m4/Ns(145). The second part of this chapter successfully 
characterised the key processing parameters of the custom-built electrospinning 
system, which are necessary for the fabrication of nanoscaled fibrous scaffolds for 
tissue regeneration. These processing parameters are also important for the control of 
scaffold fibre size, morphology and architecture.  
 
3.4.1 Structural Analysis of Human Native Hyaline Cartilage and 
Bovine Nasal Collagen  
The human hyaline cartilage provided insight into the morphology and fibre diameters 
of the collagenous framework in the natural ECM. The native cartilage collagen fibres 
have been reported to exhibit diameters ranging from 20nm to 300nm(26). Although 
both native human hyaline cartilage and reconstituted bovine collagen fibre diameters 
fall within the range of diameters reported in the literature, the difference in species 
may account for the difference in the fibre diameters. Another explanation to the 
difference in the diameters of the collagen fibres observed here is that the native 
human cartilage contains extracellular matrix materials which are predominantly 
polysaccharides that affect the average fibre diameter(146). The presence of 
polysaccharides in the native ECM may concentrate the collagen and promote their 
collision-induced interaction with subsequent fibril growth, resulting in larger 
diameters. The lack of polysaccharide macromolecules to inter-disperse the collagen 
molecules during self-assembly may have accounted for the lack of interfibrillar 
spaces (Fig. 3.4b). Nonetheless, the ability of collagen molecules to self-aggregate 
into fibrils has been observed(42). The typical cross striated appearance of collagen 
can be clearly seen upon self-assembly (Fig. 3.4b), which was not present on the 
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fragments of non-assembled collagen (Fig. 3.4a). The effects of changes in pH and 
temperature on self-assembly of collagen observed here confirmed the findings 
reported in other studies, where a neutral pH and temperature above 35°C would 
favour the self-assembly of collagen molecules into polymeric fibres(147). As 
outlined in Chapter 1, the nanoscaled features of the structural collagenous framework 
of the extracellular matrix are essential in promoting chondrocytic proliferation, 
differentiation and function(15;82). Thus, in order to produce a tissue scaffold which 
mimics the structural morphology and architecture of the native cartilage ECM, the 
electrospinning technique was employed. 
 
3.4.2 Parametric Study of Electrospinning 
To date, several studies have investigated the effects of various electrospinning 
parameters(53;111;112;117;118;148). However, our custom-built electrospinner 
required a systematic parametric study to characterise the effects of important 
governing parameters as our set-up may differ from that of other research centres. The 
electrospinning technique was successfully used in producing polymer fibres at 
nanoscale. Several parameters have been held constant relating to the set-up, i.e. the 
spinneret inner diameter is 0.51mm while the target distance was held at 10cm. 
Although the electrospinning process is a complex interplay between various 
parameters, the effects of the various parameters are discussed independently in the 
individual sections below. 
 
3.4.2.1 Effects of Type of Solvent 
The choice of solvent(s) for a given polymer is the first parameter to be considered for 
electrospinning. Several solution properties of a solvent will need to be considered, 
including its volatility, electrical conductivity and potential cytotoxicity. A highly 
volatile solvent with high electrical conductivity is generally required for 
electrospinning (Chapter 1). The DCM is a highly volatile solvent for PLLA, while 
pure DMF is a non-solvent. However, intrafibrillar pores were observed on the fibres 
that were electrospun using pure DCM. This observation was consistent with the 
results reported by Bognitzki et al. (Fig. 3.5a)(110). The formation of intrafibrillar 
pores is related to a rapid phase separation which is followed by a rapid evaporation 
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of volatile solvents and then a subsequent rapid solidification of the fibres, during the 
electrospinning process(110). The phase separation phenomenon, as its name implies, 
separates solvent rich regions from polymer rich regions. The solvent rich regions, on 
evaporation, result in the formation of pores. The addition of DMF, a less volatile 
solvent, reduced the rapid phase separation of the polymer and solvent as seen in the 
reduction in pores on fibres of electrospun PLLA (Fig. 3.5b and c). The rapid phase 
separation created pores on the fibres which will lead to an increase in surface area. 
An increase in surface area of the electrospun PLLA scaffolds can potentially 
contribute to an increased rate of fibre degradation by hydrolytic attack when 
immersed in culture media. However, the ability to generate pores may prove useful 
in protein adsorption, as well as other studies investigating the effects of surface 
properties and nanotopography on cell behaviour.  
 
Apart from the gradual reduction of pores, further addition of DMF up to a weight 
ratio of 7:3 resulted in fibres which were more uniform, smooth and beadless (Fig. 
3.5d). This can be explained from the fact that an addition of DMF to a polyester-
DCM solution increases the electrical conductivity as well as decreases the surface 
tension of the polymer solution(112;149). An increase in the electrical conductivity of 
a polymer solution during electrospinning induces a rise in self-repulsive charge 
within the electrospun polymer – therefore resulting in the elongation of the beaded 
segment. An increase in the solvent conductivity also yields fibres with smaller 
diameter due to a prolonged elongation of the electrospinning jet. A reduction in 
surface tension of the polymer solution further prevents the formation of beads. Thus, 
this may account for the reduction of beaded fibre formation with the addition of 
DMF in this study. This finding is consistent with previously reported 
studies(112;117;149).  
 
A low conductivity solution results in insufficient elongation of a jet by electrical 
force which is necessary to produce uniform fibres. When polymer macromolecules 
are dissolved in a solvent, they are orientated into an entangled network during the 
elongation flow of the electrospinning jet. This jet elongation persists as the fibres 
solidify. In a polymer solution with low conductivity, the contraction of the radius of 
the electrospinning jet, which is driven by surface tension causes the remaining 
solution to form beads(117). The addition of DMF to a DCM-based polymer solution 
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increases the conductivity therefore facilitates the electrospinning process in the 
production of fibres with smaller diameters and without beads. However, the potential 
cytotoxic effects of solvents need to be considered as a further increase in non-volatile 
organic solvents such as DMF may be detrimental to cells. The DCM:DMF weight 
ratio of 7:3 as a solvent for PLLA has been found to be safe for cell culture(102). 
Excessive non-volatile solvent which remains in the fibres may also dissolve the 
underlying fibres yielding fused fibres and junctions resulting in a more rigid or 
collapsed scaffold(101;107).  
 
The solvent combination weight ratio of 7:3 of DCM to DMF has been selected for 
subsequent studies in this chapter, as it produces fibres without pores. Nonetheless, 
the production of smooth, uniform, beadless and nanoscale fibres also depend on the 
interplay of several other processing parameters of electrospinning as discussed 
below. 
 
3.4.2.2 Effects of Polymer Concentration 
Apart from the choice of solvents, two other important parameters of an 
electrospinning polymer solution to be considered are the molecular weight of the 
polymer and the polymer concentration. Both parameters have been considered to be 
the most effective parameters in controlling the electrospun fibre diameter and 
morphology(64;101;112;118;150). The molecular weight reflects the length of a 
polymer. In the case of a poly(α-hydroxyester) such as the PLLA, the linear 
molecular structure resembles the configuration of a chain. At a given polymer 
concentration, the number of chain entanglements increases with the length of the 
polymer (i.e. the molecular weight); alternatively, the same number of entanglements 
can be achieved at a fixed molecular weight by increasing the polymer concentration. 
Chain entanglements have been described as the physical overlapping between 
polymers, thus resulting in the interlocking of chains. In electrospinning, sufficient 
chain entanglements are required to overcome the effects of surface tension for the 
formation of fibres(112;151;152). For the formation of a stabilised electrospinning jet, 
it has been reported that more than 2.5 entanglements per chain is required(151). The 
molecular weight of the PLLA selected for electrospinning in this study was set at 
300kDa, similar to the “high molecular weight PLLA” studied by Tan et al.(112). 
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The results described above (Fig. 3.6 and 3.7) showed that the diameters of 
electrospun fibres increased with increasing polymer concentration. The minimum 
polymer concentration to effectively electrospin uniform fibres was found to be at a 
polymer concentration of 2.5%(w/w) with an average diameter of 220 ± 13nm, which 
was comparatively lower than that reported by Tan et al. at polymer concentration of 
3.5%(w/w) with fibre diameter of 322nm(112). Fibres electrospun below a polymer 
concentration of 2.5%(w/w), appeared fragmented and contained electrosprayed 
droplets. These fragmented fibres may not be suitable for use as tissue scaffolds 
despite its nanoscaled mean diameter ranging from 70 - 150nm. The transition 
observed between the production of fragmented fibres and electrospraying droplets to 
the formation of uniformly smooth fibres with increasing polymer concentration, 
demonstrated the role of chain entanglement with the increase in polymer 
concentration.  
 
The production of beaded fibres was observed at polymer concentration of 2.5, 3.0 
and 4.0%(w/w) but the amount of beads was also dependent on the rate of delivery of 
the polymer solution (see discussion below on the rate of delivery). The formation of 
electrospun beaded fibres largely depends on solution viscosity, net charge density 
and surface tension of the solution(117). Changing the polymer concentration alters 
the solution viscosity. A higher polymer concentration and net charge density would 
reduce the surface tension as well as encourage the elongation of a polymer jet – thus 
favouring the production of beadless fibres. At a low polymer concentration, surface 
tension on the other hand predominates – favouring the formation of beaded fibres. 
Thus, in this study, the predominance of surface tension may account for the beaded 
fibre morphology at polymer concentration of 4.0%(w/w) and below; while above a 
polymer concentration of 4.0%(w/w), uniform bead-free fibres were observed at 
polymer concentrations of 5.0 and 7.5%(w/w). In the study reported by Tan et al., the 
minimum polymer concentration to achieve bead-free fibres was at a polymer 
concentration of 4.5%(w/w) which was lower but relatively in agreement with our 
findings[polymer concentration of 5.0%(w/w)](112). The surface tension at a polymer 
concentration of 2.5%(w/w) can also account for the higher bead circularity (closer to 
1, indicating a circular-shaped bead) as compared to the lower bead circularity (closer 
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to 0, indicating a more spindle-shaped bead) at a higher polymer concentration of 
4.0%w/w, at a given rate of delivery (Fig. 3.11).  
 
The fibre morphology has been found to change from circular to ribbon-shaped as 
seen with the increase in polymer concentration from 2.5 to 5.0%(w/w). The fibres 
electrospun at a polymer concentration of 7.5%(w/w) consisted entirely of ribbon-
shaped fibres which may account for its plateau or dip as well as the larger standard 
deviation in diameter measurements on Fig. 3.6 and 3.7, as averages of the widths and 
heights of the fibres were taken. Ribbon-like fibre morphology is caused by the rapid 
solvent evaporation during electrospinning, resulting in the collapse of the polymer 
fibre with intact polymer “skin” as described by Koombhongse et al.(153) (Fig. 3.13). 
As a whole, the effects of polymer concentration on the fibre diameter and 
morphology presented in this chapter were in agreement with previously reported 
studies(101;112;117;150;151;154). 
 
 
Fig. 3.13 Schematic illustration of formation of ribbon-shaped fibres during electrospinning. 
Rapid phase separation during electrospinning results in collapse of the polymer 
fibre(107;153). 
 
3.4.2.3 Effects of Accelerating Voltage 
The accelerating voltage is a crucial factor for the initiation of electrospinning of a 
polymer solution. A high voltage supply is required to induce the necessary coulomb 
self-repulsive charges in the polymer solution and to generate an external electric 
field, in order to overcome the surface tension forces of the electrospinning solution. 
In general, an accelerating voltage of approximately 6kV is sufficient for the 
formation of a polymer solution Taylor Cone as well as jet initiation(101;152). The 
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initiation of electrospinning jets in this study was observed at a similar accelerating 
voltage of approximately 6kV. In theory, after the initiation of the electrospinning jet, 
further increase in the accelerating voltage would increase the coulomb repulsive 
forces at the surface of the initial polymer solution, thus resulting in more polymer 
solution being removed in the electrospinning jet, leading to an increase in jet 
diameter(150;152). This may explain the initial increase in fibre diameter as observed 
when the accelerating voltage was increased to 10 - 15kV at polymer concentration of 
2.5, 3.0, 4.0, 5.0 and 7.5%(w/w). 
 
A further increase in the accelerating voltage would result in a further amplification in 
the charges on the electrospinning jet, leading to a further enhancement of the 
coulomb self-repulsive force. This coulomb self-repulsive force further accentuates 
the whipping instability as well as the elongation of the jet, hence thinning the 
electrospun fibre as it “whips” through mid-air en route to the collector(155-157). 
This may account for the decrease in fibre diameters observed from accelerating 
voltage of 15 to 20kV, at polymer concentrations 3.0 – 7.5%(w/w). At this point, 
when additional increase of accelerating voltage causes the coulomb self-repulsion 
forces to greatly exceed the forces of surface tension - multiple jets of fibres split 
from the main electrospinning jet, yielding fibres with smaller diameter but may lack 
uniformity(112;150). This may account for the smaller fibre diameters observed at 
polymer concentrations of 5.0 and 7.5%(w/w) electrospun at an accelerating voltage 
of 25kV. The findings of the effects of accelerating voltages on electrospun fibre 
diameters were consistent with previously reported studies(150;155;156;158).  
 
As mentioned earlier, at a lower polymer concentration of 1.0 - 1.5%(w/w), higher 
accelerating voltages of 20 to 25kV result in the electrospraying of the polymer. 
Electrospraying occurs when the polymer concentration is too low to allow sufficient 
polymer chain entanglement, coupled with the dominance of surface tension as a 
result of a relatively high solvent to polymer content. Consequently droplets of the 
polymer break away from the initial electrospinning jet when a sufficient accelerating 
voltage is received(101). Several electrospinning studies have reported a positive 
correlation between accelerating voltage and the production of beads. This may be 
due to an increased instability of the jet when the Taylor Cone is receded into the 
spinneret as a result of excessive removal of polymer solution during 
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electrospinning(101;118;150). However, the increase in accelerating voltage in this 
study did not significantly influence the production of beads on fibres, which was 
consistent with data reported by Zuo et al.(157). 
 
As a whole, although alterations in fibre diameters were observed with a change in 
accelerating voltage, the effects on fibre diameters were less significant compared to 
that of polymer concentration. This was in agreement with the findings of several 
previous studies(112;158-160). 
 
3.4.2.4 Effects of Rate of Delivery of Polymer Solution 
The rate of delivery of the polymer solution governs the amount of solution available 
to maintain the Taylor Cone for electrospinning, hence the production of fibres. The 
interplay between the supply of polymer solution to the tip of the spinneret (governed 
by the rate of delivery) and the removal of polymer solution during electrospinning 
(controlled by the accelerating voltage) will need to be balanced for the production of 
uniform beadless fibres. At a given accelerating voltage, an increase in the rate of 
delivery during electrospinning would result in an increase in the volume of polymer 
solution drawn towards the target collector. Consequently, there may be a 
corresponding rise in fibre diameter and bead production(118;157). Nonetheless, 
some studies have reported the insignificant effect of the rate of delivery on the final 
fibre size and morphology(112). In this chapter, several observations were made on 
varying the rate of delivery of the polymer solution.  
 
First of all, the diameters of fibres of polymer concentration of 1.5, 2.5, 5.0 and 
7.5%(w/w), produced at 0.2mL/hr were significantly high compared to those 
electrospun between 0.4 – 1.0mL/hr. As described in the results section, at polymer 
concentration of 2.5 – 7.5%(w/w), the diameter of fibres electrospun at 1.0mL/hr were 
significantly decreased compared to the rate of delivery between 0.2 – 0.8mL/hr. No 
significant changes in fibre diameters were observed between the 0.4 – 0.8mL/hr rates 
of delivery. Contrary to the findings reported in previous studies(112;118;152), the 
increase in the rate of delivery primarily decreased the fibre diameter. This could be 
related to the fact that at higher rate of delivery, more polymer solution was carried by 
the electrospinning. Initially, the solvent on the surface of the jet evaporates leaving 
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behind a “polymer skin” which still holds some polymer solution within its core. As 
the jet travels further in mid-air, more solvent from the core is evaporated therefore 
causing a greater collapse of the entire jet leading to a further contraction in the fibre 
diameter.  
  
By increasing the rate of delivery, an increase in the rate of fibre production was 
observed but at the expense of producing beaded fibres. This can be explained by the 
fact that an increase in the rate of polymer solution delivery would “dilute” the charge 
density applied at a constant accelerating voltage(161). This would lead to a reduction 
in self-repulsive forces necessary for the elongation of the jet during electrospinning. 
As a result, surface tension would predominate, causing the formation of beads. This 
proportional increase in beaded fibres with the increase in the rate of delivery is 
consistent with the currently reported studies(118;157). The effects of the surface 
tension on the morphology of the beads can be seen from the decreasing trend in 
circularity with increasing polymer concentration. The trend in bead circularity 
demonstrated in this chapter is in keeping with the results reported by Lee et al.(154).  
 
In this study, an increase in the rate of delivery from 0.6mL/hr also increases the size 
of material plug accumulated at the tip of the needle. The accumulation of polymer 
plug was observed especially at polymer concentration of 5.0%(w/w) and above. 
These plugs frequently clogged the flow of the polymer solution and required frequent 
manual removal of plugs. This resulted in wastage of the polymer material and 
disruption to the electrospinning process. The rate of delivery at 0.2 - 0.4mL/hr may 
be an ideal parameter for the fabrication of electrospun PLLA scaffold for further 
tissue engineering studies in this thesis.  
 
3.4.2.5 Effects of Type of Collector 
The aluminium rods of the mandrel have been used to collect fibres spun at a PLLA 
concentration of 2.5%(w/w) and above. The space between the rods makes the 
collection of the fibres for SEM simple without disrupting the fibres. Materials spun 
at a polymer concentration below 2.5%(w/w) were collected directly onto glass cover 
slips mounted flat aluminium plate. This was to ensure that fibres as well as 
electrosprayed droplets were collected. The aluminium rods aligned the fibres 
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perpendicular to the rods while the fibres deposited on the glass cover slip were 
randomly aligned. Although both types of collectors ensured adequate collection of 
fibres in this parametric study, further modifications to the collector will need to be 
made in order to produce scaffolds for tissue culture at a larger scale. To produce 
sufficient scaffolds, the diameter of the rotating mandrel will need to be increased 
(from the current 12cm to approximately 30cm) to increase the catchment area. 
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3.5 Conclusion 
The first aim of this chapter was to examine the structural features of the hyaline 
cartilage extracellular matrix. The human hip articular cartilage, together with the 
reconstituted bovine nasoseptal collagen provided insight to the nanoscaled 
architecture of cartilage tissue. The understanding of the structural organisation and 
self-assembly properties of the native cartilage gathered in this chapter formed the 
basis for the fabrication a structurally mimetic tissue scaffold for cartilage 
regeneration. The electrospun nanofibrous scaffold produced in this study appear to 
resemble the structural features seen in the native human cartilage (Fig. 3.14).  
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fibre production and to a certain extent the fibre size. An increase of rate of delivery 
was also correlated with the production of beaded fibres. The target distance of 10cm 
ensures adequate deposition and collection of fibres while the type of collector affects 
the alignment of fibres. From this study, the optimal range of parameters required to 
produce uniform, and bead-free nanoscaled electrospun PLLA fibrous scaffold have 
been determined (Table 3.1). With the use of our electrospinner, operated at the 
optimal range of parameters determined in this chapter, a structural biomimetic tissue 
scaffold can be fabricated for further tissue engineering studies in this thesis.  
 
PLLA molecular weight 300kDa 
Type of solvents and ratio DCM:DMF, 7:3 
Polymer concentration 2.5 - 4.0%(w/w) 
Target distance 10cm 
Rate of delivery 0.2 - 0.4mL/hr 
Accelerating voltage 10 – 15 kV 
Type of collector Dependent on the desired fibre alignment  
 
Table 3.1. Current optimal electrospinning parameters determined for the fabrication of 
PLLA fibrous scaffolds using the in-house built electrospinner. This set of parameters will 
form the key processing parameters in the fabrication of PLLA scaffold for subsequent 
chapters of this thesis.  
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Chapter 4  
Biofunctionalised Electrospun Scaffolds with 
Cell-mediated TGF-β1 Activation: In-vitro Study 
4.1 Introduction 
Growth factors are one of the most vital bioactive cues in providing the appropriate 
regulatory signals to promote proliferation, maintain differentiation and induce matrix 
production(19;162). However, in-vivo applications of growth factors for tissue 
regeneration is still impractical due to their short half-lives and uncontrolled-dose 
related adverse effects(142) (Chapter 1, Section 1.7). As a result, attempts in tissue 
engineering have been made to incorporate growth factors into scaffold delivery 
systems to overcome these challenges(50;79;142). Growth factors such as fibroblast 
growth factor-2 (FGF-2), transforming growth factor- β1 (TGF-β1), platelet-derived 
growth factor (PDGF) and insulin-like growth factor 1 (IGF-1) are well known for 
their proliferative and anabolic effects in cartilage tissue engineering(17;19;162-165). 
Among these growth factors, TGF-β1 has been selected for this study for its broad 
spectral chondrogenic multi-regulatory roles such as inducing cell proliferation, 
maintaining chondrogenic differentiation, and promoting extracellular matrix (ECM) 
production(166;167). TGF-β1 is a growth factor that is secreted by chondrocytes and 
most cell types. Therefore successful TGF-β1 research outcomes may be transferable 
to other fields of tissue engineering. 
 
In the native cartilage ECM, the TGF-β1 is secreted by chondrocytes in its latent 
form(168). The latent TGF-β1 consists of a mature (active) TGF-β1 and its pro-
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peptide which is also known as the latency-associated peptide (LAP)(166;169) (Fig. 
4.1). The LAP consists of two 249-residue polypeptide chains, dimerised by two 
disulphide bonds at cysteine-223 (Cys-223) and Cys-225 positions(170;171). The 
LAP associates with the mature TGF-β1 by non-covalent interactions, forming the 
latent TGF-β1 complex, also known as small latent complex (SLC). The SLC is then 
bound to the latent TGF-β1 binding protein (LTBP) forming the large latent complex 
(LLC) which is covalently anchored to the ECM. This complex formation between 
SLC and LTBP is mediated by an intramolecular disulphide exchange between the 
third 8-cysteine (8-Cys-3) domain of LTBP with a pair of Cys-33 residues of 
LAP(170;171) (Fig. 4.1).  
 
The LAP-TGF-β1 association preserves the bioactivity of the growth factor. The half-
life of the latent TGF-β1 of rats has been reported to be greater than 100 minutes as 
opposed to the short 2 - 3 minutes of the active form(172). Therefore in the native 
ECM, the latent TGF-β1 complex acts as a “storage” for the growth factor(173). The 
activation of TGF-β1 involves the disruption of the non-covalent interaction between 
the LAP and TGF-β1. There are several mechanisms known to activate the latent 
TGF-β1. These include proteases, thrombospondin-1, low pH and reactive oxygen 
species(166;169;174). The LAP also possesses two RGD sequences which when 
attached to a cell, activates the TGF-β1(169). 
 
In general, TGF-β1 has a growth stimulating effect on mesenchymal cells, whereas in 
epithelial and endothelial cell origin the effects on growth have been found to be 
inhibitory(174). Although the use of TGF-β1 in various studies has been shown to 
positively regulate osteogenesis, angiogenesis and chondrogenic proliferation and 
differentiation, its multipotency has its own drawbacks. The cell response varies 
depending on the dosage level, length of exposure and the target tissue(174). A 
prolonged exposure and excessively high dose of TGF-β1 may result in pathological 
conditions such as extensive fibrosis, hypertrophic scarring and formation of 
osteophytes(174-176). These adverse reactions may be counter productive in the 
development of a functional biological tissue replacement. Therefore, it would be 
highly beneficial to design a system capable of inducing cell-mediated TGF-β1 
activation. The novel tissue engineering strategy proposed in this thesis is to 
incorporate the latent TGF-β1 onto an electrospun scaffold system, therefore allowing 
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cells to sense and activate the TGF-β1 as required. For this reason, the proposed 
biofunctionalisation strategy is to anchor the entire latent TGF-β1 complex onto the 
electrospun scaffold. To date, little is known about the effects of using the latent TGF-
β1 complex as a cell-mediated bioactive cue.  
 
In this chapter, two techniques of scaffold biofunctionalisation are described. The 
techniques involved initial scaffold surface modification using ammonia plasma, with 
or without the addition of a heterobifunctional crosslinking agent, sulfosuccinimidyl-
4-(N-maleimidomethyl) cyclohexane-1-carboxylate (sulfo-SMCC). The combined 
effects of the nanoscale scaffold fabrication and subsequent biofunctionalisation with 
latent TGF-β1, on cell behaviour are reported here using primary human nasal 
chondrocytes for cartilage regeneration applications. 
 
 
Fig. 4.1. Schematic representation of the natural occurrence of the latent TGF-β1 complex in 
the native ECM. The latent TGF-β1 (LTGF) is attached to the latent TGF-β binding protein 
(LTBP) which is anchored to the ECM(169). The latency associated peptide (LAP) offers 
protection and “stores” the active TGF-β1. The 3D protein structure of the active TGF-β1 was 
obtained from the RCSB Protein Databank (PDB 1KLC). The visual molecular dynamic 
(VMD) model of the TGF-β1 molecule (yellow, white, turquoise) were rendered using VMD 
software(177) (University of Illinois, USA). 
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4.2 Materials and Methods 
4.2.1 Scaffold Fabrication by Electrospinning 
The non-woven PLLA fibrous scaffolds were electrospun using our custom built 
electrospinner as described in Chapter 3. Briefly, 3.0%(w/w) PLLA (Mw~300kDa, 
Purac Biochem, UK) dissolved in dichloromethane/dimethylformamide [70:30(w/w)] 
(AGTC Bioproducts, UK) was electrospun at 0.4mL/hr, 10kV and 10cm target 
distance. 
 
The electrospun scaffolds were then sectioned using a sterile scalpel (Blade No.22, 
Swann-Morton, UK) into 1.5 × 1.5cm2 and 4 × 4cm2 squares prior to the sterilisation 
procedure. They were sterilised by ultraviolet irradiation in a sterile laminar flow 
hood for 30 minutes, followed by rinsing in 70%(v/v) ethanol solution. A portion of 
the scaffolds were rinsed in sterile PBS, and used as a control for physical and 
biological characterisation of scaffolds (see below) while the remaining portion were 
allowed to dry in the sterile cell culture hood. The scaffolds were then ready for 
subsequent surface modification using ammonia gas plasma. 
 
4.2.2 Biofunctionalisation of Scaffolds  
4.2.2.1 Surface Modification of Electrospun Scaffolds by Plasma 
Treatment  
The electrospun PLLA 3.0%(w/w) scaffolds were treated with ammonia gas (NH3) 
plasma using a plasma instrument (Plasprep 5, Gala Instrumente, Germany). The 
treatment process was performed at a range of exposure times (2, 5 and 10 mins) and 
powers (10 - 100W), while the pressure was kept constant at 2.0mbar. Surface 
chemical analyses were performed using X-ray photoelectron spectroscopy (XPS) and 
ninhydrin assay to identify incorporated surface amine groups.  
 
4.2.2.2 Biofunctionalisation of Scaffold with Latent TGF-β1 Complex 
In order to evaluate the growth factor bioactivity of as a result of the orientation of the 
latent TGF-β1, two different immobilisation strategies were performed to incorporate 
the latent complex onto the electrospun scaffolds. The first technique anchors the 
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latent TGF-β1 at non-specific sites of the LAP (random immobilisation) while the 
second crosslinks the latent TGF-β1 complex at a specific predicted site, cysteine-33 
(Cys-33) position of the LAP (Fig. 4.1), using sulfo-SMCC (orientated 
immobilisation). 
 
For the random immobilisation of the recombinant human latent TGF-β1 (R&D 
Systems, UK) onto the PLLA scaffolds, freshly prepared NH3 plasma-treated PLLA 
scaffolds were immediately immersed in latent TGF-β1 solution (0.75µg/mL in PBS) 
for 2 hours at room temperature (Fig. 4.2). The supernatant was removed and the 
scaffold rinsed three times with sterile PBS.  
 
For oriented immobilisation of the latent TGF-β1 (0.75µg/mL), the surface amine 
groups of the scaffolds were covalently linked to the cysteine residues of the latent 
TGF-β1 using sulfo-SMCC (Sigma, UK) as a heterobifunctional crosslinker (Fig. 
4.2). The N-hydroxysuccinimide (NHS) end of this reagent typically couples to 
molecules containing primary amines, corresponding to the surface amine groups on 
plasma treated PLLA scaffolds, by formation of stable amide bonds at pH 7. The 
maleimide end of sulfo-SMCC couples specifically with free sulfhydryl groups by 
thioether linkage at pH 6.5 - 7.0. The latter reaction was predicted to occur between 
the cys-33 residue of LAP and the maleimide end of sulfo-SMCC.  
 
Briefly, plasma treated PLLA samples were rinsed gently three times with sterile PBS 
to ensure the removal of unwanted free radicals generated from the plasma treatment. 
The scaffolds were then immersed in a 3mg/mL sulfo-SMCC solution in distilled 
water and left to react for 2 hours under agitation (orbital shaker) in a sterile cell 
culture cabinet. The supernatant was discarded and the scaffolds were rinsed three 
times with sterile PBS. The maleimide treated scaffolds were then immersed in a 
solution of recombinant latent TGF-β1 (0.75µg/mL) in sterile PBS for 2 hours. The 
supernatant was removed and the scaffold rinsed three times with sterile PBS. Finally, 
both types of biofunctionalised scaffolds were then placed in respective cell culture 
well plates for cell seeding. 
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Fig. 4.2. Schematic illustration of both random and orientated biofunctionalisation of PLLA 
scaffolds with latent TGF-β1, following ammonia plasma surface modification and chemical 
modification with sulfo-SMCC. 
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4.2.3 Characterisation of Biofunctionalised Scaffolds 
4.2.3.1 Surface Chemistry Analyses using XPSa and Ninhydrin Assay 
X-ray photoelectron spectroscopy (XPS) is a quantitative spectroscopic technique for 
surface chemical analysis. It can used to characterise elemental composition and 
chemical of a polymer surface. The depth of analysis has been reported to be typically 
less than 10nm from the surface. 
 
In an ultra-high vacuum environment, the XPS utilises monochromated x-rays to 
excite core electrons of atoms in a sample. This leads to the ejection of electrons 
(photoelectrons) which have characteristic kinetic energy that are unique to the 
elements of the sample. The photoelectrons are then received by a detector and their 
characteristic kinetic energies are analysed. Since it is the binding energy of electron 
in the sample which is the important physical parameter, the spectrometers are 
programmed to convert the kinetic energies of emitted electrons and present the 
results in the form of binding energies. The binding energy can be derived from the 
emitted kinetic energy using the equation below: 
 
EK = hv – EB – φSP         (4.1) 
 
Where EK is the measured kinetic energy of the emitted electron, hv is the energy of 
the exciting X-ray photon, EB is the electron binding energy in the sample and φSP is 
the work function of the spectrometer (~5eV)(178;179). 
 
In the field of biomedical and tissue engineering, the XPS has been used to 
characterise various surface modified biomaterials and protein adsorption on 
surfaces(180-182). By providing the essential information on elemental composition 
and chemical state, approaches to surface engineering technologies can be optimised. 
In this thesis, the XPS technique was performed to characterise the effects of 
ammonia plasma surface modification of the electrospun scaffolds. 
 
                                                 
a The XPS analysis and data processing was performed by Ms. Emily Smith at the Centre for Surface 
Chemical Analysis, University of Nottingham. The processing protocol and results described in this 
chapter are based on the report of analysis provided by Ms. Smith (report no.:08-015). 
103 
Chapter 4: Biofunctionalisation of Electrospun Scaffolds – In-vitro Study 
 
XPS spectra of the surface modified samples and control were acquired on a Kratos– 
AXIS ULTRA DLD X-ray Photoelectron Spectroscopy Instrument using a mono-
chromated Al kα X-ray source (1486.6eV) operated at 10mA emission current and 
10kV anode potential – 100W. A photoelectron analyser take-off angle of 90° with 
respect to the sample surface was used. All measurements were taken under vacuum 
(3 x 10-9 Torr). The high resolution scans were charge corrected to the main C 1s peak 
(285eV) and then quantified to compare the amounts of each element present, using 
Kratos sensitivity factors(183). Components were fitted under the peaks to give 
chemical information. Data analysis was carried out using CASAXPS software with 
Kratos sensitivity factors to determine atomic percentage (%) values from the peak 
areas. 
 
Ninhydrin (2,2-Dihydroxyindane-1,3-dione) is a chemical used to specifically 
determine the presence of primary amine groups. The reaction of ninhydrin with 
primary amine groups produces a dark blue (Rheumann’s Blue) colour. The assay was 
performed as previously described(184;185) to quantitatively detect the amount of 
amine groups on the ammonia plasma surface modified PLLA scaffolds. Briefly, the 
scaffolds and controls were immersed in 1M ninhydrin solution for 1 minute in glass 
vials. The vials were then heated up to 80°C for 15 minutes to accelerate the reaction 
between ninhydrin and the amine groups on the scaffolds. The ethanol component 
was allowed to evaporate under reduced pressure for a further 15 - 20 minutes. After 
the removal of the adsorbed ethanol, the scaffolds were dissolved in 5mL of 1,4-
dioxane. The absorbance was measured at 570nm on a UV-vis spectrophotometer 
(Lambda 25, Perkin Elmer, USA). A calibration curve was obtained using glycine 
standards (Fig. 4.3, please see Appendix 1.6 for protocol). 
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Fig. 4.3. Glycine standard curve for ninhydrin assay. The R2 value was 0.9984. 
 
 
4.2.3.2 Quantification of Latent TGF-β1 on Scaffolds using an 
Immunoassay 
The quantification of the immobilised latent TGF-β1 was performed on 
biofunctionalised scaffolds and compared to controls (Table 4.1) using a modified 
procedure described previously(168). The latent TGF-β1 biofunctionalised scaffolds 
were initially digested with 0.3U/mL of plasmin (Sigma-Aldrich, UK) in phenol free 
DMEM for 3 hours at 37°C to release the latent TGF-β1 from the scaffold. The 
reaction was stopped by the addition of aprotinin (Sigma-Aldrich, UK) to a final 
concentration of 5µg/mL. The supernatant was then collected and subjected to 
acidification with subsequent neutralisation. This was performed to release the active 
TGF-β1 from the latent complex. Briefly, 20µL of 1N HCl was added to every 100µL 
of supernatant and incubated at room temperature for 10 minutes. The acidified 
samples were then neutralised (pH 7.2 - 7.6) by adding 1.2N NaOH/0.5M HEPES. 
Subsequently, quantification of the activated TGF-β1 using Quantikine Human TGF-
β1 Immunoassay (R&D Systems, UK) was performed as per manufacturer’s protocol. 
The standard curve for the quantification of TGF-β1 was generated as per 
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manufacturer’s protocol (Fig. 4.4). The amount of TGF-β1 released from the latent 
TGF-β1 biofunctionalised scaffolds were calculated using this standard curve. 
  
Sample ID Description 
PLLA Untreated electrospun scaffolds as control 
ptPLLA Plasma treated electrospun scaffolds as control 
TGF Plasma treated electrospun scaffolds with media supplementation of 
10ng/mL of TGF-β1 for up to 7 days 
pLTGF 
 
Plasma treated electrospun scaffolds with immediate random 
immobilisation of latent TGF-β1 
SMC Plasma treated electrospun scaffolds modified with sulfo-SMCC  
sLTGF Plasma treated electrospun scaffolds modified with sulfo-SMCC and 
conjugated with latent TGF-β1 (orientated immobilisation) 
Table 4.1. Experimental groups and their sample identification (ID). These sample ID will be 
used to refer to respective groups throughout the study.  
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Fig. 4.4. Standard curve of Quantikine TGF-β1 immunoassay with an R2 value of 0.9889. The 
curve was achieved as per manufacture’s protocol. 
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4.2.3.3 Cell Culture 
Human primary nasal septal chondrocytes used in this study were kindly provided by 
Dr. Reza Ghazanfar (Imperial College London, UK). The chondrocytes were 
expanded up to third passage in chondrocytic growth media (CGM) consisting of 
DMEM (41966, Gibco, UK) supplemented with 2mM L-glutamine (Gibco, UK), 
1%(v/v) non-essential amino acid (Gibco, UK), antibiotics-antimycotics (Gibco, UK) 
(100 U/mL penicillin, 1000U/mL streptomycin, 0.25µg/mL AmphotericinB), 
50µg/mL L-ascorbic acid (Sigma, UK) and 10%(v/v) fetal bovine serum (Gibco, UK). 
The cells were maintained at 37°C in a humidified 5% CO2 atmosphere. The culture 
media was replaced every 3 days. Cells were then harvested and seeded on to 1.5 × 
1.5cm2 scaffolds (see Table 5.1) for all biological assays at a seeding density of 9000 
cells/cm2. For the gene expression studies, samples were seeded at 3.125 × 
104cells/cm2 on 4 × 4cm2 scaffolds. Approximately 5 × 105 cells were snap-frozen and 
used as day-0 specimen for gene expression analysis. 
 
In order to evaluate the true effects of the latent TGF-β1 biofunctionalised scaffolds in 
chondrocytic cell culture without the influence of any other growth factors, serum-
free media(165;186) was used throughout the experiment. The serum-free media 
consisted of CGM supplemented with 100nM dexamethasone (Sigma, UK), ITS+ 
premix (BD Bioscience, UK) (diluted for final concentrations of 6.25µg/mL insulin, 
6.25µg/mL transferrin, 6.25µg/mL selenious acid, 1.25mg/mL bovine serum albumin, 
5.33µg/mL linoleic acid), but without fetal bovine serum. Serum-free media was 
replaced every 3 days. Cells cultured on plasma treated scaffolds (TGF experimental 
group) received an additional 10ng/mL of human recombinant TGF-β1 (R&D 
Systems, UK) supplementation for up to 7 days and were used as a control. The cell-
scaffold constructs were collected at 1, 7 and 14 days for evaluation of cell viability, 
metabolic activity and gene expression.  
 
4.2.3.4 Cell Viability Assay 
Cell viability was assessed using the LIVE/DEAD® Viability/Cytotoxicity Kit 
(Molecular Probes, Netherland). The assay was performed on days 1, 7 and 14. At 
each of time point, samples were rinsed gently with warm sterile PBS (Gibco, UK) 
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prior to the incubation with the Live/Dead solution (2µM calcein-AM and 4µM 
ethidium homodimer-1) at room temperature in the dark for 30 minutes. The cell-
scaffold constructs were analysed by fluorescence microscopy using an Olympus BX-
51 reflected fluorescence microscope equipped with Olympus DP070 colour digital 
camera and Olympus DP Controller software (Olympus UK Ltd., UK) for analysis. 
Intracellular esterase activity in live cells converts calcein AM into fluorescent green 
calcein (495 - 515nm), which is then retained within the cells. Ethidium homodimer-1 
only enters dead cells with ruptured cell membranes, and undergoes a 40-fold 
enhancement of fluorescence upon binding to their DNA causing the nuclei of the 
dead cells to fluoresce red (495 - 635nm). The dyes are virtually non fluorescent 
before interacting with the cells. The fluorescence microscopy images were taken 
from two samples with triplicate images. The number of viable cells (green) and dead 
(red) cells was counted. Cell viability was then calculated as a percentage average of 
live cells over total number of cells (green + red) and presented as mean percentage ± 
standard deviation.  
 
4.2.3.5 Cell Metabolic Activity Assay  
The effects of the various scaffolds on cell proliferation was assessed using the 
CellTiter 96™ Aqueous One Solution Cell Proliferation Assay (Promega, UK) (186). 
The cell proliferative activity is determined colorimetrically using tetrazolium 
compound MTS [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium] which is bio-reduced in mitochondria of metabolically 
active cells into coloured formazan product that is soluble in tissue culture medium. A 
higher absorbance indicates a higher metabolic activity may be associated with 
proliferation of cells. The assay was performed on days 1, 7 and 14. Briefly, the 
samples (cell-scaffold constructs) were transferred to new well plates and rinsed 
gently in sterile PBS (three times). The samples were then incubated with 400µL 
phenol red free DMEM plus 80µL of CellTitre 96 reagent, for 4 hours, at 37°C in a 
humidified 5% CO2 environment. Aliquots of the supernatant (100µL) were 
transferred to 96-well plates in triplicate and optical density was measured at 490 nm 
using a microplate reader Anthos 2020 (Biochromo Limited, UK). A sample 
incubated under the same conditions in the absence of cells was used as a blank. After 
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the readings were obtained, all samples were rinsed gently with PBS (three times), 
and then resuspended in 400µL sterile deionised water. All samples were then 
subjected repeated freeze-thaw cycles for DNA extraction. DNA content was 
quantified using the ND-1000 UV-Vis Spectrophotometer (Nanodrop®, USA). The 
experiment was performed in triplicate and the results, normalised to DNA content, 
were presented as percentage averages ± standard deviation. 
 
4.2.3.6 Real-Time Reverse Transcriptase Polymerase Chain Reaction 
(RT-PCR) 
PCR is a technique used to replicate and amplify any nucleic acid sequences. It 
consists of repetitive cycles of initial thermal separation of DNA chains (also known 
as denaturation, typically at 94°C) to provide templates for subsequent enzymatic 
propagation of complimentary deoxynucleotides binding. These complimentary 
binding of deoxynucleotides are initiated at an annealing temperature (typically 40 - 
72°C), by a short synthetically produced DNA sequence called a primer. A DNA 
polymerase then attaches specific nucleotides to the primer according to base pairing 
rules(187). This step replicates the DNA segment of interest. The entire process is 
then repeated to thermally separate the replicated segment from the template DNA, 
which subsequently becomes a template itself. This leads to an amplification of the 
desired segment of DNA following several repetitive cycles.  
 
Since the invention of PCR in 1983, the technique has undergone a series of 
evolutionary development which gave rise to the RT-PCR. The advent of RT-PCR 
meant that the identification and quantification of a specific RNA transcript can be 
achieved with a small amount of starting material. As its name implies, a reverse 
transcriptase (also called RNA-dependent DNA polymerase) synthesises a 
complimentary chain of DNA using the same process described above(187;188). The 
complimentary DNA (cDNA) is then used for subsequent amplification and 
quantification of genes.  
 
The increasing importance of genetic quantification and profiling in scientific 
research and medical diagnostics has led to the development of quantitative real-time 
RT-PCR technologies - in terms of chemistry and automated instrumentation. The 
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term real-time refers to the technique of simultaneous data collection and display 
throughout the PCR process, hence combining amplification and detection into a 
single step. This is accomplished using different fluorescent chemistries. As the 
chemicals only fluoresce when bound to the PCR product, the fluorescence intensity 
is directly proportional to the concentration of product of amplification. As the 
fluorescence emission is monitored and recorded over time, the point in time or PCR 
cycle where the fluorescence signal significantly increases over a set threshold or 
background intensity can be indentified. This point in the PCR cycle is known as the 
cycle threshold (CT). The CT can be correlated with the initial starting amount of 
cDNA template. Thus, the higher the initial amount of template, the earlier a 
significant fluorescence signal is detected(189;190). The real-time RT-PCR uses the 
same principles as conventional RT-PCR. However there are two fundamental 
differences: (1) The PCR product of real-time RT-PCR is detected and quantified 
using a fluorescent marker while the conventional method uses gel electrophoresis, 
and (2) The real-time PCR product accumulation is measured at every PCR cycle 
whereas in conventional RT-PCR only the end point of intensity is measured(187).  
 
In a real-time RT-PCR study, variations may arise from both reverse transcriptase 
reaction and the PCR process itself which may lead to unreliable results. Differences 
in the efficiencies of the reverse transcriptase and PCR amplification will result in 
differences in the cumulative amount of the final PCR product. Although the 
quantification in real-time RT-PCR is based on the CT, the potential variation in 
reverse transcriptase and PCR efficiencies must be corrected for. This is achieved by 
normalisation of the target gene to a housekeeping gene. A housekeeping gene is a 
gene which is expressed at a constant level, in all tissues and at all phases of 
development. The commonly used housekeeping genes include: β-actin, a 
cytoskeletal protein, glyceraldehyde-3-phosphate dehydrogenase (GAPDH), a 
glycolytic enzyme and ribosomal RNA 18S (18S) which is responsible for protein 
synthesis(187;191). The 18S has been found to be the most stable gene and least 
affected by exogenous factors, thus most suitable for normalisation for various cell 
types including cartilage(191-193). 
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The aim of tissue engineering is to produce an alternative substitute that carries the 
structure and function unique to tissue it is designed to replace. As mentioned in 
Section 1.2, specialised cells or stem cells are often required to regenerate tissues with 
specific function. In the first instance, autologous cells are an appropriate source to 
avoid risks of transmittable diseases. However, the isolation and expansion of cells 
often lead to a process of dedifferentiation which results in the loss of specific cell 
function. Various strategies in attempt to recover the differentiated states of the tissue 
engineered cells have been reported. To evaluate the success of their strategies, gene 
expression studies using the reverse transcriptase polymerase chain reaction (RT-
PCR) technique have been central in providing the essential information at genetic 
level. In this thesis, the RT-PCR technique has an important role in the assessment of 
cell behaviour. It is therefore essential to have an understanding of the basic principles 
of real time RT-PCR. 
 
In this thesis, total RNA was extracted from the chondrocytes by the addition of 10µL 
–mercaptoethanol in 1mL RLT-Buffer (QIAGEN, UK). Total RNA was isolated 
using the RNeasy mini kit, treated with RNase-free DNase 1 (both QIAGEN), 
according to the manufacturer’s protocol and quantified using the ND-1000 UV-Vis 
Spectrophotometer (Nanodrop®, USA). 1000ng of total RNA was reverse transcribed 
(RT) into cDNA and a mastermix prepared for each reaction containing: 10µL 
Taqman™ universal mastermix (Applied Biosystems, USA), 7µL 0.1%(v/v) 
diethylpyrocarbonate (DEPC) water (Invitrogen Ltd, UK), 2µL extracted cDNA and 
1µL Taqman probe (Applied Biosystems, USA). Taqman Gene Expression Assays 
used to amplify genes are detailed in Table 4.2. 18S was used as a control gene. Each 
reaction was carried out in triplicate. The PCR reaction was initiated by a 2 minute 
50°C and 10 minute 95°C step to optimise thermal cycling conditions for the ABI 
Prism 7700 sequence detection system (Applied Biosystems, USA) used to detect 
relative quantification of gene expression. This was followed by PCR amplifications 
performed for 40 cycles in a Corbett Rotor-Gene 6000 (Corbett Life Science, 
Australia) at 95°C for 15 seconds and 60°C for 1 minute. The target signal was 
plotted against the number of cycles and the threshold level was set at 0.05. 
Comparison of all data was taken at the intercept, where sample reactions crossed this 
phase of amplification. Our results were correlated using the comparative CT 
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method(194). Fold changes in gene expression were presented as mean ± standard 
deviation change relative to day 0 cells.  
 
Gene name Symbol Catalogue 
no. 
Accession no. Chromosome 
Location 
SRY (sex determining 
region-y)-box 9 
Sox9 Hs00165814 NM000346 Chr.17 
67,630,455 – 
67,634,156 
Collagen Type 1 Col1A1 Hs00164004 NM000088 Chr. 17 
45,632,113 – 
45,633,974 
Collagen Type 2,  
alpha 1 
Col2A1 Hs00156568 NM001844.4 Chr.12 
46,649 -46,688 
Eukaryotic 18S rRNA 18S Hs99999901 X03205 N/A 
Table 4.2. Taqman™ gene probes used in this study with details of their sources and 
specificities. 
 
4.2.4 Statistical Significance 
The means and standard deviations of the results were calculated using the SPSS 12.0 
software package (SPSS Inc., Chicago, USA). The Mann-Whitney U Test for two 
independent samples was performed to determine statistical significance between 
various scaffolds. A p value of <0.05 was considered to be significant. 
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4.3 Results 
4.3.1 Characterisation of Scaffolds 
4.3.1.1 Surface Chemistry Analyses using XPS and Ninhydrin Assay 
Surface chemical analysis using XPS demonstrated that nitrogenous species were 
incorporated onto the surfaces of PLLA following ammonia plasma treatment. In the 
XPS spectra (Fig. 4.5), the intensity of surface nitrogenous species (400.0eV) on 
PLLA surfaces increased proportionally with the increase of both plasma treatment 
exposure time and power when compared to untreated PLLA scaffolds. The surface 
elemental compositional analysis (Table 4.3) revealed that at a plasma treatment 
power of 50W, the surface nitrogenous species increased with an increase in the 
treatment time – with the highest being at an exposure time of 10 minutes (3.0 ± 0.1 
atomic %). When the scaffold plasma treatment was operated at a power of 100W for 
2 minutes, an amount of surface nitrogenous species comparable to that of 50W for 10 
minutes was observed (2.9 ± 0.2 atomic %). The highest amount of surface 
nitrogenous species was detected on the plasma treated scaffolds when the plasma 
treatment was operated at a power of 100W for 10 minutes (5.2 ± 0.3 atomic %). In 
other words, at an exposure time of 10 minutes, a treatment power of 100W would 
incorporate approximately 70% more nitrogenous species than at a treatment power of 
50W.  
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Fig. 4.5. XPS spectra of ammonia plasma surface modified PLLA scaffolds at various 
exposure power (W) and time (min). (a) Non plasma treated control, (b) 50W 2min, (c) 50W 
5min, (d) 50W 10min, (e) 100W 2min, (f) 100W 5min, (g) 100W 10min. 
 
Chemical quantification using the ninhydrin assay demonstrated that the density of 
primary amine groups on the PLLA scaffold surfaces increased with longer exposure 
time and higher power during plasma treatment. The findings of the ninhydrin assay 
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were consistent with the results of the XPS analysis. The highest density of primary 
amine groups (66.4 ± 4.3nmol/mg PLLA) was found in scaffolds subjected to a 
plasma treatment power of 100W and 10 minutes exposure time (Table 4.3). At an 
exposure time of 10 minutes, an increase in plasma treatment power from 50W to 
100W, increased the amount of primary amine groups incorporation by approximately 
75%. The combined techniques of surface chemical analyses confirmed that the 
incorporation of amine groups onto the surface of PLLA electrospun scaffolds using 
ammonia plasma treatment were successful. 
 
  Atomic % (N 1s)*
Amount of NH2
(nmol/mg PLLA)** 
PLLA control 0.0 0.0 
50W - 2 min 0.6 ± 0.1  27.9 ± 0.3 
50W - 5 min 1.2 ± 0.2 33.2 ± 0.6 
50W -10 min 3.0 ± 0.1 37.9 ± 0.8 
100W - 2 min 2.9 ± 0.2 44.8 ± 1.2 
100W - 5 min 4.2 ± 0.3 57.8 ± 1.4 
100W – 10 min 5.2 ± 0.3 66.4 ± 4.3 
Table 4.3. Amount of nitrogen and primary amine groups detected on the surface modified 
PLLA scaffolds at various plasma treatment power (W) and exposure time (min). (*) 
determined by XPS; (**) determined by ninhydrin assay. 
 
4.3.1.2 Quantification of Latent TGF-β1 on Scaffolds using 
Immunoassay 
The results of the TGF-β1 immunoassay showed that the latent TGF-β1 complex was 
successfully grafted onto the electrospun scaffold surfaces, using both the random and 
orientated latent TGF-β1 immobilisation approach. An average of 195.4 ± 34.3pg/cm2 
of TGF-β1 was released from the pLTGF scaffold group (random immobilisation), 
which was significantly higher than sLTGF and control (p<0.05). Interestingly, an 
average of 14.1 ± 1.7pg/cm2 of TGF-β1 was released from the sLTGF scaffolds 
(orientated immobilisation), i.e. approximately 10-fold less than the pLTGF group. 
No TGF-β1 was detected on the rest of the control scaffolds 
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4.3.2 Biological Characterisation of Scaffolds 
4.3.2.1 Cell Viability Assay 
Primary human chondrocytes cultured on the various scaffolds were evaluated for 
cytotoxicity using Live/Dead assay on days 1, 7, and 14 (Fig. 4.6). This qualitative 
method showed a high live to dead ratio across experimental groups indicating that all 
plasma treated scaffolds were non-cytotoxic to primary human chondrocytes and 
maintained cell viability for up to 7 days (>80%). At day 14, cell viability declined in 
all experimental groups to the range of 70 - 80% except for the TGF group (57.7%).  
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4.3.2.2 Cell Metabolic Activity Assay 
The effects of the various scaffold types on cell metabolic activity of the primary 
human chondrocytes were evaluated using MTS assay at 1, 7 and 14 days. At day 1, 
cell metabolic activity of both latent TGF-β1 functionalised scaffold groups were 
significantly lower than other groups (Fig. 4.7). Cell metabolic activity remained 
significantly low in the pLTGF group at day 7. The results here show a general 
declining trend in cell metabolic activity with time. No significant differences 
between experimental and control groups were found at day 14.  
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Fig. 4.7. MTS assay of primary human chondrocytes cultured on various scaffold types at 1, 7 
and 14 days. Results were normalised to amount of DNA (see Appendix 1.7) and presented as 
mean ± standard deviation. Symbols (○) and (▲) indicate significant differences when 
compared to the pLTGF and sLTGF groups, respectively (p<0.05).  
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4.3.2.3 Real-Time Reverse Transcriptase Polymerase Chain Reaction 
(RT-PCR) 
The mRNA expression of Sox9 and Col1A1 from the chondrocytes cultured on the 
various scaffold types were analysed using real-time RT-PCR (Fig. 4.8). The results 
showed that latent TGF-β1 biofunctionalised scaffolds (pLTGF group) significantly 
up-regulated Sox9 expression by approximately 10-fold when compared to day 0. 
This level of expression was also significantly higher than all other scaffold groups in 
this experiment. Col1A1 was significantly higher in the TGF group, as compared to 
other scaffold groups.  
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Fig. 4.8. Real-time RT-PCR data showing mRNA expression profiles of primary human 
chondrocytes cultured on various scaffold types for 14 days. Expression levels of Sox9 and 
Col1A1 were normalised to the 18S housekeeping gene and day 0 expression levels. Average 
change ± standard deviation of repeated experiments (n=3) are presented. The following 
symbols represent significant differences with (♦◊) TGF, (●○) pLTGF and (▲) sLTGF 
groups. Solid symbols denote Col1A1 gene whereas open symbols indicate Sox9 gene. The 
expression of both genes were significantly higher in the TGF and pLTGF groups when 
compared to the rest of the groups (p<0.05). 
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4.4 Discussion 
The TGF-β1 has long been used as a growth inducing factor in tissue engineering. 
Faced with the need to overcome its drawbacks, various growth factor delivery 
systems have been previously explored(134;138;141;143;195). The key concept 
behind the scaffold system developed in this study was to guide cell-mediated 
activation of growth factor. This allows the cells to determine their own proliferation 
and function as necessary, preventing uncontrolled TGF-β1 effects which may lead to 
pathological conditions. To achieve this, the latent TGF-β1 complex was selected as a 
concept latent protein model for the development of a novel biomimetic tissue 
regenerative scaffold. Our results confirmed that the latent TGF-β1 biofunctionalised 
scaffold design successfully influenced chondrocytic behaviour and induced the 
highest level of Sox9 expression in this experiment. To our knowledge, this is the first 
study to report cell-mediated activation of growth factor for tissue engineering 
applications. In addition, the key principle of this research is in-line with the current 
trends in tissue engineering of inducing regenerative ability of engineered constructs 
by mimicking the structural and biological functions of the native tissue(82;84). The 
biological and physicochemical characterisations of the latent TGF-β1 functionalised 
PLLA scaffold were performed to verify the hypothesis of this study. 
 
PLLA is a US Food and Drug Administration (FDA) approved biomaterial for 
biomedical applications. It was the polymer of choice for this study as it has been 
shown to exhibits superior ability in maintaining structural integrity and in supporting 
chondrocytic proliferation when compared to other members of its poly α-hydroxy 
ester family such as PGA, PDLGA 50:50, PDLGA 85:15, and PDLLA(15;49). In this 
study, PLLA fibrous scaffolds were produced by electrospinning. 
 
Electrospinning is a scaffold nanofabrication technique often used for its ability to 
mimic the fibrous structural architecture of tissues, such as the collagen type II 
network of cartilage ECM(82;84;196). In this study, the electrospun fibres produced 
and used for subsequent plasma surface modification were homogenous, non woven, 
randomly aligned, non beaded, smooth and uniform. 
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Since the PLLA backbone lacks reactive functional groups necessary for chemical 
conjugation, scaffold surface modification was performed using ammonia plasma 
treatment. The plasma treatment technique is a powerful, yet simple, fast and cost 
effective method for biopolymer surface modification without alterations to the 
polymer bulk properties. This technique introduces reactive functional groups and 
alters the surface chemistry of biomaterials commonly used in tissue engineering such 
as PLLA, PGA and polycaprolactone (PCL), rendering them more hydrophilic for 
tissue engineering applications(113;114;197). Oxygen and ammonia gas plasma 
treatments have previously been shown to graft reactive functional groups such as 
hydroxyl, carbonyl and amine on to polyester material surfaces(113;114). These 
functional groups were used for further surface adsorption and immobilisation of 
peptides and proteins such as arginine-glycine-aspartate (RGD) sequences, gelatine 
and collagen onto polymer surfaces and scaffolds(113;197-199). The results from the 
surface chemical analyses showed that the PLLA scaffold surface was functionalised 
with primary amine groups necessary for the subsequent conjugation with the latency 
associated peptide component of the latent TGF-β1 complex. The incorporation of 
these amine groups allowed further maleimide functionalisation of the scaffold, for 
subsequent conjugation with the thiol group of the latent TGF-β1 complex. 
 
The TGF-β1 immunoassay revealed that the latent TGF-β1 complex has been 
successfully anchored onto the plasma treated electrospun scaffold surface. The direct 
linkage (random immobilisation) of the latent TGF-β1 to plasma treated scaffolds 
(pLTGF) was more efficient in anchoring the latent TGF-β1 complex, as compared to 
the orientated immobilisation approach that required the additional heterobifunctional 
crosslinker sulfo-SMCC (sLTGF). This could be due to the following reasons:  
(1) the LAP has limited free thiol groups for cross linkage;  
(2) the location of the free thiols may be sterically hindered; and  
(3) the short spacer in sulfo-SMCC further limits its scope to react with thiol groups.  
 
A combination of these three reasons may have contributed to the lower binding 
capacity observed in the sLTGF group. The immunoassay also demonstrated that the 
scaffold surface-bound latent TGF-β1 complex remained available for enzymatic and 
chemical activation. The bioavailability of the TGF-β1 on the latent TGF-β1 
121 
Chapter 4: Biofunctionalisation of Electrospun Scaffolds – In-vitro Study 
 
biofunctionalised scaffolds was further confirmed by primary human chondrocytic 
culture.  
 
Expansion of cell number was carried out in serum containing media. However, to 
assess the efficacy of the various scaffold systems in promoting cell proliferation and 
chondrogenic differentiation, the primary human chondrocytes were cultured in 
serum-free media(SFM)(165;186) to avoid the influences of other growth factors. The 
TGF group was the only exception, receiving SFM supplemented with 10ng/mL of 
active TGF-β1. 
 
The results of Live/Dead assay demonstrated that the latent TGF-β1 biofunctionalised 
electrospun scaffolds were non cytotoxic and sustained cell viability of over 70% 
throughout the experiment. The TGF group, despite receiving TGF-β1 (10ng/mL) 
supplementation for up to 7 days, failed to sustain the level of cell viability seen in the 
latent TGF-β1 group. The general declining trend in cell viability over time may be 
related to the use of complete serum-free media.  
 
The serum-free environment is a well established in-vitro tool, which is used to revert 
the mitotic cell cycle induced by serum, into the interphase cycle(200). It is used 
when cells are required to re-express the differentiated function after being induced to 
proliferate to obtain the required cell numbers. It is also important to note that cells in 
an intact organ or tissue can only express specific function while they remain in the 
interphase. Chondrocytes naturally arrest in an infinite interphase cycle in the native 
cartilage(200). In this study, the serum-free environment together with other 
chondrogenic components have been used to revert the mitotic cell cycle 
(proliferation) induced by serum, into the interphase cycle to promote differentiation. 
A decrease in cell proliferation has been shown to occur when dedifferentiated 
chondrocytes redifferentiate on three dimensional culture systems in-vitro(201). 
Therefore, the significantly lower cell metabolic activity in the latent TGF-β1 
biofunctionalised scaffold groups, from day 1 (both pLTGF and sLTGF) and in the 
pLTGF group on day 7, may suggest that a similar redifferentiation process may have 
taken place in the chondrocytes.  
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Chondrocytes are well known to dedifferentiate and lose their chondrocytic functions 
with every passage number in-vitro(33). In this study, the primary human 
chondrocytes were cultured up to third passage prior to seeding onto the various 
scaffold groups. Col2A1 was not detectable at day 14. This could be due to the use of 
highly passaged chondrocytes. The recovery of chondrogenic differentiation has been 
described as a slow process(202). Studies have also shown that passaged 
chondrocytes only expressed Col2A1 gene after 21 days of in-vitro culture(11;186). 
Therefore, a longer term study is required to evaluate the chondrogenic potentials of 
the biofunctionalised scaffolds.  
 
Despite this relatively highly passaged cell culture in-vitro, our RT-PCR results 
demonstrated that both TGF group and the latent TGF-β1 biofunctionalised scaffold 
from pLTGF group significantly up-regulated the cartilage specific transcription 
factor Sox9 at day 14, as compared to the rest of the groups. Sox9 is a key 
transcription factor for chondrogenic differentiation as it directly activates and up-
regulates the expression of Col2A1(203-205). This transcription factor is expressed in 
all chondrocytes (except hypertrophic chondrocytes)(205), however its expression 
declines with increasing passage(206). The up-regulation of Sox9 induced by TGF-
β1, seen in the TGF group, was consistent with a previously reported study(207). 
Interestingly, the up-regulation of Sox9 in the pLTGF group was significantly higher 
(by approximately 30%) than the TGF group.  
 
It is also important to highlight that the highest Sox9 expression level was induced by 
the amount of latent TGF-β1 available from the pLTGF scaffold (195.4pg/cm2 
scaffold) which was approximately 150-fold lower than the standard TGF-β1 
supplementary dose received by the TGF group (10ng/mL)(17;163;208;209). The 
results from the pLTGF group demonstrated that the technique of immobilisation of 
latent TGF-β1 described in this study preserved the bioavailability of the growth 
factor to cells. Although the anchorage of the latent TGF-β1 on the scaffold surfaces 
may not resume the intended configuration as seen in its native environment [latent 
TGF-β1 complex bound at cys-33 to the latent TGF-β1 binding protein(170;171)], the 
latent TGF-β1 remained protected and available for activation by primary human 
chondrocytes.  
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The TGF group on the other hand expressed the highest level of Col1A1 which marks 
the pattern of dedifferentiation towards a fibroblast-like phenotype. TGF-β1 is well 
known to have positive effects on matrix production and chondrocytic 
differentiation(50;210-212). However, studies have reported the suppressive effects of 
TGF-β1 on collagen type II synthesis and down-regulation of chondrocytic 
differentiation(162;213-215). The high Col1A1 gene expression results of the TGF 
group were consistent with the studies that have reported the inhibitory role of the 
growth factor on chondrogenesis. The sLTGF group did not significantly up-regulate 
Sox9 gene expression. This may reflect the small amount of TGF-β1 present on the 
sLTGF scaffolds. 
 
From our studies, we can deduce that there are two possible aspects of the TGF-β1 
which influenced the behaviour of the chondrocytes. Firstly, the dosage of the growth 
factor and secondly, how the growth factor was presented to the cells. A high dose 
and frequent supplementation of growth factor does not necessarily result in the 
desired response (as seen in the low Sox9 and up-regulation of Col1A1 in TGF 
group). Conversely, a dosage 150-fold lower, coupled with the presentation of the 
growth factor in its latent form to cells, resulted in a change in the pattern of gene 
expression of the chondrocytes. 
 
4.5 Conclusion 
The concept behind the scaffold design presented in this chapter is that the 
biofunctionalised scaffold directs cell-mediated activation of growth factor, thereby 
allowing the cells to control their own growth, function and environment. This is the 
key distinction from the current studies in bioactive factor delivery. The latent growth 
factor remains protected on the biofunctionalised scaffolds until released by cells 
when required. Cell-mediated activation implies controlled activation or release of a 
desired signal at a physiological rate when necessary, as well as reducing unwanted 
adverse effects. The results and outcomes of this study may mean a step closer to 
guiding cells towards regenerating functional cartilage tissue, as opposed to allowing 
extensive reparative fibrous scarring to occur as a result of uncontrolled cytokine 
induction mentioned above. Although the results of this study are preliminary and 
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time points are relatively short, it is proof of concept of cell-mediated activation of 
growth factor can be achieved by the strategies proposed. However, further 
experiments to assess the tissue regenerative capacity in a “physiological culture” 
condition is required. In order to evaluate the efficacy of the biofunctionalised 
scaffolds in a “physiological culture” condition without any other supplementation of 
serum or growth factors, in-vivo studies were performed. This is described in the 
following chapter.  
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Chapter 5  
Biofunctionalised Electrospun Scaffolds with 
Cell-mediated TGF-β1 Activation: In-vivo Study 
5.1 Introduction 
Research in Medicine often requires experiments to be conducted on animal and/or 
human subjects (in-vivo studies) for the evaluation of a therapeutic intervention. At 
times, moral dilemmas related to the experiment may be encountered. These moral 
issues must be thoroughly considered when planning an experiment and approved by 
the appropriate ethics committee. There are two main ethical theories which form the 
basis for moral justification in research, and they are the utilitarian theory 
(teleological), where the moral justification is based on the scale of the perceived 
advantage, while the deontological theory consists of judging the nature of the 
research regardless of its outcomes(216). These ethical perspectives in conducting 
experiments with animals are essential to a researcher and should always be 
acknowledged to minimise ethical dilemmas. 
 
In the development of a successful tissue engineered product, the use of experimental 
animals is often necessary for the assessment of product safety and efficacy – prior to 
the translation into clinical applications for human. In the UK, the use of animals is 
strictly regulated by the Home Office.  
 
In 1987, the Animal (Scientific Procedures) Act 1986 (ASPA 1986) was enforced to 
protect animals used for experimental and other scientific purposes in the United 
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Kingdom. The ASPA 1986 determines which animals are considered “protected”, 
which procedures are considered to be regulated, defines specific responsibilities of 
staff in an animal facility establishment [e.g. project and personal licence holder, 
Named Animal Care & Welfare Officer (NACWO), Named Veterinary Surgeons 
(NVS), animal technicians] as well as provides detailed guidelines for protocols and 
procedures (e.g. Schedule 1 method of humane killing). Experiments on animals are 
only permitted legally when no other means of investigations are capable in achieving 
the specified research objectives [Animal (Scientific Procedure) Act 1986]. Even so, 
the researcher is required to minimise the number of animals and their suffering 
during experiments, by conducting preliminary in-vitro studies, careful planning, and 
refining laboratory techniques to an optimal level(217).   
 
In order to legally conduct an in-vivo experiment, a researcher must undergo an 
extensive application process which consists of two parts:  
(1) for a project licence - an extensive justification for the use of animals with detailed 
experimental protocols is proposed and subjected to a ethical review; and, 
(2) for a personal licence – the candidate is required to attend a four day training 
course with successful completion of all course assessments.  
 
Only then, can a fully trained personal licensee be permitted to perform a specific 
procedure on a specific type of animal, as detailed in the project licence. For example, 
initially the athymic mutant rat strain was not included in the description of the 
project licence (PPL 70/6600). Thus, for the purpose of utilising this mutant strain in 
this thesis, an amendment to include them in the project licence was submitted to the 
Home Office which was subsequently approved.  
 
The four day training course was absolutely essential in providing an overview of 
experiments with animals, to a researcher new to the field. Apart from gaining an 
understanding in the ethical issues and legislation behind animal studies, the course 
also provides insight into the steps necessary to ensure that the quality of animal 
welfare is maintained. The standard of animal welfare at an animal laboratory is 
crucial in providing an environment with the least possible stress levels to animals. 
This not only addresses ethical related issues, but also minimises experimental 
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variability as a result of poorly controlled environment. There are several key aspects 
of animal experiments essential to a new licensee/researcher, and they include:  
1. health and safety awareness to staff  
2. animal husbandry 
3. clinical signs of pain, stress and suffering 
4. technical handling of animals 
5. peri-operative management of animals – analgesia, anaesthesia, surgery, post-
operative recovery and potential complications. 
 
Although animal husbandry is generally managed by NACWO, every personal 
licence holder is responsible for the care of all animals, submitted under his or her 
licence. This forms the foundation to utilising animals in research and starts from 
when the animals are first obtained. First of all, the immediate animal accommodation 
requires the appropriate type and size of cages, non-toxic and non-absorbent nesting 
materials which provides insulation, environmental enrichments to encourage natural 
animal behaviour, the appropriate diet and water supplementation. These are 
considered as micro-environmental requirements. In, addition, the macro-
environmental factors will need to be adjusted to provide as close as possible a 
simulation of the natural habitat of the animals, and these include: temperature 
(approximately 19 – 23°C for rats), relative humidity (55 ± 10%), ventilation (15 – 20 
changes of fresh filtered air), light to dark cycles (12:12 hours of alternating light and 
dark cycles for most laboratory animals) and general background noise level (below 
50dB)b. 
 
Once the animals are acclimatised to their new environment, observations of their 
natural behaviour and normal activities should be noted and acquainted to. This will 
form the baseline for comparison of clinical features for the recognition of signs of 
pain and distress. The common signs of pain and distress include: un-groomed 
appearance, unusual posture, reduced food and water intake, reduction in body 
weight, abnormal bladder and bowel function and so on. These clinical features may 
be present after surgical intervention and at time distress signs can only be detected as 
a change in the normal pattern of behaviour and activities. 
                                                 
b Information from Imperial College London/Central Biomedical Services Pre-Licence Training Course 
under the Animal (Scientific Procedures) Act 1986, Module 1-4 2008 manual.  
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In-vivo experiments in Tissue Engineering may involve a breach of skin and tissue 
disruption in a surgical intervention. The extent of acute phase response and 
inflammation is proportional the scale of tissue damage. Therefore, in addition to 
pain-control and anaesthetic considerations, surgical tissue handling must be precise 
and kept to a minimum. Although the personal licensee training course included an 
overview of anaesthesiology and surgery, the detailed peri-operative management 
requires considerable thought and pre-planning in addition to the background 
knowledge of physiology and clinical experience in surgical skills. For instance, 
different stages of a surgical intervention require different but integrated 
considerations: 
 
Pre-operative stage: 
1. number of procedures/animals in a given period of time 
2. availability of operative theatre and staff assistance 
3. pre- and post-operative recovery environment in separate accommodation 
4. designation of pre-, intra- and post-operative areas 
5. pre-emptive analgesia ± prophylactic antibiotics 
6. the need for fluid resuscitation 
7. type of anaesthesia, route of administration, supplementary oxygen, related 
equipments and their availability 
8. hair clipper,  type of skin cleanser and skin marker 
9. mode of transport of cell-scaffold constructs between laboratories 
10. types of surgical instruments, sutures, sterile gloves, gowns and drapes 
11. considerations for batch surgery – bead steriliser and the number of sets of 
surgical instruments required 
12. the sequence of events from pre- to post-operative recovery with anticipation 
of potential complications 
13. pre-operative sterilisation of operation theatre/ equipments/ instruments 
14. pre-operative weight as a baseline 
 
Operative stage: 
1. the need of an assistant, anaesthetist 
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2. knowledge of the anatomy of the body part of interest 
3. knowledge of the potential physiological changes as a result of the surgical 
intervention 
4. marking of surgical sites, skin preparation and ear tagging 
5. assessment of the depth of anaesthesia 
6. the need for fluid resuscitation 
7. application of principles of surgery – sterile technique, minimal and gentle 
tissue handling, adequate haemostasis, non-tension wound closure 
 
Post-operative and recovery stage: 
1. a clean and separate accommodation/cage for recovery in a dim environment 
2. readily available supply of food and water ± further fluid resuscitation/ 
prophylactic antibiotic supplementation/ analgesia 
3. sterilisation of instruments/ change of instruments, drapes etc. 
4. preparation for the next procedure 
5. observations for post-operative complications such as pain, bleeding, 
haematoma, wound re-opening/dehiscence with anticipation for re-
anaesthetisation and revision surgery 
6. post-operative “ward-round” inspection of wounds and observation of animal 
well-being on the following day 
7. daily wound inspection and general clinical observation 
8. plan for suture removal 
 
An in-vivo experiment thus requires an exhaustive amount of time and preparation 
from applications for licences, to an in-depth understanding of animal welfare and 
science, to the detailed considerations of operative surgery.  
 
In this thesis, the aim is to develop a “cell-mediated activation of growth factor” 
scaffold system by incorporating the latent TGF-β1 onto the electrospun PLLA 
scaffolds. As described in the previous chapter, in order to assess the efficacy of this 
system in guiding cells towards chondrogenesis – the passaged chondrocytes were 
cultured in a chondrogenic serum-free environment. The chondrogenic serum-free 
environment was used to induce chondrogenic differentiation as well as to avoid the 
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masking effects from uncharacterised bioactive factors present in the serum. 
However, the long term culture in a serum-free environment may effect the survival 
of the chondrocytes as seen in the reduction of cell viability at 14 days (Chapter 4). 
Therefore, to evaluate the long term effects of the latent TGF-β1 biofunctionalised 
scaffolds on chondrogenesis without serum or additional growth factor 
supplementation - in-vivo culture of the cell-scaffold constructs was performed.  
 
In-vivo subcutaneous implantation cell-scaffold constructs was performed in athymic 
rats. This immunocompromised mutant strain is a well established model for the 
investigation of xenogenic transplantation as they are congenitally T-lymphocyte 
deficient(218). As a result of the T-cell deficiency, the athymic rats are incapable of 
mounting transplant rejection. Thus, they provide a physiological environment 
necessary to support cell survival for the investigations of the biofunctionalised 
scaffolds in this study. However, T-like cells have been found in increasing numbers 
after 4 - 6 months of age with some indications to skin allograft rejection(218). For 
this reason, the rats used in this study were obtained at 5 - 6 weeks old with the final 
post-implantation age being approximately 3-months to avoid any possibilities of 
transplant rejection. This chapter describes the in-vivo sequel to the evaluation of the 
latent TGF-β1 biofunctionalised scaffolds in promoting chondrogenesis.  
 
131 
Chapter 5: Biofunctionalisation of Electrospun Scaffolds – In-vivo Study 
 
5.2 Materials and Methods 
5.2.1 Scaffold Fabrication and Biofunctionalisation 
The non-woven PLLA fibrous scaffolds were electrospun, sterilised and subsequently 
biofunctionlised with latent TGF-β1 as described in Chapter 4. The scaffolds (1 × 
1cm2) were divided into three experimental groups (Table 5.1).  
 
Sample ID Description 
ptPLLA +/- Plasma treated electrospun scaffolds as control 
pLTGF +/- 
 
Plasma treated electrospun scaffolds with immediate immobilisation of 
latent TGF-β1 
sLTGF +/- Plasma treated electrospun scaffolds with sulfo-SMCC crosslinked 
latent TGF-β1 
Table 5.1. Experimental groups and their sample identification (ID). The symbols (+) or (-) 
indicate scaffolds seeded with cells and their cell-free controls, respectively. These sample ID 
will be used to refer to respective groups throughout this chapter.  
 
5.2.2 Cell Culture and Expansion 
Human primary nasal septal chondrocytes used in this study were a gift from Dr. Reza 
Ghazanfar (Imperial College London, UK). The chondrocytes were expanded up to 
fourth passage in chondrocytic growth media (please see Chapter 4 for details of the 
media composition). As an alternative cell source with chondrogenic potential, human 
mesenchymal stem cells (MSC, Lonza Wokingham Ltd, UK) were used and expanded 
up to third passage in MSCGM™ Mesenchymal Stem Cell Growth Medium Bullet 
Kit® (Lonza Wokingham Ltd, UK). The cells were maintained at 37°C in a 
humidified 5% carbon dioxide atmosphere. The culture media was replaced every 3 
days. 
 
Cells were then harvested and seeded on to the scaffolds (see Table 5.1) at a seeding 
density of 8 × 105 cells/cm2 scaffold, in a serum-free media (see Chapter 4 for media 
composition). Cell pellets (5 × 105cells) were snap-frozen and used as day-0 specimen 
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for gene expression analysis. After 24 hours, the cell-scaffold constructs were 
subjected to the following in-vivo implantation.  
 
5.2.3 In-vivo Implantation of Cell-Scaffold Constructs 
Eight 5 to 6-week-old female athymic rats (rnu/rnu, Harlan, UK) were allowed to 
acclimatise for 7 days. They were maintained in individually ventilated cages (four 
rats per cage) at 22°C, 50% humidity and 12 hourly night-day cycles. Sterile solid 
food and water were provided. Cell-scaffold constructs and their no-cell controls were 
implanted into individual dorsal subcutaneous pockets of the rats. This procedure was 
performed under UK Home Office approved project licence (PPL 70/6600). 
 
The rats were anaesthetised by resident veterinary surgeon, Mr. Francisco Dias, with 
inhalation of isoflurane and oxygen. Pre-emptive carprofen (5mg/kg, Pfizer Animal 
Health, USA) and prophylactic enrofloxacin (5mg/kg, Bayer plc, UK) were 
administered by subcutaneous injection before any skin incisions were made. The 
dorsa were shaved and cleansed with chlohexidine (Hibriscrub, Regent Medical Ltd., 
UK). Subsequently, three 1cm midline skin incisions were made at 1cm intervals. 
Two subcutaneous pockets were created by blunt dissection, on either side of and 
away from each incision. The cell-free control scaffolds were inserted into the left 
pockets, followed by the insertion of cell-scaffold constructs into the corresponding 
pockets on the right. All cell-scaffold constructs were inserted with the cell-seeded 
side facing upwards and away from the underlying muscular layer. The approximate 
anatomical landmarks of various scaffold groups are as illustrated in Fig. 5.1. The 
skin incisions were closed with interrupted 4/0 polypropylene sutures (Ethicon Ltd., 
UK). Post-operative prophylactic oral enrofloxacin was administered as a supplement 
in the water (0.1mg/mL) for seven days. At 2 weeks, all sutures were removed with 
the animals placed under secure manual restraint (with assistance from an experienced 
animal technician).  
 
After 6 weeks, all rats were sacrificed by neck dislocation and all implants together 
with the surrounding tissue were retrieved immediately. Each implant was divided 
into four equal quarters. The first quarter was embedded in optimum cutting 
temperature embedding compound (Bright Cryo-M-Bed, Bright Instrument Company 
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Ltd., UK) then snap-frozen in liquid nitrogen and stored at -80°C until further use for 
cryosection. For the following quarters, surrounding tissues were gently removed, as 
much as possible, from the implants. The second quarter was snap-frozen in liquid 
nitrogen for gene expression analysis. The third quarter was stored in -20°C for 
biochemical analysis. The fourth quarter was fixed in 2.5%(v/v) glutaraldehyde and 
processed as per protocol in Chapter 3 for SEM. 
 
Fig. 5.1. The approximate anatomical landmarks of implant placements in the dorsal 
subcutaneous layer of the rats. The positions of scaffold groups were rotated through the three 
levels: subscapular, low thoracic and lumbar. Dashed line indicate the dorsal anatomical 
midline as located by palpation of the spinous processes. In this figure, P, L and S represent 
ptPLLA, LTGF and sLTGF groups respectively. 
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5.2.4 Characterisation of Implanted Specimens 
5.2.4.1 Gene Expression Analysis 
The frozen implants were homogenised in a 350µL lysis buffer which consist of 10µL 
β–mercaptoethanol in 1mL RLT-Buffer (QIAGEN, UK), at room temperature, using 
TissueLyser II (QIAGEN, UK) operated at 30Hz for two 3 minute cycles. The 
following procedures for gene expression analysis were performed as described in 
Chapter 4. Taqman Gene Expression Assays used to amplify genes are detailed in 
Table 4.2 of Chapter 4 with the addition of Runx2 gene for the MSC groups (Table 
5.2). Rat subcutaneous tissue and cell-free implants were used as controls. The overall 
degree of chondrogenic differentiation can be drawn by obtaining the Col2A1/Col1A1 
gene expression ratio as both are considered as the differentiation and 
dedifferentiation markers of chondrocytes respectively(19;219-221). 
 
Gene name Symbol Catalogue 
no. 
Accession no. Chromosome 
Location 
Runt-related 
transcription factor 2 
Runx2 HS00298328 NM001015051 Chr.6 
45,622,542 – 
45,626,797 
Table 5.2. Taqman™ gene probe (Applied Biosystems, UK) used in this study with details of 
their sources and specificities. 
 
5.2.4.2 Gross Appearance of Implants 
The quarters allocated for histology were observed using a Panasonic DMC-FX36 
digital camera (Osaka, Japan), prior to being set in the embedding compound. 
 
5.2.4.3 Cryosection of Implants 
Full depth sections of 7µm thickness from all scaffold groups, were cut using a 
cryostat (Bright Instrument Company Ltd., UK) and fixed in ice-cold acetone for 5 
minutes. Sections were then used for SEM, histology and immunofluorescence 
analyses as described below. 
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5.2.4.4 Scanning Electron Microscopy of Implants 
Sections of all scaffold groups were processed and analysed using SEM as according 
to the protocol described in Chapter 3. Three fields of view from four samples with 
triplicate sections were analysed. 
 
5.2.4.5 Histology and Immunofluorescence Analyses of Implants 
Full depth sections of 7µm thickness were cut using a cryostat (Bright Instrument 
Company Ltd., UK) and fixed in ice-cold acetone for 5 minutes. Separate sections 
were stained with: (1) haematoxylin (Gill’s Formula, Vector Laboratories, USA) and 
eosin (Sigma-Aldrich, UK) to evaluate general tissue-implant morphology and 
cellular organisation; (2) 0.001%(w/v) fast green (Sigma-Aldrich, UK), 0.1%(w/v) 
safranin-O (Sigma-Aldrich, UK) and haematoxylin to assess GAG distribution; and 
for MSC groups only (3) 2%(w/v) alizarin red S (Sigma-Aldrich, UK) to identify 
calcium as a result of bone tissue formation. (For detailed histology protocol, please 
see Appendix 1.8) 
 
All solutions and dilutions used in the immunoflorescence staining procedure were 
prepared from a ‘solution-A’ buffer which consists of 1:2000 dilution of 1M MgCl2 
(Sigma-Aldrich, UK) in Dulbecco’s phosphate buffered saline (PBS, Invitrogen, UK). 
The sections were initially incubated in solution-A with 2%(w/v) bovine serum 
albumin (BSA, Sigma-Aldrich, UK) for 30 minutes at room temperature to block non-
specific binding sites. The sections were then rinsed (3×) in solution-A. All primary 
and secondary antibodies were incubated in a humidified chamber at 37°C for 1 hour. 
To reveal the presence of donor cells, sections were incubated with a mouse 
monoclonal antibody specific to a human nuclei antigen (Millipore, UK) – at a 1:50 
dilution with 2%(w/v) BSA. For the detection of human type I and II collagen 
production, separate sections were incubated with a rabbit anti-collagen I polyclonal 
and mouse anti-collagen II monoclonal antibodies, at a dilution of 1:80 and 1:100, 
respectively (both from Abcam, UK). The sections were then rinsed (3×) in solution-
A and incubated separately with: (1) Texas Red® conjugated sheep polyclonal to 
rabbit antibody for the detection of collagen I (596 - 620nm); and (2) 
diaminotriazinylaminofluorescein (DTAF) conjugated goat monoclonal to mouse 
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antibody for the detection of human nuclei and collagen II (both at a dilution of 
1:1000 and from Abcam, UK) (495 - 528nm). Following the incubation period, all 
sections were rinsed (3×) in solution-A, blotted, and then a small drop of 
VECTASHIELD mounting medium containing 4’6-diamindino-2-phenylindole 
(DAPI) (Vector Laboratories, USA) was added to the sections to reveal all DNA (358 
- 461nm) and cover slips were placed on the sections. The cell-free sections were used 
to evaluate species cross-reactivity of the antibodies. A human nasal septal cartilage 
and sections stained only with the secondary antibodies were used as positive and 
negative controls respectively. Immunofluorescence (IF) microscopy was then carried 
out using an Olympus BX-51 fluorescence microscope equipped with an Olympus 
DP070 colour digital camera and Olympus DP Controller software (Olympus UK 
Ltd., UK). Experiments were performed on four samples with triplicate sections.  
 
5.2.5 Statistical Analysis 
The means and standard deviations of the results were calculated using the SPSS 12.0 
software package (SPSS Inc., USA). The Mann-Whitney U Test for two independent 
samples was performed to determine statistical significance between various 
scaffolds. The p value of <0.05 was considered to be significant. A post-hoc power 
analysis was performed with the two-sample t-test using the PASS 2008 software 
(NCSS, USA) to evaluate the power of the experiment as well as to determine the 
sample size for further studies. The results of the power analysis and sample size 
estimation are discussed presented in Table 5.3 in the discussion of this chapter. 
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5.3 Results 
Post-operative recovery of all rats was unremarkable. All wounds healed without any 
complications. All implants were well tolerated throughout the experiment. All rats 
remained healthy and well throughout the 6 week period.  
 
5.3.1 Gene Expression Analysis 
The mRNA expression of Sox9, Col2A1, and Col1A1 for the implants together with 
their cell-free controls were analysed using real-time RT-PCR (Fig. 5.2). Runx2 
expression was analysed in addition to the three genes for the MSC seeded constructs. 
No signals were detected on all cell-free implants and rat subcutaneous tissue for all 
gene probes except 18S.  
 
The Sox9 was expressed across all experimental groups (Fig. 5.2a). The Sox9 
expression observed in pLTGF+ groups which was approximately 1.2-fold and 3.9-
fold higher when compared to sLTGF+ groups. Col2A1 expression was expressed in 
both latent TGF-β1 biofunctionalised scaffolds (pLTGF+ and sLTGF+) while it was 
undetectable in the control scaffold group (ptPLLA+) (Fig. 5.2b). The Col1A1 
expression was detected in all scaffold groups with no significant differences between 
groups (Fig. 5.2c). The Col2A1/Col1A1 gene expression ratio of the sLTGF+ group 
was approximately 1.5-fold higher than the pLTGF+ group, although no statistical 
significance was found.  
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Fig. 5.2. Real-time RT-PCR quantification of gene expression of in-vivo cultured primary 
human chondrocytes on various scaffold types for six weeks. Expression levels of (a) Sox9, 
(b) Col2A1, and (c) Col1A1 were normalised to the 18S housekeeping gene and day 0 
expression levels. (d) Col2A1/Col1A1 gene expression ratio indicating the degree of 
chondrogenic differentiation. Average fold changes ± standard deviation are presented (n=4). 
The following symbols represent significant differences (p<0.05) with (*) ptPLLA+, and (●) 
sLTGF+ groups. 
 
In the MSC culture, Sox9 expression was detected in all experimental groups with no 
significant differences between them (Fig. 5.3a). Interestingly, Col2A1 expression 
was detected in all experimental groups (Fig. 5.3b). However, no Col2A1 was 
detected in the initial hMSC day 0 samples. As a result, no baseline Col2A1 
expression at day 0 was available for further normalisation. Consequently, only the 
∆CT results were analysed and presented below, instead of the complete comparative 
∆∆CT of Col2A1 (Fig. 5.3b). Although no statistical significance were found in 
Runx2 and Col1A1 expressions, an up-regulated trend can be seen in the ptPLLA+ 
group when compared to the two latent TGF-β1 biofunctionalised groups (Fig. 5.3c 
and d).  
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Fig. 5.3. Real-time RT-PCR quantification of gene expression of in-vivo cultured human 
MSC on various scaffold types for six weeks. Expression levels of (a) Sox9, (c) Runx2, and 
(d) Col1A1 were normalised to the 18S housekeeping gene and day 0 expression levels. In (b) 
Col2A1 expressions were only normalised to the 18S housekeeping gene because no Col2A1 
was detectable in the human MSC day 0 culture, as indicated by the symbol (∆CT). Average 
fold changes ± standard deviation are presented (n=4).  
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5.3.2 Gross Appearance of Implants 
The gross appearances of the scaffold and implants were observed between 
experimental groups and between the seeded cell types (Fig. 5.4). In general, the post-
implantation scaffolds carried a yellowish hue (compared to the original white 
appearance of the preimplanted scaffold as indicated by “C” in the Fig. 5.4) and were 
found to be encapsulated with fibrous tissue. No differences in appearance were noted 
between experimental groups as well as between chondrocytes and MSC. 
  
 
Fig. 5.4. Representative gross appearances of implants. In this figure, P, L and S represent 
ptPLLA, LTGF and sLTGF groups respectively while “-” and “+” indicates the cell-free 
control and the cell-seeded scaffolds respectively. Scaffold “C” represents a pre-implanted 
scaffold. The differences in shapes of the implants may be related to the natural fibrous 
encapsulating reaction and/or the site of implantation where movements of the site may have 
altered the origin square shape. Scale bar = 1cm. 
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5.3.3 Scanning Electron Microscopy of Implants 
SEM images of sections from all scaffold groups and both cell types indicated that 
tissue products were integrated into the scaffolds (Fig. 5.5) 
 
Fig. 5.5. Representative SEM images of sections of in-vivo implanted scaffold groups for 
both chondrocytes and MSC. Images were taken at low (250×, scale bar = 200µm) and high 
(6500×, scale bar = 10µm) magnification.  
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5.3.4 Histology and Immunofluorescent Staining of Implant Sections  
In order to confirm the presence of the donor human cells at 6 weeks, 
immunofluorescence detection of a specific human nuclei antigens revealed that the 
human nasal chondrocytes and MSC were located adjacent to the scaffolds (D-I of 
Fig. 5.6 and 5.7). The cell-free implants (A-C of Fig. 5.6 and 5.7) and human nasal 
cartilage (Fig. 5.8) were used as controls to confirm the specificity of the anti-human 
nuclei antibody.  
 
Fig. 5.6. Immunofluorescence detection of donor cells using an antibody specific to a human 
nuclei antigen. The three columns represent the three scaffold groups as indicated by their 
experimental ID. Images A-C represent the respective cell-free control groups, while D-F 
were seeded with primary human chondrocytes. Images G-I are higher magnification images 
of D-F. The silhouette of the scaffolds can be seen traversing these representative images 
horizontally (A-F). The presence of donor cells (green) were distinguished from the 
surrounding rat cells (blue) as indicated by the arrows in images D-I. Scale bars: A-F, 500µm; 
G-I, 200µm. 
 
 
143 
Chapter 5: Biofunctionalisation of Electrospun Scaffolds – In-vivo Study 
 
 
Fig. 5.7. Representative images of immunofluorescence detection of donor human MSC using 
an antibody specific to a human nuclei antigen. The three columns represent the three scaffold 
groups as indicated by their experimental ID. Images A-C represent the respective cell-free 
control groups, while images D-F were seeded with MSC. Images G-I are higher 
magnification images of D-F. The presence of donor cells (green) were distinguished from the 
surrounding rat cells (blue) as indicated by the arrows in images D-I. Scale bars: A-F, 500µm; 
G-I, 200µm. 
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Fig. 5.8. Representative images of control specimens for immunofluorescence detection of the 
human cell nuclei. Human nasal cartilage was used as a control to show positive staining (A, 
C) for the antibody specific to human nuclei (DTAF labelled, green), which was co-localised 
using DAPI (blue). The human nuclei can be seen to stain both green and blue within well 
defined lacunae (C). Negative controls were stained with DAPI only (B, D). Scale bars: A-B, 
500µm; C-D, 200µm.  
 
Haematoxylin and eosin (H&E) examination revealed that all scaffolds were 
integrated with the surrounding tissue on both surfaces of the scaffolds (Fig. 5.9 and 
5.11). Cells can be found within the thickness of each scaffold. Histostaining with 
safranin-O on both cell types and alizarin red S on MSC were negative and non-
specific respectively (Fig. 5.9 and 5.11). Human nasal cartilage was used as a positive 
control for safranin-O, type I and II collagen immunofluorescent stains (Fig. 5.13). In 
chondrocyte-seeded implants, human type II collagen was detected in pLTGF+ group 
only (O of Fig. 5.9 and 5.10), while type I collagen was found in ptPLLA+ scaffold 
(H of Fig. 5.9 and 5.10). There was no type II collagen detected across all scaffold 
groups in the MSC-seeded implants (Fig. 5.11). However, type I collagen was found 
in both ptPLLA+ and pLTGF+ (J and S of Fig. 5.11) 
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Fig. 5.9. Representative histochemical and immunofluorescence images of haemotoxylin and 
eosin (H&E, first column), safranin-O (second column), Type II collagen (third column), and 
Type I collagen (fourth column) staining of implant sections. All experimental groups are as 
indicated by their IDs in respective rows. H&E images show tissue integration onto the 
scaffolds. The representative images in the second column revealed negative staining for 
safranin-O (stains red for proteoglycans) across experimental groups. In the third and fourth 
column, cell nuclei stain blue, type II collagen stains green and type I collagen stains red. 
Type II collagen was only detected on pLTGF+ group (O) while type I collagen in ptPLLA+ 
group (H) as indicated by arrows. The enlarged images of O and H are shown in Fig. 5.10. 
Cell-free implants acted as controls for type I and II collagen immuno-localisation, showing 
no cross-reactivity of the antibodies to rat tissue. Scale bar: 500µm. 
 
146 
Chapter 5: Biofunctionalisation of Electrospun Scaffolds – In-vivo Study 
 
 
Fig. 5.10. Enlarged images O and H from Fig. 5.8 to illustrate the production of type II and I 
collagen by the implanted human chondrocytes (arrows). Scale bars: 500µm. 
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Fig. 5.11. Representative histochemical and immunofluorescent images of haemotoxylin and 
eosin (H&E, first column), safranin-O (second column), alizarin-red (third column), type II 
collagen (fourth column), and type I collagen (fifth column) staining of implant sections. All 
experimental groups are as indicated by their IDs in respective rows. General tissue 
integration onto the scaffolds is demonstrated by H&E staining. Images of safranin-O and 
alizarin red staining showed negative and non-specific signals respectively. Type II collagen 
was not detected as shown on the images of the fourth column. Type I collagen is stained red 
and shown in ptPLLA+ and pLTGF+ groups (J, S, arrows). (See Fig. 5.12 for enlarged 
images of J and S). Scale bars: 500µm. 
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Fig. 5.12. Enlarged images J and S from Fig. 5.11. These images show that only type I 
collagen production was detectable in both ptPLLA and pLTGF groups by the MSC. Scale 
bars: 500µm. 
 
 
 
Fig. 5.13. Positive controls of cartilage extracellular matrix with safranin-O staining and 
immunofluorescence labelling of human type I and II collagen. Images were taken at the 
chondro-perichondrial interface from cryosections of human nasal cartilage with intact 
perichondrium, to differentiate cartilage specific matrices (proteoglycan and type II collagen) 
from the fibrous perichondrial tissue (type I collagen). (A) Cartilage matrix stained red for 
proteoglycan with safranin-O. (B) Type II collagen fluoresced green while type I collagen in 
the perichondrium was labelled red. Scale bars: 500µm. 
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5.4 Discussion 
The results of this study demonstrated that the latent TGF-β1 biofunctionalised 
scaffolds induced significantly higher chondrogenic differentiation with type II 
collagen production in the in-vivo cultured primary human nasal chondrocytes, as 
compared to the control group. The findings of this in-vivo experiment also confirmed 
that the concept of cell-mediated activation of growth factors has been achieved by 
both scaffold biofunctionalisation methods described in Chapter 4. Interestingly, a 
converse effect was observed, on both of the latent TGF-β1 biofunctionalised scaffold 
groups, in the MSC implants - where the control group encouraged relatively stronger 
pattern of expression of Col1A1 and Runx-2 expression.  
 
For the evaluation of gene expression, the absence of signals on all gene probes on 
cell-free control implants and rat subcutaneous tissue suggested that the gene probes 
used in this study were specific to human genes - with the exception of the 18S 
housekeeping gene. This suggested that the housekeeping gene may have cross-
reacted with the rat tissue and resulted in a “dilution effect” on the rest of the genes, 
when the relative expressions were evaluated - as the 18S would have been derived 
from both human and rat origins. Despite this “dilution effect”, the expression of 
human genes was detectable, amongst a larger pool of rat genes. The detection of 
human specific genes with RT-PCR also indicated that both human chondrocytes and 
MSC survived the entire period of implantation within the rat subcutaneous layer. The 
presence of the donor cells were further confirmed with the anti-human nuclei 
immunofluorescence staining.  
 
 Sox9 is well known to be a transcription factor that directly regulates the type II 
collagen (Col2A1) gene expression(204;222). The Sox9 gene is one of the earlier 
markers of mesenchymal cells undergoing condensation and its expression has been 
reported to parallel Col2A1 during embryonic chondrogenesis(223). It is expressed in 
all chondroprogenitor cells (prechondrocytes, early chondroblasts, columnar 
chondroblasts) as well as chondrocytes, except hypertrophic chondrocytes(223-226). 
Once normal chondrocytes are isolated from its natural environment, a 
dedifferentiation process occurs. This process of chondrocytic dedifferentiation is 
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classically characterised by the down-regulation of cartilage-specific genes (e.g. Sox9 
and Col2A1) with the gradual rise of Col1A1, a fibrogenic or osteogenic marker 
which is also considered to be a chondrocyte dedifferentiation marker(227). These 
changes are typically seen when chondrocytes are cultured and passaged in-
vitro(206;228;229). Chondrocytes lose their differentiated functions as early as the 
first passage. Although this process is reversible, the capacity to redifferentiate 
reduces rapidly with increasing passages. A near total lost of this capacity has been 
reported to occur from the third passage onwards(13).  
 
The chondrocytes used in this experiment have been expanded up to fourth passage. 
The dedifferentiated characteristics have been indicated in the previous chapter where 
the Col2A1 was undetectable at two weeks of in-vitro culture. Remarkably, at week 6 
of this in-vivo study, Col2A1 expression was induced in the same batch of 
chondrocytes (fourth passage) which were seeded on to the latent TGF-β1 
biofunctionalised groups (pLTGF+ and sLTGF+). This confirmed that the 
dedifferentiated chondrocytes have been induced to redifferentiate by the latent TGF-
β1 biofunctionalised scaffolds. The expression of Col2A1 was undetectable in the 
implanted controls (ptPLLA+) despite the presence of Sox9. Although Sox9 is 
required for the activation of Col2A1 gene, the RT-PCR results demonstrated that the 
Sox9 expression in the ptPLLA+ group was not sufficient in activating the Col2A1 
gene in the absence of the latent TGF-β1 biofunctionalised scaffolds. Although the 
Sox9 expression in the sLTGF+ group was significantly low compared to the 
ptPLLA+ group, the Col2A1 was activated. Interestingly, the level of Sox9 expression 
seen in the pLTGF+ group, which was 3.9-fold higher than that of sLTGF+, was not 
accompanied by a proportional rise in the Col2A1 expression when compared to the 
sLTGF+ group. This “anti-parallel” or inverse proportion between Col2A1 and Sox9 
in the chondrocytic group may be a gene profile characteristic of in-vitro passaged 
adult human chondrocytes, where the expression of Sox9 correlates to a lesser extent 
with the presence of Col2A1(206;222;229). This may be due to a decrease in Sox9 
binding activity to the Col2A1 gene enhancer site with every increasing passage(222).  
 
Although no statistical significance was observed, the degree of differentiation can be 
seen at 1.5-fold higher in the sLTGF+ as compared to pLTGF+ (Fig. 5.2d). This was 
surprising considering the quantified amount of anchored TGF-β1 on sLTGF was one 
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order of magnitude lower than pLTGF (Chapter 4). This may be related to the 
orientation of the incorporated latent TGF-β1 as it may have governed how the 
appropriate signals were presented to the cells. Theoretically, the orientation of the 
latent TGF-β1 in the sLTGF may be a closer simulation of the natural latent TGF-β1 
complex in the native environment as illustrated in the introduction of Chapter 4. This 
chondrogenic differentiated state of the latent TGF-β1 biofunctionalised groups was 
evident in the immunofluorescence detection of type II collagen. The human type II 
collagen was detected in sections of pLTGF+ group which further confirmed the 
chondrogenic efficacy of the biofunctionalised scaffolds (Fig. 5.9). Unfortunately, the 
quantitative determination of type II and I collagen contents were inconclusive using 
an inhibition ELISA technique(230;231) (see Appendix 1.9). This was because the 
antibodies used in the assays cross-reacted with rat tissue as demonstrated by the 
positive signals in rat tissue controls. Further work will involve the determination of a 
suitable alternative method of quantification of Type I and II collagen. Preliminary 
assessment of species cross-reactivity of the quantification methods (with rat tissue) 
will need to be verified prior to the commencement of a full scale in-vivo experiment. 
The integration of tissue products can be seen on haematoxylin and eosin staining as 
well as SEM images (Fig. 5.5). 
 
The negative staining for proteoglycan with safranin-O in the chondrocytic group, 
could reflect the slow recovery of the differentiated function in dedifferentiated 
chondrocyte(202). In addition, the TGF-β1 has been reported to reduce the 
glycosaminoglycan synthesis in mature chondrocytes and increase the degradation of 
aggrecan by up-regulating aggrecanase activity(232;233). This may explain the 
negative staining of safranin-O in both latent TGF-β1 biofunctionalised groups. The 
type I collagen on immunofluorescence, found in the ptPLLA+ group, was consistent 
with the Col1A1 gene expression and lack of Col2A1 expression - further confirmed 
that the chondrocytes remained in their dedifferentiated state. The latent TGF-β1 
biofunctionalised scaffolds induced the highly passaged human nasal chondrocytes to 
re-express differentiated chondrogenic genotype as well as type II collagen 
production. However, the latent TGF-β1 did not evoke a similar chondrogenic 
response in the MSC group, when compared to the chondrocytic group.  
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The TGF-β1 has been reported to induce chondrogenesis in adult human MSC in-vitro 
(165;234;235). The TGF-β1 has been reported to be less effective in inducing 
chondrogenesis in human bone marrow derived MSC as compared to the TGF-β2 and 
TGF-β3 isoforms(234). In this chapter, although no statistical significance was 
observed in the gene expression data between experimental groups in the MSC 
culture, the RT-PCR results presented above suggested that the latent TGF-β1 of both 
biofunctionalised groups may have down-regulated the Runx2 and Col1A1 gene 
expression in the MSC, by approximately 50%, when compared to the ptPLLA+ 
group (Fig. 5.3c and d). It is likely that the presence of the latency associated peptide 
of the latent TGF-β1 may be a contributing factor. Both Sox9 and Runx2 have been 
reported to be co-expressed during mesenchymal condensation, in chondrocytic 
precursor cells and chondrocytes(225;226;236). Runx2 is also an essential 
transcription factor that guides mesenchymal precursors towards osteogenic lineage as 
well as promotes osteoblastic differentiation. Nonetheless, its expression has been 
reported to be inhibited by TGF-β1 in osteoblastic cells(237). Therefore, the latent 
TGF-β1 may have evoked a similar inhibitory response on osteogenesis in the MSC 
as seen in the non-specific alizarin red S stained sections and the relatively lower 
Runx2 and Col1A1 gene expression results in both biofunctionalised scaffolds.  
 
The Col2A1 expression was detected in all experimental groups but not in day 0 
MSC. This was as expected with the use of undifferentiated MSC. However, the 
absence of the Col2A1 in the day 0 MSC meant that the conventional comparison of 
the expression of the gene of interest (relative to the internal control – 18S), could not 
be made with the “untreated control” as according to the full equation of comparative 
CT method. The comparative CT method is a mathematical model that calculates 
changes in gene expression as a relative fold difference between experimental and 
calibrator samples. The following equations show the full formula to the comparative 
CT method(238;239):  
 
Fold change = 2-∆∆CT         (5.1) 
 
2-∆∆CT = [(CT gene of interest – CT internal control)sample A – (CT gene of interest - 
CT internal control)sample B]       (5.2) 
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where the CT is the threshold cycle, the quantitative endpoint which is defined as the 
“PCR cycle at which the fluorescent signal of the reporter dye crosses an arbitrarily 
placed threshold”; the internal control is usually a housekeeping gene used as a 
reference; the sample A may be the treated sample and the sample B, the untreated 
control/the calibrator sample(239). According to Schmittgen et al., RT-PCR data may 
be presented in the form of 2-∆CT as they are considered as normalised individual data 
points which are unrelated to a calibrator(239). Therefore, in this study, comparisons 
of the Col2A1 expression of the MSC group can only be made between the 
experimental groups without reference to the fold change from the commencement of 
the experiment. Although no statistical significance were observed between 
experimental groups with low levels of expression, the Col2A1 expression of the 
pLTGF+ group were approximately 30% higher than both ptPLLA+ and sLTGF+ 
groups. 
 
The presence of Sox9, Runx2, and Col1A1, together with the detectable Col2A1 may 
indicate that some of the MSC may have been guided towards: (1) a chondrogenic 
lineage or (2) a co-existence of both chondrogenic and osteogenic subpopulations as 
many growth factors that promote chondrogenesis in MSC, are also implicated to a 
certain extent in the process of osteogenesis(240). Nonetheless, the negative staining 
of safranin-O, alizarin red S together with statistically inconclusive gene expression 
data showed that additional cues are required for an effective induction of the MSC. 
Further investigations using MSC may require a longer in-vitro culture of 
approximately 1 week, in the chondrogenic serum-free media to ensure adequate 
induction of the MSC towards a chondrogenic lineage, prior to the in-vivo 
implantation(240;241). As mentioned earlier, the TGF-β2 and TGF-β3 have been 
shown to be more effective in inducing chondrogenesis in human bone marrow 
derived MSC when compared to the TGF-β1(234). Since TGF-β1, TGF-β2, and TGF-
β3 are synthesized in a similar way, associated with its latency-associated 
peptide(169) - a scaffold biofunctionalised with a latent form of the TGF-β2 or TGF-
β3 may be a more suitable chondrogenic scaffold system for the bone marrow derived 
MSC. Nonetheless, at present time, a recombinant form of the latent TGF-β2 or TGF-
β3 is yet to be commercially available.  
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This in-vivo study represents a pilot study to gain an initial insight into the potential 
tissue regenerative outcomes of the latent TGF-β1 biofunctionalised scaffolds in an 
in-vivo setting. A pilot study was also necessary to identify the potential technical and 
logistical difficulties that might occur throughout the experiment. Several aspects of 
this in-vivo experiment posed as potential impediments and they include:  
(1) the limited familiarity with various peri-operative equipments such as the use of a 
bead-steriliser and an anaesthetic machine; 
(2) the distance between the cell culture laboratory and the animal facility meant that  
additional precaution was necessary for the safe and sterile transportation of the cell-
scaffold constructs; 
(3) the spatial and anatomical feasibility of implanting six 1cm2 scaffolds (the three 
experimental groups together with their cell-free controls) interspaced at 1cm on the 
dorsum of a rat;  
(4) the tolerance of the rats to the implants as well as the surgical procedure (in both 
short and long term);  
(5) the limited familiarity with tissue handling (surgically) in rats; 
(6) the tolerance of the implanted human cells to its host environment;  
(7) the potential adverse effects of pharmacological agents e.g. enrofloxacin on the 
donor human cells and their chondrogenicity;  
(8) unforeseen obstacles related to sample processing, for example, species cross-
reactivity of detection probes of assays and antibodies.  
 
For these reasons, a pilot study was essential to identify potential problems and 
uncertainties which may arise from various aspects of a new in-vivo study. This 
prevented unnecessary wastage of scientific resources and is also considered ethically 
more humane to the use of laboratory animals. This chapter also established the 
foundation for a further definitive in-vivo study with a larger sample size. With a 
sample size of 4 rats per cell type, the post-hoc power of the experiment has been 
calculated based on the means and standard deviations of the chondrogenesis endpoint 
gene of interest – the Col2A1. However, only the chondrocyte group was selected for 
analysis due to their statistical significance relative to the control. The power of an 
experiment is the probability of detecting a specified effect at a specified level of 
significance. The powers of the pLTGF and sLTGF groups were 6.1% and 83.9% 
respectively (Table 5.3). Conventionally, the power of an experiment is set between 
155 
Chapter 5: Biofunctionalisation of Electrospun Scaffolds – In-vivo Study 
 
80 – 90% in order to have a high chance of detecting a significant effect(242). This 
means that the higher the power, the larger the number of animals that will be needed 
for the experiment. In this chapter, the sample size of four rats were sufficient to 
achieve a power of 83.9% in the sLTGF group of the chondrocyte culture, while the 
sample size of pLTGF group will need to be doubled in order to achieve a power 
greater than 80% (Table 5.3). Since both biofunctionalised scaffolds and their controls 
were implanted in the same experimental unit (rat), the sample size required for 
further substantive in-vivo assessment of the scaffolds will be a minimum of 8 rats per 
time point to achieve a power of greater than 80%. 
 
 
 
 pLTGF sLTGF 
Power of experiment 6.1% 83.9% 
 
Minimum sample size required: 
 
 
 
 
For power > 90% 10 5 
For power > 80% 8 4 
Table 5.3. Post-hoc power analysis of experiment on the chondrocyte group and 
determination of sample size required for further in-vivo studies with the biofunctionalised 
scaffolds. Based on the power analysis calculated on the Col2A1 expression of the 
chondrocytic groups, the minimum number of rats (sample size) for further in-vivo 
experiments for a given time point can be estimated according to the desired power. The 
calculations were performed using the PASS 2008 software (NCSS, USA), with α = 0.05. 
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5.5 Conclusion 
This in-vivo sequel to the in-vitro development of latent TGF-β1 biofunctionalised 
tissue scaffold has demonstrated and confirmed the proof of concept of a system 
capable of inducing cell-mediated activation of growth factor. The highly passaged 
human nasal chondrocytes (fourth passage) have been shown to re-express the 
Col2A1 gene as well as produce type II collagen on latent TGF-β1 biofunctionalised 
scaffolds. The results of this chapter suggested that the presentation of signalling cues 
to cells may be as important as the dosage, in guiding the appropriate cell behaviour. 
The outcome of its application also depends on the type of cells as well as the 
appropriate cell signalling factor used. Although the scale of this in-vivo study is 
preliminary, the proof of concept of cell-mediated activation of growth factors may 
provide a platform technology for further development of a growth factor delivery 
scaffold system for tissue regeneration.  
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Chapter 6  
Conclusions 
The field of tissue engineering has advanced remarkably in recent decades, to meet 
the rising demands for functional tissue replacements in treating injuries and diseases. 
In cartilage tissue engineering, the majority of the research studies have been driven 
by the orthopaedic surgical specialty in search of an ideal articular cartilage 
substitutes. Nevertheless, the advancements made may be applicable to cartilage 
regeneration for facial plastic reconstruction.  
 
Even so, few tissue engineered products are clinically available for medical 
treatments. Although current trends in tissue engineering have evolved to focus on 
biomimicking the structure and function of the native tissue, its size and complexity 
remain an enormous challenge to the scientific and medical community. For this 
reason, the first fundamental step in tissue engineering research begins at the 
molecular and cellular level. An in-depth understanding of the intricate interactions 
between the cells and their extracellular matrix is vital to substantiate the 
advancement of tissue engineering. 
 
In this thesis, a multidisciplinary approach has been applied in the development of a 
scaffold system which mimics the structural architecture as well as the function of the 
native cartilage tissue. The first study (Chapter 3) examined the structure of the native 
articular hyaline cartilage architecture comparing human to bovine origins. With the 
advent of micro-characterisation techniques, great insight into the nanoscale 
framework of the native hyaline cartilage extracellular matrix was achieved. The 
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human articular cartilage was more readily available for this initial study due to the 
prevalence of degenerative osteoarthropathy. However, a further in-depth nanoscale 
structural characterisation of the human nasoseptal and auricular cartilage would 
benefit the advancement of cartilage tissue engineering for facial reconstructive 
surgery, should specimens become available. It is likely that a full in-depth regional 
nano-structural characterisation of facial cartilages may need to be performed on 
cadaveric specimens because the availability of normal complete facial structures 
from the clinical practice that are suitable for scientific studies, are extremely rare. 
 
In order to recreate the structure architecture of the cartilage, an FDA approved 
biopolymer poly(L-lactide) was selected and electrospun into non-woven nanofibrous 
scaffolds. The fibre diameter and general scaffold morphology resembled the native 
cartilage. On achieving scaffold architectural resemblance by electrospinning, the 
subsequent study focused on developing a functional scaffold by incorporating the 
latent TGF-β1. Amongst a range of known growth factors, TGF-β1 was selected for 
its broad spectral regulatory effects on chondrogenesis. Nonetheless, the shortcomings 
of the TGF-β1 such as a short half-life and potential dose-related adverse systemic 
effects may limit its use in an in-vivo setting.  
 
In facing this challenge, the subsequent study developed a cell-mediated activation of 
growth factor system by incorporating the latent TGF-β1 onto the electrospun 
scaffolds. Based on the knowledge that the TGF-β1 is secreted in its latent form by 
chondrocytes in the native extracellular matrix and is protected by its latent peptide 
hence prolonging its half-life - the latent TGF-β1 was utilised as the model latent 
growth factor. Physicochemical characterisation techniques confirmed that the latent 
TGF-β1 was successfully incorporated onto the scaffolds and activated by means of 
acid as well as enzymatic treatment. The biofunctionalised scaffolds were shown to be 
non-cytotoxic and induced in-vitro dedifferentiated human primary nasal 
chondrocytes to express significantly higher cartilage-specific transcription factor 
Sox9 compared to the conventional media supplementation method of active TGF-β1 
at 14 days. These initial results established that the concept system of cell-mediated 
activation of the latent TGF-β1 had been achieved. As the cell culture assessments of 
latent TGF-β1 biofunctionalised scaffold required a serum-free environment, the 
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potential longer term effects of the biofunctionalised scaffolds would necessitate 
further evaluation in an in-vivo physiological condition. 
 
The six weeks in-vivo study demonstrated that the latent TGF-β1 biofunctionalised 
scaffolds significantly up-regulated cartilage-specific markers and re-differentiated 
the dedifferentiated primary human nasal chondrocytes. This further confirmed that 
the cell-mediated activation of growth factor had been successful and transferable to 
the in-vivo setting. In addition, the outcome induced by this system will depend on the 
cell types used. Although these results were promising in promoting chondrogenic 
differentiation, further investigations are required to determine ways to increase the 
production of cartilage matrix by the cells.  
 
First of all, further studies may need to focus on a larger expansion of cells for a 
higher seeding density in-vivo. A seeding density of greater than 1 × 106cells/cm2 may 
be required for a more effective promotion of chondrogenesis(74;243-245). However, 
this may mean a further increase in the number of passage which will inevitably result 
in further loss of chondrogenic capacity. In addition, a longer pre-implantation in-
vitro culture period with chondrogenic serum-free media may be required to allow the 
cells to undergo the process of chondrogenic differentiation. The exact length of time 
for this will need to be determined, to allow sufficient time for the cells to re-
differentiate in the in-vitro serum-free environment without compromising cell 
survival. Together with a higher seeding density, an implantation period beyond 6 
weeks, possibly extending up to or greater than 3-6 months, may also contribute to 
chondrogenesis(246-249).  
 
The cartilage tissue, like any other specialised tissue in the body - requires specific 
culture conditions, mechanical stimulation and multiple signalling molecules to 
maintain its differentiated state. Thus, the incorporation of these essential 
requirements is likely to further induce and promote chondrogenesis from multiple 
angles. For instance, expanded chondrocytes seeded onto the biofunctionalised 
scaffolds may benefit from a medium term (approximately 4 – 6 weeks) in-vitro 
culture in a dynamic condition provided by a bioreactor. This is to simulate the 
physiological flow of interstitial fluid which not only encourages nutrient-waste 
exchange but also stimulates cartilage matrix production(250-252). The bioreactor 
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culture system also enables the precise control of oxygen tension which will further 
encourage chondrogenic differentiation(11).  
 
The chondrogenic serum-free media described in this thesis may also benefit from an 
additional combination of anabolic growth factors – namely insulin-like growth factor 
and bone morphogenetic protein-2. These growth factors have been shown to 
synergistically enhance the effects of TGF-β1 in chondrogenesis(19;143;253). These 
growth factors, coupled with the employment of dynamic mechanical induction 
during culture will further encourage the synthesis of cartilage matrix. The 
mechanical properties of the resultant constructs will also be determined. The novel 
concept of this research may also be applicable to other forms of scaffold systems. 
Currently, a member of our research group is investigating the possible methods of 
incorporating the latent TGF-β1 in a hydrogel scaffold for the purpose of developing 
an injectable system. 
 
As this thesis aimed to establish the proof of a novel concept in growth factor/protein 
activation, the work described here was focused on the conception process and its 
characterisations. First, the anchorage of the latent protein onto the electrospun 
scaffold was established. Then, biocompatibility, cytotoxicity and the ability to 
produce cartilage matrix were determined. As mentioned above, further work to 
increase the production of cartilage matrix from the tissue engineered constructs is the 
next essential step. Once sufficient matrix production has been established, the 
possible in-vivo inflammatory effects will be determined. This will involve using 
substituting human chondrocytes with murine autologous chondrocytes harvested 
from auricular cartilages of immune competent specimens such as Sprague-Dawley 
rats (Harlan Hsd:Sprague-Dawley®TM). Blood C-reactive protein, white cell count 
analyses(254) together with histological comparison with immunocompromised 
athymic rats will demonstrate the immunogenicity of the resultant tissue engineered 
construct. The inflammatory response may also be influenced by the degradation 
products of poly(α-hydroxyesters) such PLLA and PGA which are essentially 
polymeric chains of lactic acid and glycolic acid. As scaffold surface modification 
inevitably results in polymeric chain scission, the degradation products as a result of 
hydrolysis would create an acidic environment which may be detrimental to cell 
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growth. Evaluation of degradation would involve structural analysis with SEM as well 
as XPS scaffold surface chemical analysis at various time points. Both techniques 
would demonstrate physical and chemical changes of the scaffolds. Degradation of 
scaffolds will also affect the mechanical properties of the construct. Therefore, the 
mechanical properties of the resultant constructs will also be determined. As 
mentioned previously, the natural structure and composition of cartilage confer the 
tensile strength, compressive stiffness and elastic modulus(26;251). Different zones of 
cartilage possess different mechanical properties due to the variation in structural 
organisation as well as its composition. Therefore, the final tissue engineered cartilage 
construct will require mechanical properties that reflect its native counterpart. This 
will be evaluated at various pre- and post-implantation time points. 
 
In conclusion, the proof of concept presented in this thesis may form a technological 
platform for further development of a scaffold system equipped with cell-mediated 
growth factor or protein activation – ultimately towards a structurally and functionally 
biomimetic scaffold for optimal tissue regeneration. 
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Appendices 
1.1 Step Wise Dehydration and Critical Point Drying for SEM 
1. Grow the cells in flasks 
2. Follow sub-culturing protocol to get the cells in suspension 
3. Count the cells using trypan blue protocol 
4. Workout the density of cells needed to seed on the materials 
5. Seed the cells and allow them to grow for desired period of time 
6. Make sure that you do not pipette or pour the solutions on top of the cells 
(there is a very high chance of washing the cells off) 
7. Wash the cells with PBS twice 
8. Fix the cells with 2.5% glutaraldehyde in PBS for 40 minutes at 4ºC 
9. Rinse with PBS twice 
10. Dehydrate with graded series (increasing concentration) of ethanol 
a. 25% - 5 minutes 
b. 50% - 5 minutes 
c. 70% - 5 minutes 
d. 90% - 5 minutes 
e. 100% - 5 minutes 
f. 100% - 5 minutes 
11. Incubate in hexamethylsilasane (HMDS) for 5 minutes 
12. Incubate in fresh HMDS for 5 minutes 
13. Sputter coat samples with gold 
14. View under scanning electron microscope 
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1.2 Cell Culture Protocols 
Most commercially available cells are purchased in frozen form. Upon receipt these 
frozen cells must be immediately transferred to liquid nitrogen. The protocol below 
describes how to resuscitate frozen cells stored under liquid nitrogen. 
1.2.1 Resuscitation of Frozen Cells 
1. Prepare growth media 
2. Pre-warm media 
3. Label flask and 15ml centrifuge tube 
4. Add 8 ml of media to the centrifuge tube 
5. Take the ampoule containing cells out from the liquid nitrogen bank (wear 
thermal gloves and mask) 
6. Leave the ampoule at room temperature for approximately 1 minute (not more 
than 1 minute) 
7. Transfer the ampoule to the water bath at 37ºC and allow it to thaw for 
approximately 4 minutes 
8. Wipe the ampoule with a tissue soaked in 70% alcohol and transfer 
immediately to the safety cabinet 
9. Carefully pipette the cells into the centrifuge tube 
10. Rinse the ampoule with 1 ml of fresh media and add to the centrifuge tube 
11. Centrifuge the tube at 200xg for 5 minutes 
12. Take the supernatant out without disturbing the pellet 
13. Flick the tube to disturb the pellet 
14. Add 1 ml of fresh growth media and make an even suspension of cells by 
repeated pipetting 
15. Add required amount of growth media to flask 
16. Add the cell suspension to flask and mix well 
17. Transfer the flask to the incubator 
 
When the cells reach sub-confluence levels (70-80% confluent) they must be sub-
cultured and seeded onto materials or into flasks at a lower density. This procedure is 
also known as passaging or trpsinisation. Every time the cells are sub-cultured they 
increase in passage number. For experiment reproducibility cell passage number 
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should be similar in different cell culture experiments. Increased passage may result 
in phenotypic changes in cells.  
 
1.2.2 Sub-Culture of Adherent Cells 
1. Prepare growth media 
2. Pre-warm media, trpsin- ethylenediaminetetraacetic acid (EDTA), and 
phosphate buffered saline (PBS) without Ca2+ and Mg2+ 
3. Aspirate the media and discard 
4. Wash the cells with PBS 
5. Add trypsin-EDTA (approximately 1ml per 25 cm2) 
6. Rock the flask to cover the monolayer 
7. Incubate the flask at 37ºC for 4 minutes 
8. Check under the microscope to make sure the cells are detaching from the 
surface and floating 
9. Gently tap on the sides of the flask to detach the remaining attached cells 
10. Add growth media (twice the volume as trypsin) to the flask and mix well 
11. Transfer the cell suspension to a centrifuge tube 
12. Centrifuge the tube at 200xg for 5 minutes 
13. Take the supernatant out without disturbing the pellet 
14. Flick the tube to disturb the pellet 
15. Add 1 ml of fresh growth media and make an even suspension of cells by 
repeated pipetting 
16. Count the cells using trypan blue protocol 
17. Add required amount of growth media to labelled flask 
18. Add the required amount of cell suspension to flask and mix well 
19. Transfer the flask to the incubator. 
 
Cryopreservation of cells is very important in cell culture.  It enables stock of cells to 
be stored for extended period of time (e.g. many years).  It reduces the risk of 
contamination, risk of phenotypic changes, cost and need to have the cell lines in 
culture at all time.  It also enable for the experiments to be carried out using cells at a 
consistent passage number.   
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1.2.3 Cryopreservation of Adherent Cells 
1. Prepare freezing media (10% dimethyl sulfoxide (DMSO) + 90% FBS) 
2. Pre-warm freezing media, media, trpsin-EDTA, and PBS (without Ca2+ and 
Mg2+) 
3. Perform steps 3 - 14 of the sub-culture protocol 
4. Add 1 ml of freezing media and make an even suspension of cells by repeated 
pipetting 
5. Perform cell count and dilute the cell suspension in freezing media to achieve 
2 – 4 × 106 cells per ml 
6. Add 1 ml of cell suspension into labelled ampoule (cryotube) 
7. Place ampoule in a freezing flask (containing isopropanol) and leave it in a –
80ºC freezer overnight (cells freeze at a rate of 1ºC/minute) 
8. Transfer the ampoule to liquid nitrogen bank and record the position on the 
logbook 
 
1.2.4 Seeding Cells on Materials 
For reproducible results it is important to determine the number of cells/cm2 of 
material. Only by keeping the cell number constant from experiment to experiment 
can the bioactive material properties such as cell growth, attachment or the production 
of cellular factors be accurately assessed.  
 
To determine the seeding density the trypan blue exclusion assay is routinely used. 
Trypan blue is a vital dye and does not interact with the cell unless the membrane is 
damaged. Cells that exclude the dye are viable. The proportion of viable and dead 
cells can then be determined with a haemocytometer. 
 
Trypan Blue Staining of Cells 
1. Make a cell suspension according to sub-culture protocol 
2. Prepare haemocytometer and coverslip by spraying with 70% alcohol and 
drying with a clean tissue 
3. Fix coverslip on haemocytometer by moistening the coverslip with water 
or exhaled air, slide the coverslip over the chamber, and move back and 
forth exerting slight pressure until Newton’s rings (rainbow coloured 
rings) appear 
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4. Place 0.2 mL of a suitable cell suspension (in complete medium) in a 
sealed container 
5. Add 0.2 mL of 0.4% trypan blue stain and mix thoroughly (dilution factor 
of 2)  
6. Allow to stand for 2-3 min at 15 to 30°C (room temperature). Prolonged 
exposure to trypan blue kills the cells.  
7. With a pipette fill both chambers of the haemocytometer. Do not over or 
under fill the chambers. Make sure that there are no air bubbles 
8. Under a microscope count the number of viable (unstained) and non-viable 
(stained blue) cells in eight - ten 4 × 4 squares or 0.1cm2 area (Fig. A.1). 
Count the cells in the squares and touching left and top middle line 
9. Calculate the number of viable and non-viable cells/ml using the formulae 
given below 
 
Fig. A.1. Picture showing one 4 × 4 corner square (0.1 cm2) on one of the haemocytometer 
chambers. 
 
Number of viable cells/mL  
= The average number of viable cells per 0.1cm2 area 
× 104 (correction factor for volume of area indicated by brace)  
× 2 (dilution factor, 0.2ml of cell suspension in 0.4mL) 
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1.3 Live/Dead Assay 
Molecular Probes (L-3224): LIVE/DEAD® Viability/Cytotoxicity Kit *for animal 
cells* *1000 assays* 
 
Materials: 
Reagents:  
- LIVE: Calcein AM (Component A), two vials, 40µL each, 4mM in anhydrous 
DMSO 
- DEAD: Ethidium homodimer-1 (Component B), two vials, 150µL each 2mM in 
DMSO/H2O 1:4 (v/v) 
Cell culture plates and coverslips, PBS, Assay Reagents.  
 
Protocol: 
Preparation 
1. Culture cells on coverslips  
2. Thaw LIVE/DEAD assay constituents. 
3. Wash cells with PBS prior to assay to remove/dilute serum esterase activity. 
4. Treat cells with cytotoxic agents if required. 
Concentration Determination 
5. Prepare controls of both live and dead cells on coverslips. 
Kill the cells using preferred method (0.1% saponin, 10 mins; 0.1-
0.5%digitonin, 10 mins; 70% methanol for 30 mins or complement and 
appropriate IgG for 30 mins). 
6. Using the dead cell sample, select an EthD-1 concentration that stains the dead 
cell nuclei bright red without staining the cytoplasm significantly: from 0.1 to 
10µM EthD-1, typically 4µM. (20µL of 2mM EthD-1 added to 10mL PBS = 
4µM EthD-1). 
7. Using the dead cell sample, select a calcein AM concentration that does not 
give a significant fluorescence in the dead cell cytoplasm: from 0.1 to 10µM 
calcein AM, typically 2µM. (5µL of 4 mM calcein AM to the 10mL EthD-1 
Solution = 2µM calcein AM) 
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8. Using the live cell sample, check that the chosen calcein AM concentration 
produces sufficient fluorescence in the live cell sample.  
 
The Assay 
9. Add 100-150 µL of the combined LIVE/DEAD assay reagents to the surface 
of a coverslip. 
10. Incubate for 30 - 45 mins at room temperature in a covered dish to prevent 
drying. 
11. Add 10µL drop of fresh LIVE/DEAD reagent or PBS to a clean microscope 
slide, then invert the coverslip and mount on the slide. Seal slide with clear 
nail polish to prevent evaporation.  
12. View labelled cells under the fluorescent microscope. 
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1.4 Image J Manual 
1.4.1 Measuring Circularity 
1. To open an image, go to File/Open/ My pictures to select image to be 
analysed. 
2. The images chosen were of red/green/blue stack (RGB stack) as seen on 
Live/Dead images. 
3. Next go to Images/Type and select RGB stack. This converts all images to 
grey scale but this enables the program to identify red, green and blue 
spectrum on the picture. 
4. We then select the “green” picture as indicated from the top left corner of the 
image. 
5. To outline each cells, the images will need to be converted into binary form. 
Go to Process/Binary/Threshold/. Then go through the same route and select 
Outline to outline the cells. 
6. From the tool bar, select Wand (tracing) tool. 
7. Next go to Analyze/ Set Measurements to select the parameters to measure. 
Decimal places is set at 3 while Redirect to None. Then press OK. 
8. We can now select the cells by just clicking on the image and a window 
displaying the results of the measurements will appear. 
9. Do not forget to label the cells everytime we have selected them for 
measurement. Analyse/ Label. 
10. Finally to save the images and results, click on File/ Save As. This can then be 
opened using another program for example Excel Analyse-it and ACDsee. 
 
An alternative method of measuring cells which are too confluent to assess, we can 
avoid step 2-6 from above. Instead, we can trace the cells manually by selecting 
Freehand Selections from the Image J tool bar on the selected image. Set 7 onwards 
should then be followed. 
 
A full detailed manual can be found on http://rsb.info.nih.gov/ij/ 
 
192 
Appendices 
 
1.4.2 To Measure Diameter of Fibres 
11. To open an image, go to File/Open/My pictures to select image to be analysed. 
12. Go to Analyse, Set Measurements, and select features of interests. Also make 
sure the decimal places are correct. 
13. Click on Straight Line Selection. Then click and drag on the scale bar for 
calibration. 
14. To calibrate the pixels to the scale bar, go to Analyse, Set Scale. Change the 
scale and units (e.g. for microns, enter um and for nanometers, enter nm) as 
accordingly. Select Global only if subsequent images carry the same scale bar 
or magnification. 
15. We can now start to measure the diameter by selecting one edge of the fibre 
and dragging it to the other edge (Fig. A.2). Go to Analyse then Measure.  
16. To label, it is important to immediately go to Analyse then Label.  
17. At the end, go to Analyse, Summarise to obtain the mean and Standard 
deviation. Finally save as described in step 10. 
 
Fig. A.2. An SEM image of electrospun PLLA fibres. This image illustrates the method 
employed for the measurement of fibre diameter using the Image J software. The black lines 
are where fibre diameters were measured, while the numbered labels indicate the number of 
fibres that has been included for analysis.  
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1.4.3 Beads measurements 
Bead circularity measurements were performed as according to Appendix 1.4.1 (Fig. 
A.3).  
 
Fig. A.3. A typical SEM image of showing the analysis of beads in electrospun PLLA fibres. 
This image illustrates the method employed for the measurement of fibre bead numbers and 
circularity using the Image J software. The black lines encircle the beads, while the numbered 
labels indicate the number of beads that has been included for analysis. 
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1.5 Tables of Electrospinning Parametric Study Data 
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1.6 Glycine Standard Curve for Ninhydrin Assay 
1. 10mL of 0.1M Glycine (Sigma, UK) was serially diluted with 50%v/v ethanol 
to achieve 0.075, 0.05, 0.025, 0.01, 0.0075, 0.005 and 0.0025mM. 
2. 1mL of each concentration was placed in a 5mL glass vial. 
3. 100µL of 1M Ninhydrin (Chapter 4) was added to each vial. Immediate colour 
change was observed. 
4. All standards were heated up to 80°C, for 15mins. 
5. Absorbance was measured at 570nm using UV-Vis spectrophotometer. 
6. The optical densities (570nm) were plotted against the concentration of 
glycine which is represented by NH2 concentration. Fig. 4.3. 
 
197 
Appendices 
 
1.7  DNA content from MTS assay samples 
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Fig. A.4. DNA concentration at day 1, 7 and 14. DNA concentration of cells from various 
scaffold types were obtained as described in Chapter 4. The DNA concentration was used for 
normalisation of MTS assay absorbance to obtain the metabolic activity of the cultured 
chondrocytes. Results are presented as mean ± standard deviation (n=3). 
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1.8 Histology Protocols 
1.8.1 Haematoxylin & Eosin Staining 
(Modified from Meyer’s Protocol from http://www.ihcworld.com/histology.htm) 
 
Materials 
Haematoxylin solution – Gill’s Formula, Vector Laboratories 
    
Eosin Y Stock Solution (1%): 
Eosin Y (Sigma-Aldrich, UK)-------------- 10 g 
Distilled water ------------------------------- 200 mL 
95% Ethanol ---------------------------------- 800 mL 
Mix to dissolve and store at room temperature. 
  
Eosin Y Working Solution (0.25%): 
Eosin Y stock solution -------------------- 250 mL 
80% Ethanol -------------------------------- 750 mL 
Glacial acetic acid (concentrated) ------- 5 mL 
Mix well and store at room temperature. 
DPX Mountant (Low Viscosity) – Bios Europe Ltd., UK 
 
Procedure:  
1. Stain acetone fixed slides in haematoxylin solution for 1-2 minutes.  
2. Rinse gently in running tap water for 10 minutes (until water runs clear).  
3. Counterstain in eosin solution for 30 seconds to 1 minute.  
4. Dehydrate through 50%, 70%, 95% alcohol, 2 changes of absolute alcohol, 2 
minutes each.  
5. Clear in 2 changes of xylene, 5 minutes each.  
6. Mount with xylene based mounting medium.  
   
Results:  
Nuclei --------------------------------------- blue  
Cytoplasm ---------------------------------- pink to red  
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1.8.2 Safranin-O and Fast Green Staining 
(Modified from http://www.ihcworld.com/_protocols/special_stains/safranin_o.htm) 
 
Materials 
0.001% Fast Green (FCF) Solution:  
      Fast green, FCF (Sigma, UK) ------------- 0.01 g  
      Distilled water ---------------------------- 1000 mL  
   
1% Acetic Acid Solution:  
      Acetic acid, glacial ------------------------- 1 mL  
      Distilled water ------------------------------ 99 mL  
   
0.1% Safranin O Solution:  
      Safranin O (Sigma, UK) -------------------- 0.1 g  
      Distilled water ----------------------------- 100 mL  
 
DPX Mountant (Low Viscosity) – Bios Europe Ltd., UK 
 
Procedure:  
1. Stain with haematoxylin solution for 1-2 minutes.  
2. Wash in running tap water for 10 minutes (until water runs clear).  
3. Stain with fast green (FCF) solution for 5 minutes.  
4. Rinse quickly with 1% acetic acid solution for no more than 10 –15 seconds.  
5. Stain in 0.1% safranin O solution for 5 minutes.  
6. Dehydrate and clear with 50%, 70%, 95% alcohol, 2 absolute alcohol and 2 
xylene changes, 2 minutes each.  
7. Mount using resinous medium.  
   
Results:  
Nuclei ---------------------------------------------- black  
Cytoplasm ----------------------------------------- gray green  
Cartilage, mucin, mast cell granules ----------- orange to red  
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1.8.3 Alizarin Red S Staining 
(http://www.ihcworld.com/_protocols/special_stains/alizarin_red_s.htm) 
 
Description: Alizarin Red S, an anthraquinone derivative, may be used to identify 
calcium in tissue sections. The reaction is not strictly specific for calcium, since 
magnesium, manganese, barium, strontium, and iron may interfere, but these elements 
usually do not occur in sufficient concentration to interfere with the staining. Calcium 
forms an Alizarin Red S-calcium complex in a chelation process, and the end product 
is birefringent. 
   
Fixation: Neutral buffered formalin or alcoholic formalin fixed, paraffin 
embedded tissue sections.  
  
Positive Control: mouse embryo or a know calcium containing tissue sections 
 
Solution and Reagents: 
Alizarin Red Solution:
    Alizarin Red S (C.I. 58005) ----------- 2 g 
    Distilled water ------------------------- 100 mL 
    Mix well. Adjust the pH to 4.1~4.3 with 10% ammonium hydroxide. The pH is 
critical, so make fresh or check pH if the solution is more than one month old. 
  
Acetone (100%)
  
Acetone-Xylene:
   Acetone (100%) ------------------------- 50 mL 
   Xylene ----------------------------------- 50 mL 
  
Procedure: 
1. Stain slides with the Alizarin Red Solution for 30 seconds to 5 minutes, and 
observe the reaction microscopically. Usually 2 minutes will produce nice red-
orange staining of calcium. 
2. Shake off excess dye and blot sections. 
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3. Dehydrate in acetone, 20 dips. Then in Acetone-Xylene (1:1) solution, 20 
dips. 
4. Clear in xylene and mount in a synthetic mounting medium. 
  
Results 
Calcium deposits (except oxalate) -------- orange-red 
This precipitate is birefringent. 
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1.9  Biochemical Characterisation of In-vivo Cultured Cell-scaffold 
Constructs 
This section was performed by Mr T. Sims (Department of Cellular and Molecular 
Medicine, University of Bristol) as part of the collaboration for the in-vivo study 
(Chapter 5). Type I and II inhibition ELISA were carried out to determine the quantity 
of matrix produced by the human chondrocytes and MSC. 
 
1.9.1 Materials and Methods 
1.9.1.1 Proteolytic Digestion of Explants for Biochemical Analysis 
Dry weights of the implants were determined after freeze-drying process. The 
implants were then digested with trypsin and processed for collagen content analysis. 
The samples were initially incubated for 15 hours at 37°C with 250µL 
tosylphenylalanylchloromethane-treated bovine pancreatic trypsin prepared at 
2mg/mL in Tris Buffer, pH7.5, containing 1mM iodoacetamide, 1mM 
ethylenediaminetetraacetic acid and 10µg/mL pepstatin A (all from Sigma, UK). An 
additional 250µL of trypsin was added to all samples with a further incubation of 2 
hours at 65°C. All samples were boiled for 15 minutes at the end of the incubation to 
stop any remaining enzyme activity(230;255;256). The dry weights of the trypsin-
digested extracts were determined by obtaining the difference between dry weights of 
the initial implants and the remaining undigested materials. 
 
1.9.1.2 Determination of Type I Collagen Content by Inhibition ELISA 
The extracts were assayed by inhibition enzyme linked immunosorbent assay 
(ELISA) using a rabbit antipeptide antibody to type I collagen (230). Peptide 
SFLPQPPQ (Serine - phenylalanine - leucine - proline - glutamine – proline – proline 
- glutamine) synthesised by Dr A. Moir (Kreb’s Institute, Sheffield University, UK) 
was used as a standard in all immunoassays.  
 
Round-bottom 96-well microtiter plates (Costar, UK) were precoated with Dulbecco’s 
phosphate buffered saline (PBS; Invitrogen, UK) containing 1% (w/v) bovine serum 
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albumin (PBS-BSA; Sigma-Aldrich, UK) 100µL/well for 30mins at room 
temperature, then rinsed once with PBS containing 0.1% (v/v) Tween 20 (PBS-
Tween; Sigma-Aldrich, UK). To minimise the effects evaporation, the outer most 
wells were not used. The 8-residue peptide was used at a concentration of 4 to 
1000ng/mL to produce a standard curve for each plate. The standards and samples 
were diluted in 0.8%(w/v) sodium dodecyl sulphate (SDS; Bio-Rad, UK) in 
tris(hydroxymethyl)methylamine (Tris; BDH Laboratories, UK). The SDS was used 
to solubilise type I collagen and to dissociate any interactions with other proteins 
present within the sample. Each pre-incubated plate contained six non-specific 
binding wells, containing SDS-TRIS (100µL/well). All other wells contained 50µL of 
the rabbit anti-peptide antibody diluted 1:1000 in Tris containing 4% (v/v) Trition X-
100 (BDH, UK). The antibody in six of the wells was mixed with 50µL of SDS-Tris, 
to indicate maximum binding in the absence of inhibitory epitope. The antibody in all 
other wells was mixed with 50µL of either standard or sample, in triplicate.  
 
After an overnight incubation at 37°C in a humidified atmosphere, all samples were 
transferred to the equivalent wells of an Immulon-2 ELISA plate (Dynex 
Technologies, UK), coated with immunising peptide (40µg/mL). After 30mins at 
room temperature, the plates were rinsed three times with PBS-Tween and incubated 
for 1 hour at 37°C with alkaline phosphatase-conjugated goat anti-rabbit antibody 
(Southern Biotechnology, USA) diluted 1:1000 in PBS-BSA containing 0.1%(v/v) 
Tween 20. The plates were then rinsed three times in PBS-Tween and once with 
distilled water. Subsequently, 0.5mg/mL alkaline phosphatase substrate disodium p-
nitrophenyl phosphate (Sigma-Aldrich, UK) in 8.9mM diethanolamine (Sigma-
Aldrich, UK), 0.25mM MgCl2 (pH9.8) for 30 minuntes. Absorbance was measured at 
405nm using a microplate reader Anthos 2020 (Biochromo Limited, UK). The mean 
absorbance from the six non-specific binding wells was subtracted from the 
absorbance value of all wells from the same plate.  
 
As the 8-residue peptide was used as the standard in all assays, a conversion factor 
was used to calculate the amount of type I collagen present in all samples. The 
molecular weights of the α1-chain of human type I collagen and the 8-residue peptide 
were calculated from their amino acid sequences – 96962 and 999 respectively. As 
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type I collagen consists of two α1 (I) chain and one α1(II) chain, the concentration of 
type I collagen (ng/mg) extracted from the implants was calculated by multiplying the 
concentration of extracted peptide by 146 [i.e. (96962×3)/ (999×2)]. 
1.9.2 Determination of Type II Collagen Content by Inhibition ELISA 
The type II collagen content was determined by an inhibition ELISA, using a mouse 
monoclonal antibody to denatured type II collagen, COL2-3/4m developed by 
Hollander et al.(231). Peptide CB11B, CGKVGPSGAP[OH] 
GEDGRP[OH]GPP[OH]GPQY (cysteine – glycine – lysine – valine – glycine – 
proline – serine – glycine – alanine – hydroxyproline – glycine – glutamate – 
aspartate – glycine – arginine – hydroxyproline – glycine – proline – hydroxyproline 
– glycine – proline – glutamine - tyrosine), synthesised by Dr A. Moir, was used as 
standards. 
 
Round-bottom 384-well microtiter plates were blocked and rinsed as described for 
type I collagen. To minimise the effects evaporation, the outer most wells were not 
used. 20µL of 50mM Tris, pH7.6 were added to 6 wells of each plate and considered 
as non-specific binding wells. 10µL/well of COL2-3/4m antibody diluted 1:600 in 
Tris was added to each well of the preincubated plates, except the non-specific 
binding wells. This was to provide a detectable but inhibitable level of binding. 
10µL/well of Tris was added to 6 wells, which already contained 10µL/well of COL2-
3/4m antibody - to indicate maximum binding in the absence of inhibitory epitope. 
10µL of peptide CB11B was used at a concentration of 0.5 to 6µg/mL to produce a 
standard curve for each plate. Subsequently, 10µL of samples were added to each 
remaining wells in triplicate. 
 
After an overnight incubation at 37°C in a humidified atmosphere, 10µL of all 
samples were transferred to the equivalent wells of an Immulon-2 ELISA plate 
(Dynex Technologies, UK), precoated with bovine type II collagen (40µg/mL) 
(Sigma-Aldrich, UK).  
 
After 30mins at room temperature, the plates were rinsed three times with PBS-
Tween and incubated with 10µL of alkaline phosphatase-conjugated goat anti-mouse 
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antibody (Zymed Laboratories, USA) diluted 1:1000 in PBS-BSA containing 0.1% 
(v/v) Tween 20, for 1 hour at 37°C. The plates were then rinsed three times in PBS-
Tween. Subsequently, 10µL of alkaline phosphatase substrate solution consisting of 
disodium p-nitrophenyl phosphate 0.5mg/mL (Sigma-Aldrich, UK) in 8.9mM 
diethanolamine (Sigma-Aldrich, UK), 0.25mM MgCl2 (pH9.8) for 30mins. 
Absorbance was measured at 405nm using a microplate reader Anthos 2020 
(Biochromo Limited, UK). The mean absorbance from the six non-specific binding 
wells was subtracted from the absorbance value of all wells from the same plate. The 
percentage inhibition of binding by samples and standards was calculated relative to 
the mean absorbance from the six maximum binding wells on the same plate, which 
represented 0% inhibition (100% binding).  
 
The molecular weights of the human type II collagen α1-chain and of peptide α1(II)-
CB11B were each determined from their amino acid sequences(231). It was assumed 
that there are 99 hydroxyproline and 20 hydroxylysine residues of the α1(II) chain. 
Based on this, the molecular weights of the α1(II) chain and α1(II)-CB11B peptide 
were calculated as 98291 and 2231 respectively. Therefore, the concentration (µg/mg) 
of type II collagen extracted from cartilage was calculated by multiplying the 
concentration of extracted α1(II)-CB11B by a factor of 44. Type I and II collagen 
contents were presented as mean ± standard deviation (n=4).  
 
1.9.3 Results and Discussion 
The cell-free implants and rat subcutaneous tissue obtained distant from the dorsal 
implantation sites were used as controls. Both controls showed positive signals to 
both which strongly suggest that both antipeptide antibodies for type I and II collagen 
detection cross-reacted with the rat tissue (Fig. A.7 and Fig. A.8). This meant that 
matrices produced by human cells were indistinguishable from rat tissue. Further 
work utilising antibodies which are highly specific to human type I and II collagen 
will need to be performed.  
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a b 
Fig. A.7. Determination of collagen contents using the inhibition ELISA for the primary 
human chondrocytic group. (a) Type II collagen content, (b) Type I collagen content. For 
sample group ID, see Chapter 6. Mean ± SD are presented (n=4). 
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a b 
Fig. A.8. Determination of collagen content using the inhibition ELISA for the MSC group. 
(a) Type II collagen content, (b) Type I collagen content. For sample group ID, see Chapter 5. 
Mean ± SD are presented (n=4). 
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